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General Introduction 
This chapter is an introduction to the research on erythrocytes, microparticles and regulatory 
T cells that is presented in the subsequent chapters. The first part of this chapter briefly 
discusses the main functions and characteristics of the erythrocyte. The second part 
focusses on erythrocyte aging and removal, transfusion side effects, and anemia of 
inflammation. The third part discusses the functions of erythrocyte-derived and platelet-
derived microparticles in the context of health, disease and transfusion medicine. In the 
fourth part, a brief overview of the immune system and its role in tissue homeostasis is 
given. In the final part, the scope of this thesis is presented. 
 
I - The erythrocyte 
Erythrocytes, commonly known as red blood cells, are the most abundant cells in the 
circulation, and are the principal means of oxygen delivery to and CO2 removal from the 
peripheral tissues. The erythrocyte owes its ability to transport oxygen to its high hemoglobin 
content. In the human lung, the erythrocytes take up oxygen at the alveolar-capillary 
interface, which they release whilst traversing the capillary network in the peripheral tissues. 
This oxygen release is stimulated by the CO2 that is produced by metabolically active 
tissues. Upon entering the erythrocyte, CO2 is converted into HCO3- and H+ by the enzyme 
carbonic anhydrase. The subsequent decrease in intracellular pH serves as a signal for 
hemoglobin to release oxygen. 
Erythrocytes are biconcave disks with an approximate diameter of 7 µm and maximum 
thickness of 2.5 µm. Unlike almost all the other cells of the body, erythrocytes do not contain 
intracellular organelles such as a nucleus, endoplasmic reticulum, Golgi apparatus, and 
mitochondria, which enables a maximal hemoglobin content and plasma membrane 
deformability. Erythrocytes must be able to undergo large passive deformations in order to 
pass through the narrow capillaries of the microvasculature and the fenestrae in the spleen. 
The shear stress that erythrocytes experience when traversing the vessels and the 
deoxygenation of their hemoglobin trigger the release of potent vasodilators in the form of S-
nitrosothiol and ATP, which promote the passage of the erythrocyte. ATP promotes the 
release of NO by the vascular endothelium, which is further enhanced by the shear stress 
that the passing erythrocytes exert on the endothelium. This physiological activity is 
exemplary for the complex interactions between the erythrocyte and its environment. 
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II - Erythrocyte aging and removal 
In the red bone marrow, multipotent hematopoietic stem cells proliferate and differentiate to 
form erythroblasts [1], which produce large quantities of hemoglobin and ultimately expel 
their nuclei to form reticulocytes. The reticulocytes mature into erythrocytes in the bone 
marrow, a process which is completed after their release into the circulation. This maturation 
process is characterized by loss of intracellular organelles such as mitochondria and 
ribosomes [2,3], and by extensive membrane remodeling [4,5]. In the circulation, the 
average lifespan of the human erythrocyte is approximately 120 days [6], which means that 
200 billion erythrocytes have to be removed and replaced every day. 
Physiological autoantigens 
During their stay in the circulation, erythrocyte aging results in an increase in autologous IgG 
binding, which ultimately leads to the phagocytosis of old erythrocytes by Kupffer cells in the 
liver (Figure 1) [7]. The work of Marguerite Kay has uncovered that the binding of 
physiological autoantibodies to senescent erythrocytes is associated with changes in band 3. 
These changes are thought to be triggered by the binding of denatured hemoglobin to the 
cytoplasmic domain of band 3 (Figure 1) [7]. It has been suggested that selective tyrosine 
phosphorylation of oxidized band 3 by Syk may play a role in the recruitment of hemoglobin-
bound band 3 molecules in large membrane aggregates that show a high affinity to 
physiological autoantibodies [8]. 
 
 
FIGURE 1. Erythrocyte birth, aging and removal. 
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Band 3 
The Cl-/HCO3- exchange protein band 3, or anion exchanger 1, is the most abundant protein 
in the erythrocyte membrane, facilitates the transport of CO2 through the body [9], and 
controls the rate of glycolysis in the erythrocyte by reversible binding of key enzymes such 
as glyceraldehyde 3-phosphate dehydrogenase [10]. Band 3 is present in three distinct 
protein complexes within the erythrocyte membrane: as an ankyrin-bound, tetrameric band 3 
complex, as a dimeric band 3 complex bound to the protein 4.1–GPC junctional complex, 
and as freely diffusing dimeric band 3 complexes (Figure 2) [11]. The cytoplasmic domain of 
band 3 functions as the main anchorage site of the plasma membrane for the cytoskeleton 
by binding ankyrin, protein 4.1, protein 4.2 and adducin [12-14], and thereby plays a crucial 
role in the mechanical integrity and the deformability of the erythrocyte. Band 3 also interacts 
with various integral membrane proteins including glycophorin A, RhAG and/or Rh from the 
rhesus complex (Figure 2) [15,16]. 
 
FIGURE 2. Band 3 multiprotein complexes in the human erythrocyte membrane. CA II – carbonic 
anhydrase II, GAPDH – glyceraldehyde 3-phosphate dehydrogenase, GPA – glycophorin A, GPB – glycophorin 
B, GPC – glycophorin C, Hb – hemoglobin,  LW – Lewis blood group system, PFK – phosphofructokinase, Rh – 
rhesus blood group system, RhAG – Rh-associated glycoprotein blood group system (van den Akker et al.[11], 
adapted from Salomao et al.[17]) 
 
Erythrocyte deformability 
Another mechanism of removal centers on the reduced deformability of aged erythrocytes 
[18-20]. Erythrocyte deformability is governed by the viscosity of the cytoplasm - largely 
determined by its hemoglobin concentration -, the surface area-to-volume ratio (S/V), and 
the mechanical properties of the plasma membrane - primarily determined by its protein and 
lipid constituent organization - including the interaction between plasma membrane 
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constituents with the cytoskeleton [19,21,22]. As previously mentioned, the erythrocyte has 
to undergo large deformations in order to pass through the narrow capillaries of the 
microvasculature and the fenestrae in the spleen. Poorly deformable erythrocytes tend to get 
stuck in the spleen, which may trigger phagocytosis [23-25]. Indeed, enhanced splenic 
sequestration of abnormal erythrocytes with reduced deformability is associated with a 
decreased life span and anemia in several erythrocyte membranopathies [26]. During its 
time in the circulation, the erythrocyte loses membrane surface due to continuous membrane 
vesiculation [27-29]. This vesicle shedding is thought to constitute a mechanism for the 
removal of damaged/aged membrane patches, postponing the untimely recognition and 
elimination of functional erythrocytes [29-33]. In addition, vesiculation also contributes to the 
gradual loss in deformability observed during physiological erythrocyte aging [34], as it leads 
to a reduced S/V ratio and increased mean cellular hemoglobin concentration [34,35]. This 
might induce their eventual removal by splenic sequestration. 
Phosphatidylserine exposure 
The lipid part of the plasma membrane of the erythrocyte is composed of equal proportions 
of cholesterol and phospholipids [26]. While cholesterol is evenly distributed between the 
outer and inner leaflet of the membrane, the four dominant phospholipids are asymmetrically 
distributed. Phosphatidylcholine and sphingomyelin (SM) are primarily located in the outer 
leaflet, while phosphatidylethanolamine and phosphatidylserine (PS) are predominantly 
found in the inner leaflet (Figure 3) [36,37]. Various phospholipid transport proteins have 
been implicated in membrane phospholipid asymmetry. “Flippases” transport phospholipids 
from the extracellular to the cytoplasmic membrane leaflet, while “floppases” do the 
opposite, both in an energy-dependent manner (Figure 3). In contrast, “scramblases” move 
phospholipids bi-directionally down their concentration gradients by an energy-independent 
mechanism that is triggered by a rise in cytoplasmic calcium (Figure 3) [38]. A novel calcium-
activated cation channel (TMEM16F) required for calcium-induced membrane phospholipid 
scrambling was recently identified, and was found to be mutated in patients with Scott 
syndrome, a disease characterized by defective calcium-induced phospholipid scrambling 
activity [39-41]. The plasma membrane lipid composition is involved in erythrocyte 
homeostasis [42,43], as exemplified by the altered erythrocyte morphology and survival in 
patients with hemoglobinopathies and severe liver diseases, due to a disturbed membrane 
lipid asymmetry and lipid metabolism, respectively [43,44]. The maintenance of phospholipid 
asymmetry, in particular the exclusive localization of PS in the inner plasma membrane 
leaflet, has several functional implications. One such implication is the association between 
an increase in PS exposure and vesiculation [45]. 
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FIGURE 3. Phospholipid distribution and its regulation in the erythrocyte membrane. ATP – adenosine 
triphosphate, PC – phosphatidylcholine, PE – phosphatidylethanolamine, PS – phosphatidylserine, SM – 
sphingomyelin (© Frans Kuypers 2011) 
 
Externalization of PS to the outer leaflet of the plasma membrane is a hallmark of apoptotic 
cell death for many cell types [46-49]. Once exposed, PS is recognized by macrophages 
which in turn phagocytoze the targeted cell, either directly via PS receptors [50-52], or 
through PS-mediated opsonisation of cells with lactadherin [53,54]. This has led to the 
broadly supported postulate that PS exposure by erythrocytes promotes their removal from 
the circulation. PS exposure on erythrocytes indeed leads to their phagocytosis by Kupffer 
cells of the liver and macrophages of the spleen in mice [55]. A recent study has shown that 
stress-induced PS exposure by erythrocytes leads to their recognition by PS receptors TIM-1 
and TIM-4, and triggers their removal by TIM-1 and TIM-4-positive phagocytes [50]. Another 
study demonstrated that endothelial cells bind PS-positive erythrocytes via stabillin-1 and 2, 
greatly enhancing phagocytosis of these erythrocytes [56]. These findings suggest that liver, 
splenic, and/or vascular endothelium cooperate with resident macrophages in the removal of 
PS-positive erythrocytes. Interestingly, few erythrocytes (<1%) in the human circulation 
expose PS regardless of their age [57], suggesting that PS exposure either does not occur 
during physiological erythrocyte aging, or leads to the rapid removal of the PS-exposing 
erythrocyte. In erythrocyte pathologies such as sickle cell anemia, thalassemia and 
spherocytosis, erythrocyte survival inversely correlated with phosphatidylserine exposure 
[58]. 
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Another mechanism involved in erythrocyte removal involves the membrane protein CD47. 
CD47 is generally known as a marker of “self”, as it has been shown to inhibit erythrocyte 
phagocytosis by macrophages of the reticulo-endothelial system [59-61]. A recent study 
adds another dimension to the CD47 story, by showing that a conformational change in 
CD47 induced by experimental erythrocyte aging enables thrombospondin binding and 
subsequent phagocytosis by splenic macrophages in vitro [62]. It is reasonable to assume 
that several of the above-mentioned clearance mechanisms act simultaneously in an effort 
to efficiently remove old and/or damaged erythrocytes in vivo. 
 
Side effects of erythrocyte transfusion 
Erythrocyte transfusions are given to raise the hemoglobin concentration in patients with 
severe anemia, or after acute blood loss due to surgery and trauma. Erythrocytes as well as 
platelets and plasma are isolated from whole blood of healthy donors by centrifugation. The 
collected erythrocytes are stored in specially designed plastic bags containing a preservative 
solution at 4°C. In the Netherlands, the leukocyte numbers in the product are strongly 
reduced by centrifugation and subsequent filtration prior to storage in SAG-M preservation 
solution. Dutch legislation dictates that erythrocyte concentrates can only be used for 
transfusion within 35 days after their collection, in order to meet the international quality 
standards of 75% erythrocyte survival at 24 hours after transfusion and 0.8% hemolysis in 
the concentrate [63,64]. 
Although the more than 100 million annual voluntary blood donations help save millions of 
lives worldwide [65], erythrocyte transfusions can also have serious side effects, such as 
acute lung injury, iron deposition resulting in severe organ damage, vasoconstriction, and 
formation of alloantibodies and autoantibodies [66]. There are a number of changes that 
occur during erythrocyte storage that may cause the observed side effects after transfusion. 
These “storage lesions” include vesiculation [30,67], decreased deformability [68,69], 
decreased 2,3-bisphosphoglycerate [70], ATP and glutathione [71] concentrations, 
potassium leakage [72], and hemolysis [73].  
Immune-mediated side effects 
The erythrocyte contains a complex set of regulatory systems that may induce erythrocyte 
removal after physiological or pathological injury such as osmotic shock, oxidative stress 
and/or energy depletion [74]. Modulation of these pathways is progressively lost during 
storage [75,76], and this may result in accelerated aging and the removal of up to 30% of the 
transfused erythrocytes within 24 hours after transfusion [77]. Disruption of these systems 
likely include a reduction of the threshold for activation of the pathways governing PS 
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exposure [78], and may trigger aberrant expression of pathogenic epitopes on stored 
erythrocytes and their vesicles [79]. 
Frequent erythrocyte transfusions may induce the formation of alloantibodies. This is 
especially problematic in the steadily increasing number of transfusion-dependent patients. 
Almost half of these patients acquire alloantibodies at some point in time, and in 
approximately 10% of the patients erythrocyte autoantibodies are detected. Some patients 
that produce these autoantibodies develop autoimmune hemolytic anemia, which can be life-
threatening [80,81]. Observations such as these suggest that erythrocyte antigenicity 
changes during storage, potentially leading to autoantibody production after transfusion 
against these neoantigens. Murine studies suggest that erythrocyte transfusions can 
augment inflammation [82,83], that may enhance the risk of immune responses towards 
erythrocyte autoantigens. 
Storage duration versus clinical outcome 
The wealth of data available on the gradual changes observed in the erythrocyte during 
storage [84] has long since sparked the discussion that longer storage time increases the 
risk of transfusion side effects. Multiple studies have reported that increased storage age of 
transfused erythrocytes is an independent risk factor for a number of adverse endpoints [85-
91]. In contrast, several other studies did not find any difference between short and long 
stored erythrocytes on clinical outcome [92-95]. The use of either leukocyte-reduced or non-
leukocyte-reduced erythrocyte products in these studies may explain the observed 
discrepancies [96]. Thus far, there are no completed prospective randomized controlled 
studies examining the effect of storage duration of transfused erythrocytes on morbidity and 
mortality [96-98]. To definitively answer this question two large clinical trials are currently 
underway: The US-based initiative Red Cell Storage Duration Study (RECESS), and the 
complementary UK and Canadian co-initiative Age of Blood Evaluation (ABLE) [98].  
 
Anemia of inflammation 
Inflammation arising from various etiologies, including autoimmune disorders, infection and 
in particular sepsis, promote anemia [99-101]. The preferred treatment is directed at the 
underlying disease. However, when inflammation persists there are only a few options for 
treatment of “anemia of inflammation” [99]. Approximately 40% of critically ill individuals, 
including those with severe sepsis, receive at least one erythrocyte concentrate in the 
intensive care unit, with a mean of five concentrates per patient, equaling half of the total 
human blood volume. In these patients, erythrocyte transfusions are associated with 
increased morbidity and mortality [101]. Because anemia is a comorbid condition that is 
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associated with poor outcomes in various chronic disease states, understanding its 
pathogenesis is essential for the development of new remedies [99]. 
Next to changes in systemic iron homeostasis and defective erythropoiesis [99,100], also a 
reduced erythrocyte lifespan contributes to anemia of inflammation [102-104]. While iron 
homeostasis and defective erythropoiesis have been extensively studied in these conditions, 
erythrocyte survival has received little attention so far [99]. Phagocytic capacity is enhanced 
during inflammation [105], providing a possible explanation for enhanced erythrocyte 
clearance. Alternatively, the wide range of changes occurring in the circulation during 
systemic inflammation might impact erythrocyte characteristics directly. Indeed, alterations in 
erythrocyte shape, deformability, and aggregability were observed in patients with severe 
sepsis [106,107]. To date no mechanistic explanation has been provided for these changes.  
Erythrocyte membrane lipid remodeling in anemia of inflammation 
Membrane protein modification could not be causally linked to the altered erythrocyte 
rheology observed in patients with severe sepsis [108]. However, lipid metabolism is 
markedly altered during inflammation, as exemplified by enhanced lipase activity and by 
changes in lipid constituents in the plasma [109], and could thus affect erythrocyte 
membrane lipid composition. This hypothesis is supported by the finding that the incubation 
of erythrocytes from healthy volunteers with plasma of septic patients resulted in enhanced 
PS exposure and ceramide content [110]. Ceramide is a bioactive lipid involved in many 
cellular processes including apoptosis, senescence and inflammation [111,112], possibly 
associated with the tendency of signaling receptors to cluster in ceramide-enriched 
platforms. In addition, the formation of these platforms alters membrane curvature and 
decreases plasma membrane integrity [113,114]. Sphingomyelinases (SMases) are the 
principal enzymes for the generation of ceramide [115]. Since in a variety of diseases, 
including sepsis, inflammation triggers the secretion of acid SMase in the blood, this SMase 
is likely responsible for the ceramide formation in erythrocytes [110]. 
 
III - Microparticles 
Microparticles (MPs) were first described by Peter Wolf in 1967, when he observed a halo of 
debris surrounding activated platelets which he termed “platelet dust” [116]. They are 
defined as plasma membrane-derived vesicles with a diameter of 100 to 1000 nm that 
expose molecules specific to the parental cell [117-119]. The majority of the blood-borne 
MPs are generated by erythrocytes and platelets [119-121]. Depending on their origin, MPs 
may contain an array of signaling molecules, including receptors, cytokines and bioactive 
lipids, but also mRNA and microRNA. This molecular composition renders MPs vectors of 
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biological information. As such they play an active role in homeostasis and pathogenesis, 
the latter including atherosclerosis, various malignancies, autoimmune disorders, and 
infection [118,122]. 
Erythrocyte-derived microparticles 
During aging, the erythrocyte produces numerous vesicles, often termed red cell 
microparticles (RMPs), that expose PS and autoantigens, which are probably responsible for 
their rapid removal from the circulation [30,31,121,123]. Data from in vitro studies suggest 
that RMPs are likely to be actively involved in pathophysiology as well. For example, RMPs 
from erythrocyte storage units were found to modulate platelet function [124], and to be 
highly procoagulant [125,126]. RMPs can transfer biologically active molecules, exemplified 
by the transfer of CD59 from control erythrocytes to CD59-lacking erythrocytes of patients 
with paroxysmal nocturnal hemoglobinuria [127]. Furthermore, RMPs may contribute to the 
procoagulant state and vaso-occlusions in sickle cell disease [120,128]. RMPs from malaria-
infected erythrocytes were found to be major inducers of systemic inflammation during 
malaria infection [129,130].  
Platelet-derived microparticles 
In contrast to what the name implies, the majority of the ‘platelet-derived microparticles’ 
(PMPs) in the circulation are not derived from platelets, but from megakaryocytes [131,132]. 
PMPs are likely to be important mediators of coagulation, not only by exposing procoagulant 
factors [119,126,133], but also by providing a platform for the binding of additional platelets 
to the subendothelial matrix [119,134]. PMPs may be involved in various other processes, 
such as hemostasis, maintenance of vascular health, and immunity [135]. Prominent 
examples are the involvement of PMPs in vasoregeneration [136,137], and their assistance 
in leukocyte-leukocyte interaction via P-selectin binding to PSGL-1 [138]. A recent study 
showed that enhanced glycoprotein VI-mediated PMP generation leads to a PMP build-up in 
the joint fluid of patients suffering from inflammatory arthritis (but not osteoarthritis), inducing 
an inflammatory response via interleukin-1 signaling [139]. 
Microparticles in transfusion medicine 
Not only in vivo, but also in vitro during blood bank storage, erythrocytes and platelets shed 
MPs [30,140]. These MPs may be responsible for some of the side-effects commonly 
observed after transfusion [141-145]. RMPs from storage products are enriched in removal 
signals such as PS, immunoglobulins, and complement [30,145]. The supernatant of 
erythrocyte transfusion units, which contains many RMPs that were shed during storage, 
was found to have the ability to modulate the functions of T cells [142], neutrophils [146], 
macrophages [141], and monocytes [147] in vitro. Transfusion unit supernatants also caused 
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lung inflammation and coagulopathy in a rat model [148]. These findings strengthen the view 
that a high dose of RMPs may induce or augment the inflammatory and/or immunological 
side-effects of transfusion, including autoantibody formation [149]. 
Next to coagulation, platelets also have an important role as immune mediators [150,151], 
making PMPs likely candidates for immune regulation as well [144,152-154]. Side-effects of 
platelet transfusion include fever and acute lung injury [153], and enhanced PMP levels in 
platelet units correlated with various allergic transfusion reactions [152]. The ability of PMPs 
to interact with leukocytes [138,152], as well as their potential to induce CD40L-mediated B 
cell activation [155], underscore their ability to affect the immune system. The plethora of 
signaling molecules on PMPs makes it even more likely that they contribute to the 
transfusion burden [135,156]. While most circulating PMPs originate from megakaryocytes 
[131,132], P-selectin-positive PMPs from platelet transfusion units constitute an important 
part of the storage PMP burden, and likely have distinct biological activities [152,157].  
 
IV - The immune system 
Our immune system has evolved to defend the body against harmful pathogens. Immune 
responses are strictly regulated to allow rapid initiation of immune activity upon infection, and 
quick resolution of the response after elimination of the pathogen, in order to prevent tissue 
damage. In addition, the immune system must be kept in a resting state in normal situations 
to prevent harmful responses against the body’s own tissues and the commensal 
microorganisms. Parallel to immune surveillance, immune cells also provide essential 
support for tissue homeostasis and function [158].  
The immune response 
Tissue injury caused by pathogens and/or trauma triggers the local release of various 
soluble pro-inflammatory mediators, including chemokines and the cytokines IL-1 and TNF-α 
by specialized cells such as resident macrophages. IL-1 and TNF-α promote the expression 
of selectins and integrins by the local vascular endothelium, enabling the adhesion, arrest, 
and extravasation of leukocytes, which subsequently migrate along the chemokine gradient 
towards the inflamed tissue [159]. Platelets adhere to the exposed extracellular matrix and 
the inflamed endothelial cells, further activating the endothelium and adhering monocytes, 
and release additional pro-inflammatory factors including IL-1 [160,161]. At the site of tissue 
injury, neutrophils engulf pathogens and compromised cells, and subsequently release 
proteolytic enzymes and oxygen metabolites which digest the phagocytozed material [159]. 
Monocytes recruited to the inflamed tissue differentiate into different types of pro-
inflammatory macrophages. Next to their function in phagocytozing pathogens, dead cells 
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and cell debris, these macrophages are the primary orchestrators of tissue inflammation 
[162]. 
Within days, a specific response is mustered due to antigen presentation to T and B cells by 
antigen-presenting cells like macrophages and dendritic cells. CD4+ helper T (TH) cells 
support the further activation of other effector cells of the adaptive immune system including 
B cells and CD8+ cytotoxic T cells, through cell-cell interactions and the release of cytokines. 
The activated and differentiated B cells secrete antibodies that bind the antigen-exposing 
pathogen, assisting in their recognition by other effector cells. Activated cytotoxic T cells 
search for infected cells in the body that expose the antigen they are primed against, and kill 
these cells by disrupting their membrane and releasing an array of cytotoxins [156]. 
Immune cells regulate tissue homeostasis 
Initially, inflamed tissue is dominated by M1-polarized macrophages which promote further 
leukocyte influx and TH1-mediated and TH17-mediated inflammatory responses by producing 
IL-1, TNF-α, IL-12 and IL-23. Inflammation must be resolved in a timely manner to avoid 
unnecessary tissue damage. M2-polarized macrophages that do not secrete IL-12 , but 
instead produce anti-inflammatory factors such as IL-10, TGF-β, IL-1 decoy receptor and 
IL1-RA, gradually appear in the inflamed tissue to dampen the inflammatory process 
[162,163]. They further consolidate the resolution of inflammation by inducing regulatory T 
cell (Treg) differentiation [164], and by actively recruiting Tregs through the release of 
CCL22 [165]. 
Tregs that express the transcription factor Foxp3 play a critical role in maintaining immune 
homeostasis and dominant self-tolerance through a combination of cell-cell interactions, the 
release of soluble factors including the anti-inflammatory cytokines IL-10, TGF-β and IL-35, 
and the scavenging of the T cell survival factor IL-2 (Figure 4). The majority of the Foxp3+ 
Tregs are produced in the thymus as an antigen-primed and functionally mature T cell 
subpopulation (naturally-occurring Tregs), while some Tregs differentiate from naïve 
conventional T cells in the periphery (induced Tregs) [166,167]. Aside from their ability to 
suppress effector cell priming in lymphoid tissues [168-171], Tregs are also able to suppress 
myeloid populations and effector cells in other tissues [172]. Tregs have been shown to drive 
monocyte differentiation towards a M2-like macrophage phenotype, suggesting they 
consolidate the anti-inflammatory macrophage phenotype [173]. 
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FIGURE 4. Mechanisms potentially used by Tregs to assert tissue homeostasis in the steady state, 
during 'damage control' in inflamed tissue, and for infectious tolerance after resolution of inflammation. 
iTreg – induced Treg cell, TGF-βR – TGF-β receptor, nTreg – natural Treg cell, CO – carbon monoxide, IFN-γR – 
IFN-γ receptor (Tang et al. [174]) 
 
During the resolution of inflammation, TGF-β and other growth factors such as VEGF, FGF 
and PDGF, that are released by macrophages, platelets [175], Tregs [172,176] and various 
other cell types [175], promote angiogenesis, tissue regeneration and wound repair. 
Macrophages further regulate wound healing by phagocytozing debris, apoptotic neutrophils, 
and extracellular matrix (ECM) components that promote inflammation [177,178], and by 
releasing factors that control ECM turnover [179]. This macrophage-governed healing 
process is tightly regulated in order to restore homeostatic tissue architecture and function, 
while preventing fibrosis and scarring. 
In summary, the immune system sustains tissue homeostasis by disposing of invading 
pathogens and by supporting tissue repair and maintenance. 
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V - Scope of the thesis 
Physiological erythrocyte aging leads to membrane alterations ultimately responsible for 
their removal from the circulation. Similar membrane changes occur during erythrocyte blood 
banking, and could explain the high removal rate of part of the erythrocytes shortly after 
transfusion and the transfusion side effects. Furthermore, the changes in the erythrocyte 
membrane that occur during systemic inflammation might explain a reduced erythrocyte 
lifespan contributing to the development of anemia. In recent years, increased awareness of 
the importance of microparticles in homeostasis, various diseases and transfusion medicine, 
has stimulated research on their exact nature and function. The aim of this thesis is to 
provide more insight into the erythrocyte membrane changes that occur during storage and 
systemic inflammation, including vesiculation. In addition, we studied the potential impact of 
platelet-derived microparticles on the immune system. 
The potential formation of pathological antigens during erythrocyte storage was investigated 
in Chapter 2. Using patient plasma containing anti-erythrocyte autoantibodies, 
immunoprecipitations were performed with erythrocytes and MPs from concentrates of 
increasing storage periods. Antigen recognition by patient plasma autoantibodies was 
associated with storage time, and several membrane proteins could be identified as 
candidate antigens. The composition of the immune complexes recognized on the MPs was 
markedly different from those on the erythrocytes, indicating that their immunization potential 
differs from that of their parental cells. These data corroborate the theory that deregulation of 
the mechanisms governing erythrocyte aging contributes to transfusion-induced alloantibody 
and autoantibody formation. 
In Chapter 3, we assessed the potential of PS exposure as a parameter for donor-
dependent variation in product quality. PS exposure was determined just prior to, and during 
a 35-day storage period, and was found to correlate with common blood bank quality 
parameters and some donor characteristics. PS exposure increased with storage time, and 
correlated with hemolysis and MP concentration in the concentrate, and with the plasma 
hemoglobin concentration of the donor. Furthermore, the initial level of PS exposure was 
found to be predictive for PS exposure after osmotic stress. These findings support the use 
of PS exposure as a donor-dependent, biologically relevant parameter for erythrocyte 
transfusion unit quality. 
During systemic inflammation, as occurs in patients with severe sepsis, the lipid metabolism 
in the circulation is markedly altered, involving an enhanced activity of several lipases such 
as SMases. The functional consequences of these enzymes on erythrocyte structure and 
function were studied in detail in Chapter 4. We found erythrocytes to be very sensitive to 
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SMase-induced ceramide formation in the membrane. Ceramide build-up led to the loss of 
the discoid shape, followed by PS exposure and loss of cell integrity. In this process, 
markedly enhanced vesiculation and reduced deformability were also observed. 
Erythrocytes aged in vivo and in vitro were more sensitive to SMase-induced changes than 
younger erythrocytes. This study indicates that SMase has the potential to alter 
pathophysiologically relevant erythrocyte parameters, which is especially important in the 
context of erythrocyte transfusion in patients with prolonged systemic inflammation. 
Based on the results described in Chapter 4, we investigated sepsis-associated changes in 
the erythrocyte membrane lipid composition. In Chapter 5, we analyzed the plasma 
membrane lipid content of freshly isolated erythrocytes from healthy volunteers after 
incubation with the plasma of patients with septic shock. While ceramide could not be 
detected, we found markedly increased levels of lysophosphatidylcholine (LPC), which is 
produced by phospholipase A2. Although secretory phospholipase A2 IIA was greatly 
enhanced in the septic patient plasmas, its concentration did not correlate with the LPC 
levels. Enhanced LPC levels were not detected when erythrocytes were incubated with the 
plasma of healthy volunteers, in whom sepsis was simulated using a low dose of 
lipopolysaccharide. Interestingly, erythrocyte PS exposure increased in these subjects after 
lipopolysaccharide infusion. These data provide evidence for active remodeling, during 
sepsis, of the lipid compartment of the erythrocyte membrane, which is likely to affect 
erythrocyte survival. 
During the course of our studies we extensively studied cell-derived MPs from various 
sources. The isolation, analysis and quantification of these MPs is challenging due to their 
small and heterogeneous size. Based on our experience, we present our perspective on the 
do’s and don’ts regarding RMP and PMP isolation and characterization in Chapter 6. A 
novel regulatory function of PMPs on regulatory T cell stability is presented in Chapter 7. In 
this chapter we show that PMPs selectively bind to a specialized subset of Foxp3+ regulatory 
T cells, and that PMPs inhibit their differentiation into potentially pathogenic effector cells in a 
pro-inflammatory microenvironment. Our data indicate the direct involvement of the adhesion 
molecule P-selectin and thus suggest a role for PMPs in vascular healing by regulating the 
regulators at the sites of vascular insult. 
In Chapter 8, the findings reported in this manuscript are summarized and discussed, and 
future perspectives are outlined. 
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Abstract 
Physiological erythrocyte removal is associated with a selective increase in expression of 
neoantigens on erythrocytes and their vesicles, and subsequent autologous antibody binding 
and phagocytosis. Chronic erythrocyte transfusion often leads to immunization and the 
formation of alloantibodies and autoantibodies. We investigated whether erythrocyte storage 
leads to the increased expression of non-physiological antigens. Immunoprecipitations were 
performed with erythrocytes and vesicles from blood bank erythrocyte concentrates of 
increasing storage periods, using patient plasma containing erythrocyte autoantibodies. 
Immunoprecipitate composition was identified using proteomics. Patient plasma antibody 
binding increased with erythrocyte storage time, while the opposite was observed for healthy 
volunteer plasma, showing that pathology-associated antigenicity changes during 
erythrocyte storage. Several membrane proteins were identified as candidate antigens. The 
protein complexes that were precipitated by the patient antibodies in erythrocytes were 
different from the ones in the vesicles formed during erythrocyte storage, indicating that the 
storage-associated vesicles have a different immunization potential. Soluble immune 
mediators including complement factors were present in the patient plasma 
immunoprecipitates, but not in the allogeneic control immunoprecipitates. The results 
support the theory that disturbed erythrocyte aging during storage of erythrocyte 
concentrates contributes to transfusion-induced alloantibody and autoantibody formation. 
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Introduction  
Physiological, age-dependent removal of erythrocytes is an efficient and well-regulated 
process, consisting of controlled exposure of molecules that induce recognition of old 
erythrocytes by the immune system. This process includes senescent cell antigen formation 
on band 3, possibly in combination with phosphatidylserine (PS) exposure on the outer 
leaflet of the membrane and/or decreased CD47 expression, ultimately resulting in binding of 
autologous IgG and subsequent phagocytosis by macrophages of the reticulo-endothelial 
system [1]. During aging, the erythrocyte produces numerous vesicles, most of which 
expose PS, and that are enriched for IgG and age-related band 3 breakdown products. 
These vesicles are rapidly removed from the circulation, probably by the same mechanism 
that is responsible for erythrocyte removal. Vesiculation may constitute a protective 
mechanism to prevent untimely erythrocyte removal [2]. 
A clear picture of the molecular mechanisms involved in this age-dependent increase in 
removal signals is gradually emerging, and involves oxidative damage-induced, high-affinity 
binding of hemoglobin to band 3, activation of Ca2+-permeable channels, phosphorylation-
controlled loss of metabolism and structure, and degradation and/or aggregation of band 3 
fragments. However, the molecular details, triggers and cross-talk between these pathways 
are largely unknown [1]. 
Also, the erythrocyte contains a complex set of regulatory systems that may induce 
erythrocyte removal after physiological or pathological injury such as osmotic shock, 
oxidative stress and/or energy depletion [3]. Modulation of these pathways becomes 
progressively lost during storage [4,5], and this may result in accelerated aging and the 
removal of up to 30% of the transfused erythrocytes within 24 hours after transfusion [6]. 
Disruption of these systems may trigger aberrant expression of pathogenic epitopes on 
stored erythrocytes and their vesicles [7]. 
Frequent erythrocyte transfusions can lead to immunization and the formation of 
alloantibodies. This is especially problematic in the steadily increasing number of 
transfusion-dependent patients. Almost half of these patients acquire alloantibodies at some 
point in time, and in approximately 10% of the patients erythrocyte autoantibodies are 
detected. Part of the patients that produce these autoantibodies develop autoimmune 
hemolytic anemia (AIHA), which can be life-threatening [8]. 
We postulated that accelerated and/or altered erythrocyte aging during blood bank storage 
leads to the formation of non-physiological neoantigens that trigger the formation of 
autoantibodies. In order to test this hypothesis, we performed immunoprecipitations with 
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erythrocytes and vesicles from blood bank concentrates of increasing storage periods, using 
plasma from patients containing erythrocyte autoantibodies. Subsequently, immunochemical 
and proteomic techniques were applied to identify the captured immune complexes. Our 
findings strengthen and deepen the view that disturbed erythrocyte aging during storage is 
related to transfusion-induced, anti-erythrocyte antibody formation. 
 
Materials and Methods 
Ethics 
The study has been approved by the Committee on Research involving Human Subjects 
(CMO) of the Radboud University Medical Center (“Instituut Waarborging kwaliteit en 
veiligheid/ Commissie Mensgebonden onderzoek regio- Arnhem-Nijmegen”) and in 
accordance with the declaration of Helsinki. Written informed consent was obtained from all 
blood donors participating in this study. 
Patients and healthy volunteers 
Plasma samples from nine patients with a positive direct antiglobulin test (DAT) and 
confirmed erythrocyte autoantibodies were included in this study. Four patients were 
diagnosed with AIHA. One of these patients presented with AIHA after which a relapse acute 
myeloid leukemia was observed, while another was diagnosed with having both AIHA and 
anti-phospholipid syndrome. Two additional patients were diagnosed with immune 
thrombocytopenia and AIHA (Evans syndrome). Three patients with detectable erythrocyte 
autoantibodies without any clinical consequences were included as well (Table 1). The 
antibodies of one patient reacted with the erythrocyte Rhesus e-antigen on the patient’s 
autologous erythrocytes. In five patients anti-Wrighta (Wra) antibodies were detected, and in 
one patient additional anti-Cw antibodies were present. Cold reactive autoantibodies were 
not detected in any of the samples. Allogeneic plasma from healthy volunteer blood donors 
was used as a control. All plasma samples used in this study had been stored at -20°C 
before use. 
Isolation and storage of erythrocytes 
An erythrocyte concentrate was obtained using standard blood bank procedures, from a 
single eligible donor who was AB0, Rhesus, Wra and Cw compatible for the detected 
antibodies in the patient plasmas. Whole blood (500 ml) was collected in a Composelect 
quadruple CPD-SAGM top-and-bottom bag system (Fresenius Kabi, Bad Homburg, 
Germany), containing 70 ml CPD as an anticoagulant. After cooling and centrifugation, 
erythrocytes were isolated using a Compomat G4 (Fresenius Kabi, Bad Homburg, 
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Germany), after which 110 ml SAG-M was added to the erythrocytes. The erythrocyte 
suspension was leukocyte-depleted by in-line filtration, and subsequently stored at 2 to 6°C.  
Sampling of erythrocyte concentrates 
During a storage period of 35 days, this erythrocyte concentrate was sampled at regular 
intervals. After sampling, erythrocytes were isolated by 10 min centrifugation at 1500 g. At 
the time of blood collection, an additional EDTA tube of whole blood was collected for 
isolation of plasma and fresh erythrocytes using a Ficoll gradient. 
Isolation of erythrocyte vesicles 
Erythrocyte-derived vesicles were obtained from 35 day-old erythrocyte concentrates of two 
donors who were AB0, Rhesus and Wra compatible for the detected antibodies in the patient 
plasmas. The concentrates were centrifuged for 10 min at 1500 g to remove all cells. 
Membrane debris was then removed from the supernatant by centrifugation for 20 min at 
1500 g. Vesicles were isolated by centrifuging 1.4 ml aliquots of supernatant for 20 min at 
21,000 g. All but 25 µl of the supernatant was then removed, and the vesicle pellet was 
resuspended and stored at -80°C. 
Indirect immunoprecipitation of erythrocyte autoantigens 
Immunoprecipitation was performed using a modified version of the procedure described by 
Barker and colleagues [9]. Erythrocytes (1.5×109) were washed three times using incomplete 
Ringer (IR) solution (32 mM HEPES, 125 mM NaCl, 5 mM glucose, 5 mM KCl, 1 mM 
MgSO4, pH 7.4), before incubation for 1 h at 37°C with 500 µl plasma diluted 1/1 in IR. The 
sensitized erythrocytes were then washed three times with IR, and lysed by adding lysis 
buffer (10 mM HEPES, 1 mM EDTA, 1 mM EGTA, 1 mM benzamidin, 5 µM leupeptin, pH 
8.0). The erythrocyte membranes were pelleted by centrifugation at 21,000 g for 10 min and 
washed multiple times with lysis buffer to remove hemoglobin. The membranes were 
dissolved in 200 µl 1% TX-100 buffer (25 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1 mM benzamidin, 5 µM leupeptin, pH 7.4) or RIPA buffer (1% NP-40, 1% 
deoxycholate, 0.1% SDS, 25 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
benzamidin, 5 µM leupeptin, pH 7.4) for 30 min on ice with regular vortexing. Unless 
mentioned otherwise, the TX100 buffer was applied. Insoluble cytoskeletal components were 
removed by 15 min centrifugation at 21,000 g. The protein content of the supernatant was 
determined using the Bradford assay [10]. Supernatant (250 µl) containing 0.35 mg protein 
was incubated with 50 µl protein G Dynabeads (Invitrogen, Carlsbad, USA) for 16 h at 4°C to 
capture immune complexes. The beads were washed three times with 1% TX-100 buffer or 
RIPA buffer prior to, and directly after the incubation with the supernatant. Then the captured 
proteins were dissociated in 15 µl Laemmli sample buffer (BioRad, Hercules, USA) 
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containing 5% 2-mercaptoethanol for 30 min at 37°C. When non-denaturing conditions were 
applied, proteins were eluted using 50 mM glycine pH 2.8 for 5 min at room temperature, 
after which sample buffer was added (1/4 ratio) without 2-mercaptoethanol. Samples were 
stored at -80°C, and thawed on ice on the day of analysis. Immunoprecipitation of 
erythrocyte vesicles was performed using the same protocol without the lysis step, using a 
single vesicle aliquot per sample. Smaller (100 µl) incubation volumes were used for vesicle 
opsonisation, membrane dissolution and immune complex capture. Plasma was depleted of 
vesicles by centrifugation for 60 min at 21,000 g before being used to opsonize erythrocyte 
vesicles. Subsequent erythrocyte vesicle isolation and washing was performed by 
centrifugation for 20 min at 21,000 g. Direct anti-band 3 immunoprecipitation in vesicles was 
performed using protein G Dynabeads, opsonized with a mouse monoclonal antibody that 
recognizes an N-terminal epitope of band 3 (BIII-136, Sigma-Aldrich, St. Louis, USA),  
diluted 1:20 in 200 µl phosphate-buffered saline (PBS), pH 7.4. In the immunoprecipitation 
experiments we observed 25-30 and 50-60 kDa bands, representing the light and heavy 
chains of the bound antibodies, respectively. 
SDS-PAGE 
SDS-PAGE was performed using TGX 4-15% gels in the Mini Protean 3 system (both 
BioRad, Hercules, USA) [11]. Approximate molecular masses were calculated based on the 
Precision Plus Protein Standard (BioRad, Hercules, USA). Following SDS-PAGE (12.5 µl 
sample per lane), the gels were either used for immunoblotting, or developed using a silver 
stain [12]. Optical densities (OD) of the protein bands were determined using the GS 690 
imaging densitometer (Bio-Rad, Hercules, USA) in combination with Molecular Analyst 
version 1.5 software. Total erythrocyte membrane fractions were loaded as positive controls 
and for normalization purposes. 
Erythrocyte vesicle membrane protein biotinylation 
For immunoblotting, vesicle membrane proteins were biotinylated prior to IP. Vesicles were 
washed once with PBS pH 7.4, and labeled with 1 mM sulfo-NHS-biotin (Thermo Fisher, 
Waltham, USA) in PBS pH 8.0 for 30 min at 4°C. Residual sulfo-NHS-biotin was removed by 
two consecutive washing steps with PBS pH 7.4 containing 100 mM glycine. 
Immunoblotting 
After SDS-PAGE, the proteins were transferred to PVDF membranes using the iBlot system 
(Invitrogen, Carlsbad, USA). The membranes were then blocked with Odyssey Blocking 
Buffer (OBB, LI-COR, Lincoln, USA), and incubated for 16 h at 4°C in OBB containing 0.1% 
Tween-20 and 1/1000 rabbit polyclonal antiserum against the membrane domain of human 
band 3 (K2N6B/PMB3 [13]). After three washing steps with PBS containing 0.1% Tween-20, 
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the blots were incubated  for 1 h at room temperature in OBB, 0.1% Tween-20, 0.01% SDS, 
1/10,000 streptavidin-Alexa Fluor 680 (Invitrogen, Carlsbad, USA), and 1/10,000 goat anti-
rabbit IgG-IRDye 800 (LI-COR, Lincoln, USA). This final incubation was followed by a single 
washing step using PBS containing 0.1% Tween-20, and three subsequent washes with 
PBS. Immunoblots were scanned using the Odyssey Infrared Imaging System (LI-COR, 
Lincoln, USA), and analyzed using Odyssey Software version 2.1. 
Proteomics 
After one-dimensional gel electrophoresis and blue silver staining [14], protein bands of 
interest were excised and submitted to in-slice tryptic digestion. In case of total protein 
identification, the sample was run briefly into the gel, after which the entire product was 
excised and digested. Peptide sequencing of tryptic digests was performed by nano-liquid 
chromatography tandem mass spectrometry using the LTQ-FT ICR (Thermo Fisher, 
Waltham, USA) mass spectrometer essentially as described previously [15]. Peptide and 
protein identifications were extracted with the Mascot search engine version 2.2, using the 
Reference Sequence (RefSeq) database at the National Center for Biotechnical Information 
(NCBI) with Homo sapiens taxonomy and added sequence-tags. Carbamidomethylation of 
cysteines (fixed), oxidation of methionine (variable) and acetylation of the N-terminus 
(variable) were the modifications allowed in the search. Protein identification validation was 
performed by an in-house developed script [15]. The software classifies protein 
identifications based on the number of uniquely identified peptide sequences, clusters 
proteins sharing the same set of peptides, and validates the proteins with the following 
criteria: proteins with a single peptide must have a peptide score of >49, proteins with 
multiple peptides must have a score of >29. 
Statistical analysis 
Differences between the patient and allogeneic control group were determined using a two-
way ANOVA followed by a Bonferroni post-test. Differences within a single group were 
determined using a one-way ANOVA followed by a Tukey’s post-test. A confidence level of 
p<0.05 was considered to be significant. 
     
Results 
Altered epitope expression of erythrocytes during blood bank storage 
Storage lesions, possibly resulting in accelerated aging, are responsible for the fast removal 
of a considerable portion of the erythrocytes after transfusion. Both non-physiological aging 
and enhanced removal are likely to contribute to the antibody responses against 
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erythrocytes frequently observed in chronically transfused patients. In order to test the 
hypothesis that storage of erythrocytes under blood bank conditions leads to the formation of 
non-physiological neoantigens, a modified indirect immunoprecipitation was performed using 
plasma of six patients with erythrocyte autoantibodies (Table 1) or of healthy donors (see 
Materials and Methods), in combination with erythrocytes sampled at different time points 
from a stored erythrocyte unit. Immunoprecipitations were performed at regular intervals 
during blood bank storage. 
 
Table 1. Summary of patient information. 
Patient Clinical diagnosis Blood group DAT IAT Alloantibody Autoantibody  
1 AIHA (AML) 0 cc d ee IgG, C3 1:4 anti-Wra NS 
2 Evans syndrome 0 cc d ee IgG 1:8 - NS 
3 AIHA (APLS) AB CC D ee IgG, C3 1:1 anti-Wra NS 
4 - A CC D ee IgG 1:1 anti-Wra, -Cw NS, anti-e 
5 AIHA A Cc D Ee IgG, C3 1:1 anti-Wra NS 
6 AIHA A Cc D ee IgG 1:4 anti-Wra NS 
7 Evans syndrome 0 Cc D ee IgG 1:1 - NS 
8 - 0 Cc D ee IgG 1:1 - NS 
9 - 0 cc d ee IgG, C3 1:1 - NS 
DAT = direct antiglobulin test, IAT = indirect antiglobulin test (bovine) titer, AIHA = autoimmune hemolytic 
anemia, AML = acute myeloid leukemia, NS = non-specific, APLS = anti-phospholipid syndrome. All patients had 
a positive DAT and IAT. 
 
All plasmas tested precipitated proteins in the 90 to 100 kDa range (Figure 1). 
Immunoprecipitation using Ringer buffer instead of plasma did not result in any detectable 
protein precipitation (Figure 1A). Our data show that, although protein quantification of 
complex protein mixtures using silver staining can be problematic due to a limited dynamic 
range of the technique [16], silver staining proved to work well with the highly purified 
immunoprecipitates we obtained (Figure 1A). Both the patient and the allogeneic control 
plasmas showed a decrease in signal after the first week of erythrocyte storage. In contrast 
to the control samples that revealed a further significant decrease in signal with time, the 
signals derived from patient plasma significantly increased again with storage time (Figure 
1B). Immunoblot analysis of membrane fractions from erythrocytes of various storage 
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periods using patient and allogeneic control plasma resulted in high background signals 
and/or non-specific binding, probably due to the denaturing conditions of SDS-PAGE and 
blotting (data not shown). 
 
                             
Figure 1. Erythrocyte autoantibody immunoprecipitation of erythrocytes sampled at regular time intervals 
during storage. Analysis was performed by SDS-PAGE, followed by silver staining. (A) Protein patterns of 
precipitates obtained using Ringer, autologous plasma, and a representative example from one out of three 
allogeneic plasmas, and one out of six autoantibody-containing plasmas (patient No. 2). For the allogeneic 
controls, day 14 is missing. (B) Mean optical density (OD) of patient (●, solid line, N=6 patients) and allogeneic 
control plasma (▲, dotted line, N=3 volunteers) precipitations. Numbers indicate approximate molecular weight 
(kDa). Error bars represent standard error, *p<0.05. 
 
Freshly stored erythrocytes are recognized by naturally occurring antibodies [1]. At the later 
stages of storage, only autoantibodies present in the patient plasmas show enhanced 
binding to erythrocytes, suggesting a change in erythrocyte make-up upon storage that is 
only detectable with patient plasma. This change may be a trigger for pathological events. In 
order to determine the identity of the protein(s) involved, we proceeded to analyze the 
precipitated proteins by proteomics. 
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Figure 2. Erythrocyte autoantibody immunoprecipitation of stored erythrocytes. (A) Immunoprecipitation of 
35 day-old erythrocytes with erythrocyte autoantibody-containing patient plasma and allogeneic control plasma, 
using TX100 or RIPA extraction buffer and analyzed by SDS-PAGE under reducing or non-reducing conditions, 
followed by silver staining. A representative result (patient No. 2) from one out of three patient plasmas is shown. 
(B) Example of a silver stained gel of an immunoprecipitation of 35 day stored erythrocytes with plasma of patient 
No. 1. The same sample was used for Coomassie blue gel staining and subsequent proteomics analysis (Table 
2). Gel slices which were excised for proteomic analyses are indicated as slices I and II (see also Table S1). 
Numbers indicate molecular weight (kDa). Heavy [H] and light [L] antibody chains are indicated by arrows. 
 
Identity of the precipitated proteins 
In addition to the proteins in the 90 to 100 kDa range, immunoprecipitation of erythrocyte 
membrane fractions using patient plasmas revealed multiple other protein bands (Figure 
2A). Differential extraction experiments showed that the proteins in the 90 to 100 kDa range 
were directly targeted by the patient plasma, instead of being co-precipitated as was the 
case for several other proteins, such as the 80 kDa protein band, which dissociated from the 
immune complex under the more stringent conditions of the RIPA buffer (Figure 2A). 
Furthermore, SDS-PAGE under non-reducing conditions indicated that the precipitated 
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proteins mostly reside in one or more large complexes (Figure 2A). Heavy and light antibody 
chains (H and L in Figure 2A) are clearly visible due to the nature of the technique used. 
For proteomics analysis, an immunoprecipitation using patient plasma (patients 1, 8 and 9) 
and allogeneic plasma (control) was performed in triplicate on erythrocytes stored for 35 
days. A representative silver stained gel of one of these immunoprecipitations is depicted in 
Figure 2B. The total products of these immunoprecipitations were analyzed by mass 
spectrometry (Table 2). In addition, gel slices in the 80-100 and 70-80 kDa ranges (Figure 
2B, slices I and II, respectively) were excised from the immunoprecipitation product of the 
erythrocytes incubated with the plasma of patient 1 and analyzed by proteomics. 
In summary, the proteomic analysis revealed that erythrocyte autoantibodies from the patient 
plasma precipitate multiple proteins. The samples consisted of membrane as well as 
cytosolic proteins, all of which have been described in previous proteomic inventories of the 
erythrocyte membrane (Table 2) [17]. Furthermore they contained various plasma proteins, 
such as immunoglobulins, complement components, lipoproteins, and several 
immunoglobulins, and complement and coagulation-associated proteins. The protein 
composition of the samples from the different patient samples revealed significant overlap, 
although fewer proteins were detected in the samples of patients 8 and 9. This could be due 
to the lower titer of these plasmas (Table 1). Proteomic analysis of the allogeneic plasma 
control precipitation did not reveal any erythrocyte-related proteins. A complete list of all the 
proteins detected in the proteomics analysis is provided in Table S1. 
Finally, we attempted to elucidate the nature of the most dominant antigens. The proteomic 
analysis of gel slice I (Figure 2B) identified several proteins, including band 3 as the only 
membrane protein detected (Table S1). 
Erythrocyte autoantibodies recognize erythrocyte vesicles formed during blood banking 
During their stay in the circulation, erythrocytes form vesicles that are rapidly removed once 
they appear in the bloodstream. Vesiculation also occurs during blood banking, especially 
during the later stages of storage [18]. Since erythrocyte vesiculation in vivo may constitute a 
mechanism for the removal of damaged membrane patches, and these vesicles are 
efficiently opsonized [2,15], we investigated whether vesicles formed during blood bank 
storage were also recognized by patient anti-erythrocyte antibodies. 
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Table 2. Summary of proteins identified by proteomics analyses of erythrocyte/vesicle 
immunoprecipitations using erythrocyte autoantibody-containing plasma of patients 1, 8 and 9, and 
allogeneic plasma (control). 
Protein MW Erythrocyte Vesicle 
 (kDa) Control Patient 1 Patient 8 Patient 9 Patient 1 
Structural       
Band 3 95  + +  + 
Band 4.1 66  +  + + 
Band 4.2 80   + +  
Adducin 81  +  +  
Ankyrin 206     + 
Actin 42  + + + + 
Spectrin 246     + 
Metabolism       
GAPDH 36  +   + 
Glucose transporter 1 54  +   + 
Glutathione S-transferase 26  +    
Phosphofructokinase 85      
Type II PIP kinase 46     + 
Various       
α globin 15  +   + 
β globin 16  + + + + 
Annexin II 39     + 
Carbonic anhydrase I 29  +    
Carbonic anhydrase II 29  +   + 
HSP 70 70  +    
Stomatin 32  +   + 
Thioredoxin 12  +    
Thrombospondin 1 129     + 
Transglutaminase 3 77      
 
 
      
Ig heavy chain 50-60  +   + 
Ig light chain 25-30  +   + 
Complement       
CC 1 26   + + + 
CC 3 187  + + + + 
CC 4 193 + + + + + 
CC 5 188  + + + + 
CC 6 105    +  
CC 8 22    + + 
CC 9 63     + 
Factor B 90   + +  
Complement inhibitors       
C1 inhibitor    + +  
Clusterin 58  + + + + 
Factor H 155   + +  
Inter-α inhibitor 101-107  + + + + 
Vitronectin 54     + 
Lipoproteins       
Apolipoprotein A 31  + + + + 
Apolipoprotein B 516 + + + + + 
Apolipoprotein D 21     + 
Apolipoprotein E 
  
36 
 
 +  
 
+ 
 
+ 
Apolipoprotein L1 44     + 
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We performed immunoprecipitations using patient plasma and biotinylated erythrocyte 
vesicles isolated from 35 day-old erythrocyte concentrates (see Materials and Methods). 
These precipitates were then visualized by immunoblotting for biotinylated membrane 
proteins. In stored erythrocyte vesicles, multiple proteins were targeted by the patient anti-
erythrocyte antibodies, including the proteins in the 90 to 100 kDa range also observed in 
the erythrocyte precipitates (Figure 3A). 
    
Figure 3. Erythrocyte autoantibody immunoprecipitation of biotinylated erythrocyte vesicles from a 35 
day-old transfusion unit. (A) Immunoprecipitation with either plasma from patient No. 2, or a monoclonal 
antibody against band 3 (see Materials and Methods). Analysis was performed by SDS-PAGE, followed by 
detection of biotinylated membrane proteins (red, streptavidin) and band 3 (green, polyclonal rabbit antibody). A 
protein G bead control was included. (B) Example immunoprecipitation of biotinylated erythrocyte vesicles from a 
35 day-old transfusion unit using plasma from patient No. 1. Analysis was performed by SDS-PAGE, followed by 
detection of biotinylated membrane proteins using fluorochrome conjugated streptavidin. The same sample was 
used for Coomassie blue gel staining and subsequent proteomics analysis (Table 2). The gel slice which was 
excised for proteomic analysis is indicated as slice III (see also Table S1). Numbers indicate approximate 
molecular weight (kDa). Blots were analyzed using the Odyssey Infrared Imaging System. 
 
In order to identify the protein content of the targeted complex in these vesicles, an 
immunoprecipitation was performed in triplicate on vesicles obtained from a 35 day-old 
transfusion unit and analyzed by mass spectrometry (Table 2). An immunoblot of the 
immunoprecipitate is depicted in Figure 3B. In addition, we identified the proteins in a 240-
320 kDa gel slice from the immunoprecipitation (Figure 3B, slice III and Table S1). A 
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comparison of the erythrocyte to the vesicle precipitate shows a large overlap in their protein 
contents, including the presence of band 3. However, some clear differences were observed 
as well. Most notable are the absence of ankyrin and spectrin in the erythrocyte complex, 
and the absence of adducin in the vesicle complex (Table 2). In the vesicle 
immunoprecipitation, complement and lipoprotein peptides were much more abundant than 
in the erythrocyte immunoprecipitations (Table 2 and Table S1). 
Since band 3 was found to be part of the vesicle-derived precipitates, immunoprecipitations 
using either patient plasma or a monoclonal anti-band 3 antibody and biotinylated 
erythrocyte vesicles were performed as well (Figure 3A). These precipitates were then 
visualized by immunoblotting for biotinylated membrane proteins and band 3. The latter 
immunoprecipitation revealed a biotinylated protein pattern that is different from that 
obtained with the patient plasma, indicating that different proteins were targeted (Figure 3A). 
Although band 3 staining of the patient sample immunoblot using a polyclonal anti-band 3 
antiserum did not detect full-length band 3 (Figure 3A), several band 3 breakdown products 
that form during erythrocyte aging and storage were observed [1,15]. 
 
Discussion 
During storage under blood bank conditions, erythrocytes undergo a number of functional 
and structural alterations, known as storage lesions. An accelerated and/or disturbed cellular 
aging process is likely to trigger aberrant expression of removal signals, thereby contributing 
to the removal of up to 30% of the erythrocytes within the first 24 hours after transfusion. 
This may contribute to the immunologic responses associated especially with chronic 
transfusions [1,8]. 
Here we show that the main targets of the erythrocyte autoantibody-containing patient 
plasmas tested in this study are proteins in the 90 to 100 kDa range, which proteomic 
analysis revealed to include the membrane protein band 3. Band 3 is known to form three 
distinct complexes with other membrane and cytosolic proteins, and is the membrane 
anchorage site for the erythrocyte cytoskeleton [19]. Proteomic analysis showed that the 
band 3 binding partners adducin, ankyrin, band 4.1, band 4.2, GAPDH, hemoglobin and 
carbonic anhydrase were part of the precipitated immune complex, which suggests that 
band 3 complexes were indeed recognized. Although other candidate antigens cannot be 
completely ruled out, the observation that band 3 is the only membrane protein detected in 
the immunoprecipitates, makes it the most likely candidate antigen. Band 3 likely contains 
epitopes that trigger the harmful immune response leading to the formation of these 
erythrocyte autoantibodies [20]. This is underscored by the ability of a band 3 peptide to 
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prime T cells for a band 3 response and accelerates the development of erythrocyte 
autoantibodies and anemia in a mouse model for AIHA [21]. 
Our data reveal that autologous and allogeneic plasma predominantly reacted with fresh and 
short stored erythrocytes, possibly by the binding of naturally occurring anti-band 3 
antibodies [1]. In contrast, patient plasma autoantibody binding increased during erythrocyte 
storage, which suggests that non-physiological antigens become expressed during blood 
bank storage. One explanation for the enhanced autoantibody binding could be storage 
lesion-induced expression of erythrocyte aging-associated antigens [1,4,5]. 
Notably, previous work on erythrocyte autoantibodies, showed these antibodies to be 
specific for either band 3 or Rhesus protein [9,20]. The apparent absence of Rhesus proteins 
in our analyses is probably due to the exclusion of patient plasma that showed (partial) 
specificity toward Rhesus antigens. The presence of alloantibodies against Wra, an epitope 
located on band 3 [22], in five of the nine patients also hints at specificity for band 3 rather 
than Rhesus protein. 
A remarkable observation was the precipitation of adaptor protein 2 (AP2) complex by the 
patient plasma (Table S1), as this protein is responsible for membrane attachment of, and 
membrane protein recruitment to clathrin-coated vesicles [23]. AP2 might be a remnant from 
the reticulocyte stage that binds to one or more proteins in the precipitated complex. Band 3 
has been shown to interact with clathrin-coated vesicle machinery in kidney cells, which 
supports this possibility [24]. 
Although erythrocyte-derived vesicles formed during storage are known to be enriched in 
immunoglobulins [15,25], we here show that anti-erythrocyte autoantibodies readily 
recognized the vesicles as well. The vesicle precipitates contained spectrin and ankyrin, 
while the erythrocyte precipitates did not. The opposite was observed for adducin, which was 
present only in the erythrocyte precipitates. Ankyrin and adducin are known to reside in two 
functionally different complexes in the erythrocyte membrane, the ankyrin complex and the 
junctional complex [19]. An explanation for our observations may be the selective 
erythrocyte autoantibody binding of the band 3 - ankyrin complex in vesicles, compared to 
the selective targeting of the junctional complex in erythrocytes. The differences in protein 
composition between erythrocytes and their vesicles could also account for the absence of 
adducin in the vesicle precipitates [2,15,18]. The strikingly high complement content and 
apparent presence of autoantigens in the patient plasma vesicle precipitates indicate that 
these vesicles may be involved in clinically relevant immune responses. 
 
Chapter 2 
42 
The possibility of selective recognition of damaged or degraded band 3 in the vesicles was 
also investigated by comparing the patient plasma immunoprecipitation to that of a 
monoclonal anti-band 3 antibody. Patient erythrocyte autoantibodies appear to recognize a 
subset of the band 3 complexes in the vesicles, as there was only a partial overlap in the 
membrane proteins that were precipitated. This fits with the known selective binding of 
physiological autoantibodies to damaged band 3 [1,4]. The presence of damage-associated 
proteins (e.g. HSP70, 26S proteasome and transglutaminases) and band 3 degradation 
products in the complex precipitated using patient plasma supports this view (Table S1, and 
Figure 3, respectively) [26,27]. 
Intriguingly, vesicle-associated spectrin was biotinylated using the membrane-impermeable 
sulfo-NHS-biotin (Table S1, and Figure 3C). One possible explanation is the diffusion of the 
sulfo-NHS-biotin into damaged vesicles via membrane pores [25]. Alternatively, the 
presence of inside-out oriented membrane vesicles could explain the presence of 
biotinylated spectrin [28]. The latter implies that, after erythrocyte transfusion, intracellular 
epitopes become accessible to the immune system [29], a process generally known to be 
involved in the onset of autoimmune disorders [30]. 
The alternative erythrocyte autoantibody targeting in these vesicles, combined with the 
enhanced complement binding, support the notion that erythrocyte-derived vesicles might be 
important players in the inflammatory side-effects encountered during and after chronic 
erythrocyte transfusion [8,31]. This is in line with the increasing amount of evidence showing 
that vesicles of different cellular origins are actively involved in inflammation [32-34]. Also, 
vesicle-containing supernatants from erythrocyte concentrates were found to have immune 
regulatory functions [35,36]. 
Taken together, we have demonstrated a change in pathology-associated erythrocyte 
antigenicity during blood bank storage, which is accompanied with enhanced patient 
erythrocyte autoantibody binding. These changes probably include storage-related band 3 
breakdown, as described in previous studies [1,4]. The composition of the immune complex 
targeted in the vesicles was different from that of stored erythrocytes, implying that the 
vesicles might have a different capacity to modulate the immune system. 
These findings corroborate the hypothesis that prolonged storage increases the transfusion-
associated risks [37], in particular the formation of anti-erythrocyte alloantibodies and 
autoantibodies by transfusion-dependent patients. We aim to elucidate the molecular identity 
of the involved epitopes, the mechanism(s) underlying these changes, and their 
pathophysiological implications. 
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Table S1. Proteins identified by proteomics analyses of erythrocyte/vesicle immunoprecipitations using 
erythrocyte autoantibody-containing plasma of patients 1, 8 and 9, and allogeneic plasma (control). 
Numbers represent the identified peptide sequences per protein. Either total products or gel slices containing 
proteins of a certain MW (kDa) were analyzed. Proteins in specific gel slices were also identified (slices I and II: 
Figure 2B, slice III: Figure 3B). Skin and trypsin contaminants were excluded from this overview. 
Immunoprecipitations and proteomics analyses were performed as mentioned in Materials and Methods. 
Protein Erythrocyte Vesicle 
  Control Patient 1 Patient 8 Patient 9 Slice I Slice II Patient 1 Slice III 
Actin 0 1 3 3 2 0 1 0 
Adaptor-related protein complex 2, alpha 1 subunit 0 0 0 0 6 1 0 0 
Adaptor-related protein complex 2, beta 1 subunit 0 0 0 0 7 1 0 0 
Adducin 2 0 5 0 2 1 0 0 0 
Afamin 0 0 2 0 0 0 0 0 
Aldehyde dehydrogenase 16 family, member A1 0 0 0 0 0 2 0 0 
Alpha globin 0 5 0 0 0 1 2 3 
Alpha-1-antichymotrypsin 0 0 7 7 0 0 0 0 
Alpha-1-microglobulin/bikunin 0 0 0 2 0 0 0 0 
Alpha-2-HS-glycoprotein 0 0 2 2 0 0 0 0 
Alpha-2-macroglobulin  0 0 13 15 0 0 1 0 
Angiotensinogen 1 0 2 3 0 0 0 0 
Ankyrin 1 0 0 0 0 0 0 1 0 
Annexin A2 isoform 2 0 0 0 0 0 0 1 0 
Antithrombin III 0 0 5 5 0 0 0 0 
Apolipoprotein A 0 2 7 6 0 0 1 0 
Apolipoprotein B 2 35 22 33 0 0 63 2 
Apolipoprotein D 0 0 0 0 0 0 1 0 
Apolipoprotein E 0 3 0 4 0 0 8 0 
Apolipoprotein H 0 0 3 2 0 0 0 0 
Apolipoprotein L1 0 0 0 0 0 0 2 0 
Arginase, type I 0 0 0 0 0 0 0 0 
Band 3 (solute carrier family 4, anion exchanger, 
  
0 6 3 0 5 3 2 0 
Beta globin 0 9 3 1 4 3 6 4 
Biliverdin reductase B (flavin reductase (NADPH)) 0 1 0 0 0 0 0 0 
Carbonic anhydrase I 0 2 0 0 0 1 0 0 
Carbonic anhydrase II 0 1 0 0 0 0 1 0 
Ceruloplasmin  2 0 8 9 0 0 2 0 
Clusterin 0 4 3 3 0 0 4 0 
Complement C1s subcomponent 0 0 2 2 0 0 0 0 
Complement C6 0 0 0 1 0 0 0 0 
Complement component 1, q subcomponent, B chain 0 0 1 2 0 0 2 0 
Complement component 1, q subcomponent, C chain 0 0 2 2 0 0 3 2 
Complement component 3  0 12 3 2 0 2 20 0 
Complement component 4  5 1 16 17 0 0 4 0 
Complement component 5  0 4 3 4 0 0 24 0 
Complement component 8, gamma polypeptide 0 0 0 1 0 0 1 0 
Complement component 9 0 0 2 2 0 0 6 0 
Complement factor B 0 0 3 2 0 0 0 0 
Complement factor H isoform a 0 0 5 4 0 0 0 0 
Corticotropin releasing hormone  0 3 0 0 2 1 2 2 
Cyclin M2 0 1 0 0 2 2 2 3 
Erythrocyte membrane protein band 4.1 0 1 0 4 1 11 5 0 
Erythrocyte membrane protein band 4.2 0 0 1 1 0 0 0 0 
Eukaryotic translation initiation factor 2C, 2 0 0 0 0 7 4 0 0 
Eukaryotic translation initiation factor 4A 0 0 0 0 0 1 0 0 
Fibrinogen alpha chain 0 0 2 4 0 0 0 0 
Fibrinogen beta chain 0 0 4 2 0 0 0 0 
Fibrinogen gamma chain 0 0 5 4 0 0 0 0 
Fibronectin 1 0 0 1 1 0 0 2 3 
Glutathione S-transferase 0 1 0 0 0 0 0 1 
Glyceraldehyde-3-phosphate dehydrogenase 0 1 0 0 1 0 1 0 
Heat shock 70kDa protein 0 1 0 0 0 0 0 0 
Hemopexin 0 0 6 4 0 0 0 0 
Heparin cofactor II  0 0 2 2 0 0 3 0 
Histidine-rich glycoprotein  0 0 3 2 0 0 2 0 
Ig heavy chain 0 3 0 0 3 3 2 0 
Ig heavy chain 0 3 0 0 3 2 1 0 
Ig heavy chain 0 1 0 0 2 2 0 0 
Ig heavy chain 0 1 0 0 1 1 1 0 
Ig heavy chain 0 0 0 0 1 1 0 0 
Ig light chain 0 1 0 0 0 1 1 0 
Ig light chain 0 1 0 0 0 1 1 0 
Ig light chain 0 1 0 0 1 1 1 0 
Ig light chain 0 1 0 0 1 1 1 0 
Insulin-like growth factor-binding protein complex acid 
  
0 0 0 2 0 0 0 0 
Inter-alpha (globulin) inhibitor H1 0 0 5 4 0 0 4 2 
Inter-alpha (globulin) inhibitor H2 0 2 4 3 0 0 5 1 
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Inter-alpha (globulin) inhibitor H4 0 1 7 6 0 0 4 0 
Kininogen-1 isoform 2 0 0 6 4 0 0 0 0 
Leucine-rich alpha-2-glycoprotein 0 0 0 3 0 0 0 0 
Lipocalin 1  0 0 0 0 0 0 1 0 
Lipopolysaccharide-binding protein  0 0 0 0 0 0 2 0 
Liver phosphofructokinase 0 0 0 0 0 5 0 0 
Lysozyme  0 0 2 0 0 0 1 0 
Neuroblastoma RAS viral (v-ras) oncogene homolog 0 0 0 0 0 0 1 0 
Peptidylprolyl isomerase B  0 0 0 0 0 0 0 0 
Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 0 0 0 0 0 0 1 0 
Plasma protease C1 inhibitor 0 0 3 2 0 0 0 0 
Plasminogen 0 0 2 0 0 0 0 0 
Prolactin-induced protein 0 0 0 0 0 0 1 0 
Proteasome 26S non-ATPase subunit 2 0 0 0 0 2 0 0 0 
Prothrombin 0 0 5 3 0 0 0 0 
Serine (or cysteine) proteinase inhibitor, clade A, member 
  
0 0 0 0 0 0 1 0 
Serine (or cysteine) proteinase inhibitor, clade A, member 
 
0 0 0 0 0 0 1 0 
Serine (or cysteine) proteinase inhibitor, clade B, member 
 
0 0 0 0 0 0 0 0 
Serine (or cysteine) proteinase inhibitor, clade B, member 
 
0 0 0 0 1 0 0 0 
Serotransferrin 0 0 4 3 0 0 0 0 
Serpin peptidase inhibitor, clade A, member 3  0 0 0 0 0 0 1 0 
Serum albumin 0 0 4 0 0 0 0 0 
Serum amyloid P-component 0 0 2 3 0 0 0 0 
Solute carrier family 2 (facilitated glucose transporter), 
  
0 1 0 0 1 2 1 0 
Sorting nexin 9 0 0 0 0 0 1 0 0 
Spectrin beta 0 0 0 0 0 0 1 2 
Stomatin isoform a 0 2 0 0 0 0 10 0 
Thioredoxin 0 1 0 0 0 0 0 0 
Thrombospondin 1  0 0 0 0 0 0 2 0 
Thyroxine-binding globulin 0 0 2 1 0 0 0 0 
Transglutaminase 2 isoform a 0 0 0 0 0 2 0 0 
Transglutaminase 3  0 0 0 0 0 0 0 0 
Transmembrane protein 24 0 1 0 0 1 0 0 0 
Ubiquitin and ribosomal protein 0 1 0 0 1 1 1 1 
Urocortin  0 0 0 0 0 0 1 2 
Vitronectin  0 0 0 0 0 0 2 0 
Von Willebrand factor  0 0 0 0 0 0 4 0 
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Abstract 
Background. Exposure of phosphatidylserine (PS) on the outside of the red blood cell (RBC) 
contributes to recognition and removal of old and damaged cells. The fraction of PS-
exposing RBCs varies between donors, and increases in RBC concentrates during storage. 
Also, the susceptibility of RBCs to stress-induced PS exposure increases with storage. 
Therefore, PS exposure may constitute a link between donor variation and the quality of 
RBC concentrates. 
Materials and methods. In order to examine the relationship between storage parameters 
and donor characteristics, the percentage of PS-exposing RBCs was measured in RBC 
concentrates during storage and in fresh RBCs from blood bank donors. The percentage of 
PS-exposing RBCs was compared with RBC susceptibility to osmotic stress-induced PS 
exposure in vitro, with the regular RBC concentrate quality parameters, and with the donor 
characteristics age, BMI, haemoglobin level, gender and blood group. 
Results. PS exposure varies between donors, both on RBCs freshly isolated from the blood, 
and on RBCs in RBC concentrates. PS exposure increases with storage time, and is 
correlated with stress-induced PS exposure. Increased PS exposure during storage was 
found to be associated with haemolysis and vesicle concentration in RBC concentrates. The 
percentage of PS-exposing RBCs showed a positive correlation with the plasma 
haemoglobin concentration of the donor. 
Discussion. The fraction of PS-exposing RBCs is a parameter of RBC integrity in RBC 
concentrates and may be an indicator of RBC survival after transfusion. Measurement of PS 
exposure may be useful in the selection of donors and RBC concentrates for specific patient 
groups.  
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Introduction 
During storage in the blood bank, RBCs undergo a number of structural and biochemical 
changes, the storage lesions [1]. Some of these changes, such as a decrease in intracellular 
adenosine-5'-triphosphate (ATP), are parameters of the current RBC concentrate quality 
control system. This control system includes a 24 hour-survival of at least 75% of the 
transfused RBCs [2]. The decrease in ATP concentration is readily reversible [2], but the 
effects of the storage lesions on the capacity to deform - and thereby to deliver oxygen to the 
tissues - are hardly known [3,4]. Also, the relationship between the storage lesions and the 
development of side effects such as inflammatory immune reactions and iron accumulation 
is not clear.  
Externalized PS is a sensitive marker for fast recognition and removal of RBCs by the 
reticulo-endothelial system, as suggested by the currently available data on RBC aging in 
vivo and in vitro, on the response of RBCs to various stress treatments in vitro, and on RBCs 
in pathological conditions [5-8]. The number of PS-exposing RBCs increases with storage in 
the blood bank [6,7]. We have shown that storage is also accompanied by an increase in PS 
exposure upon hyperosmotic stress [7]. These data suggest a storage-associated lowering 
of the threshold for activation of the pathways that induce PS exposure. Various pathways 
have been proposed [6-8], but their activity and especially their response to extracellular 
stimuli after transfusion in vivo remain to be elucidated. The fraction of PS-exposing RBCs 
after near-physiological stress of stored RBCs is similar to the fraction of RBCs that 
disappears shortly after transfusion [7,9]. This suggests that control of PS exposure may be 
a determinant of RBC survival in the first 24 hours after transfusion. 
Therefore, we examined whether the degree of initial PS exposure in the donor blood is 
associated with PS exposure in the RBC concentrate and/or predictive for its susceptibility to 
stress-induced PS exposure. Our findings indicate that RBC concentrate production itself 
affects PS exposure, that initial PS exposure is correlated with RBC susceptibility to osmotic 
stress-induced PS exposure, and that PS exposure is associated with some quality control 
parameters of RBC concentrates.  
 
Materials and methods 
Donor characteristics 
A population of 97 frequent blood bank whole blood donors participated in this study (Table 
1). RBCs from an initial group of 37 donors were used to examine PS exposure before 
processing and after 6 days of storage. Fresh RBCs from an additional 37 donors were 
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included to examine PS exposure with and without the application of osmotic stress (N=74). 
Fresh RBCs from an additional 23 donors were used to determine whether the donor 
characteristics correlated with PS exposure (N=97). Fresh RBCs and RBC concentrates 
from 12 donors were used to examine PS exposure during blood bank storage. The study 
was performed following the guidelines of the local medical ethical committee and in 
accordance with the declaration of Helsinki. Written informed consent was obtained from all 
blood donors participating in this study. 
 
Table 1.  Summary of donor characteristics. 
parameter characteristics 
gender 66% male, 34% female 
rhesus D 80% positive, 20% negative 
AB0 46% O, 41% A, 13% B  
age (years) 48.9 ± 12.9 
length (cm) 176.8 ± 7.9 
weight (kg) 82.2 ± 15.1 
body mass index 26.2 ± 4.1 
haemoglobin (mmol/L) 9.2 ± 0.8 
Mean and standard deviation are given for age, length, weight, body mass index and haemoglobin (normal 
haemoglobin ranges are 8.6-11.2 for men, and 7.5-9.4 mmol/L for women). 
 
RBC isolation 
Fresh RBCs were isolated from five ml whole blood (EDTA) as described before [7]. RBC 
concentrates were collected and processed according to standard Dutch blood bank 
protocols in the regional blood bank Sanquin Blood Bank South East Region, Nijmegen, The 
Netherlands [7,9,10]. Samples of two to five ml were taken aseptically from the concentrates, 
and RBCs were washed to remove medium, plasma and vesicles using Ringer’s solution 
(NaCl 125 mM, KCl 5 mM, MgSO4 1 mM, CaCl2 2.5 mM, glucose 5 mM, HEPES/NaOH 32 
mM, pH 7.4) by repeated centrifugation (5 min, 1500g, 4oC). All experiments were performed 
in Ringer’s solution. Where indicated, osmotic stress was induced by adding 400 mM 
sucrose aseptically and incubation overnight at 37oC and 5% CO2 [7]. 
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PS measurement 
The percentage of PS-exposing RBCs was determined as described previously [7]. RBCs 
were incubated for one hour at room temperature in the dark with Ringer containing 0.2% 
bovine serum albumin (BSA), annexin V FLUOS (1:25, Roche, Basel, Switzerland) to detect 
PS, and with PE-conjugated anti-CD235a antibody (1:100, mouse IgG1, clone KC16, 
Beckman Coulter, Brea CA, USA). Flow cytometry was performed using an Epics XL-CML 
flow cytometer (Beckman Coulter, Brea CA, USA), and the data were analysed with CXP 
Analysis software version 2.2 (Beckman Coulter, Brea CA, USA). Only CD235a-positive 
events (100,000) in the RBC size range were gated for further analysis. The intra-assay 
variation in the number of Annexin V-positive RBC was ≤0.05% before and ≤0.1% after 
stress treatment. A combined anti-CD41-PC5 (1:10, BioLegend, San Diego, CA, USA) and 
anti-CD235a-PE (1:100, Beckman Coulter, Fullerton, CA, USA) antibody staining revealed 
the virtual absence of platelets and high RBC purity (>99.9%) of the samples that were 
tested. 
Vesicle isolation and quantification 
All buffers used for vesicle isolation and analysis were complemented with 0.2% BSA and 
filtered (0.22 µm) before use. Samples from RBC concentrates were centrifuged (20 min at 
1500g) twice to remove cells and cell debris. Vesicles were pelleted from the supernatant (1 
ml) by centrifugation at 21,000g for 20 minutes. The vesicle pellet was resuspended in 10 µl 
supernatant and stored at -80oC until analysis. Frozen vesicles were thawed on ice and 
washed with Ringer without calcium. Vesicles were labelled for flow cytometry analysis by 
incubation in Ringer with annexin V FLUOS (1:50, Roche, Basel, Switzerland) to detect PS, 
and with PE-conjugated anti-CD235a antibody (1:200, mouse IgG1, clone KC16, Beckman 
Coulter, Brea CA, USA) for 30 min at 4oC in the dark. After this incubation, vesicles were 
washed once by centrifugation, resuspended in Ringer, and washed Flow-Count 
Fluorospheres (Beckman Coulter, Brea CA, USA) were added (1×104) for quantification. 
Annexin V/CD235a-double-positive vesicles were quantitated using a FACsCalibur flow 
cytometer (BD Biosciences, Franklin Lakes NJ, USA) in combination with CXP Analysis 
software version 2.2 (Beckman Coulter, Brea CA, USA). Sulphate latex microspheres 
(Invitrogen, Carlsbad CA, USA; 0.9 µm) were used to determine the maximum upper 
boundary allowed for forward and sideward scatter gating. All staining solutions were 
centrifuged at 21,000g and 4ºC for 20 min prior to use to remove fluorescent aggregates. 
PE-conjugated IgG1 isotype control (Dako, Glostrup, Denmark) did not show any aspecific 
binding. 
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Quality parameters 
The blood bank quality parameters extracellular haemoglobin, pH, mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin 
concentration (MCHC), ATP and 2,3-DPG were measured as described before [7,11,12]. 
Statistical analysis 
Differences before and after whole blood processing and stress were tested with a Mann-
Whitney U test. Differences between multiple groups were assessed with a one-way ANOVA 
in combination with Tukey’s post-test. Pearson’s correlation coefficients were computed to 
measure bivariate correlations. The reported p values are two-sided, and a p value of < 0.05 
was used to assess statistical significance. 
 
Results 
Donor variation in PS exposure before and after RBC concentrate production 
As a first step to examine a putative correlation between donor characteristics and RBC 
concentrate quality, we determined whether there is donor variation in the percentage of PS-
exposing RBCs, both in freshly drawn blood before RBC concentrate production and during 
the first week of storage. A large donor variation in the amount of PS-exposing RBC was 
observed in both fresh and short stored RBC concentrates (Figure 1A). There was a small 
but statistically significant increase in the number of PS-exposing RBCs during blood bank 
processing and/or occurring within the first week of storage (Figure 1A). Osmotic stress 
induced a strong increase in the number of PS-exposing RBCs, with similar donor variation 
(Figure 1B) in the fresh RBCs and in RBCs that had been stored for one week under blood 
bank conditions. After a short storage period, RBCs were more susceptible to osmotic stress 
than fresh RBCs (Figure 1B). The latter data are in accordance with previous observations 
showing an increase in susceptibility with storage time [7]. 
PS exposure in the RBC concentrates predicts susceptibility to stress 
Since PS exposure increases with RBC storage [6,7], and is involved in the recognition and 
removal of damaged cells [5,13], stress-induced PS exposure might be involved in the 
removal of up to 30% of the transfused RBCs that is known to occur within the first hours 
after transfusion [9]. Therefore, we examined whether there is a relationship between initial 
PS exposure of RBCs and their susceptibility to osmotic stress-induced PS exposure. We 
observed a strong positive correlation between PS exposure before and after stress (Figure 
1C), showing that the percentage of PS-exposing RBCs may serve as a marker for the 
susceptibility of the entire RBC population. 
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Figure 1. Exposure of PS by RBCs before and after the first week of storage in the presence or absence 
of osmotic stress. RBCs were collected from freshly drawn blood (fresh) and from six day-old RBC 
concentrates (stored) obtained from the same donor. Using flow cytometry, the percentage of PS-exposing RBCs 
(RBC (%)) was determined before (A, *P = 0.04) and after (B, *P = 0.001) osmotic stress. Results are expressed 
as the mean ± SD (N=37). The correlation between PS exposure of fresh RBCs before and after osmotic stress 
(C) had a Pearson coefficient of 0.64 (N=74). 
 
                    
Figure 2. PS exposure during storage of RBCs under blood bank conditions. Blood was drawn from twelve 
donors, RBCs were collected from the RBC concentrates at the indicated times, and analysed for the percentage 
of PS-exposing RBCs (RBC (%)) by flow cytometry. *P = <0.0001. 
 
Relation of PS exposure with RBC concentrate quality parameters and vesiculation 
The variation in PS exposure between donors, together with the correlation with stress-
induced PS exposure, raised the question if PS exposure is related to any of the regular 
quality parameters of RBC concentrates. Therefore, the percentage of PS-exposing RBCs, 
as well as extracellular haemoglobin, pH, MCV, MCH, MCHC, ATP and 2,3-DPG of twelve 
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RBC concentrates were followed in time. In six of the twelve units tested, the percentage of 
PS-exposing RBCs started to increase in the fourth week of storage (Figure 2). In the fifth 
week, an additional three RBC concentrates showed an increased percentage of PS-
exposing RBCs. Variation in PS exposure between donors became more apparent from 
week four onwards (Figure 2). The rise in the percentage of PS-exposing RBCs ran parallel 
with a decrease in ATP, 2,3-DPG, and pH, and increases in MCV and haemolysis, 
confirming previous data [11,12]. However, only the degree of haemolysis showed a positive 
correlation with the percentage of PS-exposing RBCs at multiple time points during storage 
(data not shown). Furthermore, both the percentage of PS-exposing RBCs and the degree of 
haemolysis showed a positive correlation with the number of RBC vesicles in the 35 day-old 
concentrate (Figure 3). 
 
Figure 3. Correlation of RBC PS exposure and haemolysis with vesicle content in transfusion 
concentrates. After 35 days of storage, haemolysis was measured, and the percentage of PS-exposing RBCs 
was determined by flow cytometry detection of annexin V binding. The number of PS+CD235a+ vesicles was 
determined per mL transfusion concentrate supernatant as described in Materials and Methods. (A) Vesicle 
characteristics and quantification. (B) The correlation between vesicle number and PS exposure (RBC (%); 
Pearson coefficient of 0.64, N=12). (C) The correlation between vesicle number and haemolysis (Pearson 
coefficient of 0.67, N=12). 
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Relation of PS exposure with donor parameters 
Since the percentage of PS-exposing RBCs varies between RBC concentrates from various 
donors (Figure 1), we investigated whether it would be possible to identify donors with high 
or low PS exposure by readily available donor parameters (Table 1). In the 97 donors 
examined, the numbers of PS-exposing RBCs in freshly drawn donor blood, i.e. before blood 
bank processing, did not differ significantly between gender, age, BMI, and ABO or Rhesus 
D blood groups. There was a weak positive correlation between PS exposure with the 
haemoglobin concentration of the donor plasma (Pearson coefficient 0.21), but not with the 
other parameters (data not shown). 
 
Discussion 
Stored RBCs are less resistant to hypo-osmotic and mechanical stress-induced haemolysis 
than fresh RBCs [14]. The positive correlation we observed between PS exposure and 
haemolysis suggests that PS exposure is an indicator for RBC integrity during storage in 
blood bank conditions. Indeed, time lapse microscopy data show that PS exposure precedes 
lysis when exposed to various stressors [15]. The small, but significant difference we 
observed in PS exposure between freshly isolated RBCs and RBCs sampled from the RBC 
concentrates within the first week after processing the RBCs, suggests that processing of 
the blood before storage induces membrane restructuring. In addition, the correlation 
between the percentage of PS-exposing RBCs and vesicle concentration in RBC 
concentrates is compatible with the hypothesis that the changes in membrane organization 
that lead to the appearance of PS in the outer layer of the cell membrane, also lead to the 
generation of vesicles [12]. Our data suggest that concentrates from donors with higher 
initial numbers of PS-exposing RBCs may be less effective upon transfusion, due to 
enhanced susceptibility to physiological stress in the circulation and subsequent removal. 
We propose to test PS exposure as a novel quality parameter of RBC concentrates, since 
the conventional parameters do not accurately predict RBC survival after transfusion [16]. 
Of the donor parameters that we examined, only the haemoglobin concentration showed a 
correlation with RBC PS exposure. Therefore, it might be worth investigating whether other 
donor parameters might be predictive for PS exposure. Recent findings indicate that donor 
differences in PS exposure may reflect variation in iron status and hormonal factors [17,18]. 
Accumulation of HbA1c and other modified haemoglobin species in RBC-derived vesicles 
[19] suggests a functional relationship between haemoglobin composition and RBC structure 
in healthy donors. Thus, the recently described donor variation in the rate of haemoglobin 
glycation [20] may contribute to the variation from concentrate to concentrate. This leads to 
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our prediction that in donors, HbA1c content is positively correlated to both a decrease in 
RBC life span and PS-exposure. Indeed, the percentage of PS-exposing RBCs in individuals 
with type 2 diabetes mellitus is twice that of control subjects [21]. Similarly, the increased 
susceptibility to mechanical stress of RBC in post-menopausal women [18] may very well 
correlate with the number of PS-exposing RBCs. 
In conclusion, the correlations between PS exposure, donor characteristics and RBC 
concentrate quality parameters indicate that PS exposure may be a biologically relevant 
parameter of RBC quality. These results emphasize the need for the elucidation of the 
mechanisms that stimulate PS exposure on RBCs in vivo. Such knowledge could lead to the 
development of methods to improve RBC survival during storage and after transfusion, and 
could enable the selection of RBC concentrates - and even donors - for specific patient 
groups. It has been suggested that RBC concentrates with high haemoglobin content may 
be selected for patients with the largest blood volume [22]. Similarly, it may be feasible to 
select concentrates with the lowest PS exposure for chronically transfused and/or critically ill 
patients, or remove the RBCs that are susceptible to stress-induced PS exposure from the 
RBC concentrate. This would be of benefit especially for chronically transfused patients, as a 
reduction in the number of rapidly removed RBCs will lead to enhanced transfusion efficacy 
and a significant reduction in the rate of iron accumulation and pathological activation of the 
immune system. 
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Abstract 
Inflammation enhances the secretion of sphingomyelinases. Sphingomyelinases catalyze 
the hydrolysis of sphingomyelin into phosphocholine and ceramide. In erythrocytes, 
ceramide formation leads to exposure of the removal signal phosphatidylserine, creating a 
potential link between sphingomyelinase activity and anemia of inflammation. Therefore, we 
studied the effects of sphingomyelinase on various pathophysiologically relevant parameters 
of erythrocyte homeostasis. Time-lapse confocal microscopy revealed a sphingomyelinase-
induced transition from the discoid to a spherical shape, followed by phosphatidylserine 
exposure, and finally loss of cytoplasmic content. Also, sphingomyelinase treatment resulted 
in ceramide-associated alterations in membrane-cytoskeleton interactions and membrane 
organization, including microdomain formation. Furthermore, we observed increases in 
membrane fragility, vesiculation and invagination, and large protein clusters. These changes 
were associated with enhanced erythrocyte retention in a spleen-mimicking model. 
Erythrocyte storage under blood bank conditions and during physiological aging increased 
the sensitivity to sphingomyelinase. A low sphingomyelinase activity already induced 
morphological and structural changes, demonstrating the potential of sphingomyelinase to 
disturb erythrocyte homeostasis. Our analyses provide a comprehensive picture in which 
ceramide-induced changes in membrane microdomain organization disrupt the membrane-
cytoskeleton interaction and membrane integrity, leading to vesiculation, reduced 
deformability, and finally loss of erythrocyte content. Understanding these processes is 
highly relevant for understanding anemia during chronic inflammation, especially in critically 
ill patients receiving blood transfusions. 
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Introduction  
During their stay in the circulation for approximately 120 days, erythrocytes undergo age-
related changes involving senescent cell antigen formation, cell shrinkage, vesiculation, and 
loss of deformability. The binding of autologous IgG and exposure of recognition molecules, 
possibly including phosphatidylserine (PS), ultimately lead to recognition of senescent 
erythrocytes by macrophages of the reticulo-endothelial system [1]. Also, the deformability of 
the erythrocyte constitutes an important survival parameter, as splenic sequestration of 
abnormal erythrocytes with reduced deformability leads to a decreased erythrocyte lifespan 
and anemia in several erythrocyte membranopathies [2]. 
Chronic inflammation as occurring in various pathological conditions is associated with 
anemia and poor disease outcome [3]. This inflammation-driven anemia is especially 
troublesome in patients with severe sepsis. Furthermore, blood transfusions to counter 
sepsis-induced anemia only have a limited beneficial effect, and may lead to severe 
complications [4]. Reduced erythrocyte production can only partly explain the low erythrocyte 
count. Enhanced erythrocyte clearance is likely to contribute to the anemia, but its causes 
are largely unknown [5]. Therefore, understanding the underlying mechanisms of anemia of 
inflammation is of critical importance. 
Inflammation triggers the secretion of acid sphingomyelinase (SMase), which is involved in 
various pathologies, including diabetes, sepsis, cardiovascular and pulmonary diseases [6]. 
SMases catalyze the hydrolysis of sphingomyelin (SM), a major lipid component of cell 
membranes, into phosphocholine and ceramide [7]. Ceramide functions as a lipid second 
messenger in many cellular processes including apoptosis, senescence and inflammation, 
which is partially explained by the tendency of signaling receptors to cluster in ceramide-
enriched platforms [8,9]. Also, the formation of these rigid platforms alters membrane 
curvature and decreases plasma membrane integrity [7,10]. 
Although erythrocytes do not possess SMase activity of their own [11], and SMases have not 
been reported as part of the erythrocyte proteome [12], erythrocytes can be exposed to 
SMase secreted by vascular endothelium, leukocytes and platelets [6]. SMase treatment of, 
and direct ceramide incorporation into erythrocytes induces PS exposure [13-15]. Also, 
erythrocytes expose PS and ceramide after incubation with SMase-containing plasma of 
patients suffering from sepsis or Wilson’s disease [16,17]. So far however, only PS exposure 
and size have been studied. Pathophysiologically relevant molecular processes on the 
membrane and protein level and their association with functionally relevant parameters have 
not been addressed as yet. 
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In the current study we comprehensively addressed the changes that erythrocytes undergo 
with respect to morphology, deformability, membrane lipid organization and protein-protein 
interactions upon exposure to SMase. Time-lapse microscopy revealed that SMase-driven 
PS exposure precedes loss of membrane integrity. We also demonstrate a clear erythrocyte 
age-related increase in sensitivity to SMase, both in erythrocytes from freshly drawn blood 
and from blood bank units. Next to PS exposure as a critical removal signal, enhanced 
vesiculation, that is associated with several erythrocyte-associated pathologies [18], was 
observed. These findings reveal SMase-induced ceramide formation as a critical event in 
erythrocyte membrane reorganization on both the lipid and protein level, and provide a 
possible explanation for the reduced effectiveness and harmful side-effects of erythrocyte 
transfusion in patients with sepsis. 
 
Results 
SMase alters erythrocyte morphology and increases PS exposure 
Secretion of SMase is enhanced during inflammation and involved in the pathophysiology of 
various diseases [6]. Since SMase-induced ceramide formation changes membrane lipid 
organization, enhanced SMase activity could also affect erythrocyte physiology including 
deformability and exposure of removal signals such as PS, thereby explaining excessive 
erythrocyte clearance in anemia of inflammation. This hypothesis is supported by the 
observation that plasma of septic patients induced ceramide formation and PS exposure on 
the erythrocyte membrane [16]. 
In order to determine the sensitivity of erythrocytes to SMase, erythrocytes were incubated 
with ascending activities of SMase and analyzed by flow cytometry. Bacterial SMase was 
used as a valid surrogate for acid and neutral SMase encountered by erythrocytes in vivo 
[19]. Cytoplasmic proteins were labeled by incubation with membrane-permeable 
carboxyfluorescein diacetate succinimidyl ester (CFSE diacetate). In this way, a potential 
loss of membrane integrity was detectable through loss of fluorescence from the cytoplasm. 
Erythrocyte size, as reflected by forward scatter, significantly decreased already at 1 mU/mL, 
with a further reduction in size and a high increase in PS exposure at activities of 10 mU/mL 
and higher (Figure 1 A-C). Also, the asymmetric shape of the forward-versus-sideward 
scatter plot of the erythrocyte population was lost upon treatment, suggesting that the cell 
shape was affected (Figure 1A). The sideward scatter increased, which is indicative of the 
degree of cell granularity. In the absence of extracellular calcium during 10 and 100 mU/mL 
SMase treatment PS exposure was not induced (0.92% and 0.72% respectively), suggesting 
the involvement of a calcium-activated scramblase in this process [20]. 
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Figure 1 – Erythrocyte shape and PS exposure during SMase treatment. (A-C), Flow cytometry of 
erythrocytes treated with increasing activities of SMase for 15 min at 37ºC. Annexin V-FLUOS staining was 
performed to determine the percentage of phosphatidylserine (PS)-exposing erythrocytes. (A), Forward and 
sideward scatter (FSC and SSC, respectively) density plots are presented. (B and C) The graphs represent mean 
values of three healthy volunteers; error bars represent standard deviation; * p < 0.05. (D), Time-lapse confocal 
laser scanning microscopy of CFSE-labeled erythrocytes treated with 10 mU/mL SMase at 37ºC in the presence 
of Annexin V-Alexa 647. Confocal laser scanning microscopy was used to image fluorescence as described in 
Materials and Methods. Scale bar = 5 µm. A typical result from one of three experiments is presented. 
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While the flow cytometry analyses provided information on the erythrocyte population at a 
fixed time point, time-lapse confocal laser scanning microscopy revealed a characteristic 
sequence of events upon SMase treatment: first, erythrocytes lost their discoid shape, which 
was followed by a gradual increase in the percentage of PS-exposing cells (Figure 1D and 
supplemental Movie S1). Subsequently, some erythrocytes lost their cellular content, as 
indicated by the loss of the CFSE-signal. After 45 min of SMase treatment, a considerable 
part of the cells had an irregular membrane surface, as observed by bright-field microscopy 
(supplemental Figure S1). Intriguingly, most of these cells showed high-intensity CFSE spots 
which co-localized with the membrane irregularities (supplemental Figure S1). These 
clusters are most likely large protein clusters, since CFSE covalently binds to proteins. 
Furthermore, only a few of the irregularly shaped cells exposed PS, as compared to the 
spherical cells with a smooth surface and high PS exposure (supplemental Figure S1 and 
Movie S1). 
SMase specifically hydrolyzes SM in erythrocytes 
In order to confirm enzyme specificity and to estimate the extent of SM breakdown and 
ceramide formation, lipid analyses were performed on the membrane fractions of 
erythrocytes treated with various SMase activities. 
Consistent with the expected activity of SMase, positive-ion matrix-assisted laser desorption 
and ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) revealed the presence of 
ceramide and absence of SM in membrane lipid fractions of 10 and 100 mU/mL SMase-
treated erythrocytes (Figure 2A). In controls and 1 mU/mL-treated cells, no ceramide was 
detected. Apparently, at 1 mU/mL the extent of ceramide formation was below the detection 
limit of this method. Alternatively, the small amount of ceramide might have been 
suppressed by more abundant lipids, such as phosphatidylcholines [21]. We were not able to 
detect ceramide subsequent to analysis by combined thin-layer chromatography/MALDI as 
previously described [22]. However, after 1 and 5 mU/mL SMase treatment the percentage 
of cells with ceramide-enriched platforms was increased, as detected by 
immunofluorescence (see below). This is a strong indication that the amount of the 
generated ceramide at 1 mU/mL SMase is beyond the detection limit of mass spectrometry. 
31P nuclear magnetic resonance (NMR) spectroscopy confirmed the nearly complete 
disappearance of SM after 100 mU/mL SMase treatment of erythrocytes, while the major 
membrane phospholipids phosphatidylethanolamine (PE), phosphatidylcholine (PC) and 
phosphatidylserine (PS) were not affected (Figure 2B). Thus, the used enzyme preparation 
specifically hydrolyzed SM in the erythrocyte plasma membrane. 
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Figure 2 – Erythrocyte membrane lipid analyses after SMase treatment. Erythrocytes were treated with 
SMase for 1 h at 37ºC. (A), Positive-ion MALDI-TOF MS of isolated membrane lipids. All samples were 1:1 (v/v) 
diluted with the matrix (0.5 M 2,5-dihydroxybenzoic acid in methanol). All peaks are labeled based on their m/z 
ratios and matrix cluster ions are marked by an asterisk. (B), 31P NMR spectra of membrane lipid extracts. All 
samples were investigated in the presence of 200 mM sodium cholate in order to suppress the aggregation of 
phospholipids. Abbreviations – Cer, ceramide; SM, sphingomyelin; PE, phosphatidylethanolamine, PC, 
phosphatidylcholine; PS, phosphatidylserine. 
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Figure 3 – SMase-induced erythrocyte morphology, membrane lipid rafts and intracellular invaginations. 
SMase treatment of erythrocytes was performed for 15 min at 37ºC. (A), Electron microscopy of control and 
SMase-treated erythrocytes as described in Materials and Methods. (B), Erythrocytes stained with an anti-CD59 
antibody. (C), Quantification of CD59 cluster-positive erythrocytes. The graph presents mean values (N=2), error 
bars represent standard deviation. 200 cells were scored by eye per experiment. (D), Acrolein-fixed erythrocytes 
stained with anti-stomatin (green) and anti-band 3 (red) antibodies. (E), Z-stack of an anti-stomatin-stained, 
tubulated, erythrocyte after treatment with 10 mU/mL SMase. A Z-slice spacing of 0.25 µm was used. (F), Flow 
cytometry and confocal microscopy of erythrocytes treated with 5 mU/mL SMase, stained with anti-ceramide or 
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isotype control antibody. Confocal laser scanning microscopy was used to image fluorescence as described in 
Materials and Methods. Bright-field images are shown in combination with fluorescence images. Signal intensity 
in B and E; low = blue, intermediate = red, high = yellow/white. Scale bar = 5 µm. Representative images from 
one of two experiments are shown in all cases. 
 
SMase-induced erythrocyte membrane reorganization 
The changes in erythrocyte morphology, PS externalization, and ceramide formation, 
suggest that SMase induces major membrane reorganization. This reorganization was 
studied in more detail using electron microscopy and confocal laser scanning microscopy. 
Consistent with our observations by confocal microscopy, electron microscopy also showed 
a SMase treatment-induced loss of the typical biconcave shape (Figure 3A). A striking 
finding was the presence of structures resembling intracellular membrane vesicles, or 
endovesicles, in the SMase-treated erythrocytes. In most cells these structures were 
confined to one side of the cell in one large cluster.  
We also investigated the presence of microdomains in SMase-treated erythrocytes [23]. In 
untreated erythrocytes, the glycosyl phosphatidylinositol-anchored microdomain marker 
CD59 [24], was distributed evenly over the erythrocyte membrane (Figure 3B). SMase 
treatment at activities of 1 mU/mL and higher induced CD59 clusters that co-localized with 
the membrane irregularities observed in the bright-field images (Figure 3B). 
SMase-treated erythrocytes were also stained for stomatin, which is anchored at the 
cytoplasmic side of the membrane and is associated with lipid rafts in erythrocytes [25]. The 
findings with stomatin were similar to those obtained with CD59, although many additional 
small clusters were observed upon SMase treatment (Figure 3D). Moreover, a combined 
staining for stomatin and band 3, which is an abundant erythrocyte membrane protein 
involved, among others, in linking the plasma membrane to the cytoskeleton, revealed the 
presence of tubular plasma membrane invaginations in cross-sections of a subpopulation of 
the SMase-treated erythrocytes (Figure 3D, right-most images and Figure 3E) [26]. The 
tubular invaginations also co-localized with membrane irregularities seen in bright-field. A 
three-dimensional reconstruction and animation showing these invaginations is provided in 
the supplemental data (supplemental Movies S2 and S3). 
Finally, anti-ceramide antibody staining revealed the presence of ceramide-enriched 
platforms on SMase-treated erythrocytes (Figure 3F). It is worth to note that following 
acrolein fixation 7 to 8 times more positive events were detected (after correction for isotype 
control) than following paraformaldehyde fixation.  
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Figure 4 – SMase-induced vesiculation of erythrocytes. Erythrocytes were allowed to vesiculate in the 
presence or absence of 10 mU/mL SMase for 1 h at 37ºC. The vesicles were analyzed by flow cytometry. (A), 
Density plots of forward/sideward scatter (FSC and SSC, respectively), and Annexin V-FLUOS 
(phosphatidylserine (PS))/anti-CD235a-PE staining of plasma-derived vesicles and vesicles generated in vitro. 
Vesicles were gated according to FSC/SSC for fluorescence analysis. (B), PS and CD235a mean fluorescence 
intensity (MFI), and forward scatter of plasma-derived and in vitro CD235a+ vesicles. (C), Quantification of 
CD235a+ vesicles after erythrocyte vesiculation in the absence or presence of SMase. Fluorescent 10 µm 
counting beads were used as an internal standard. (D), Bottom left and center: Density plots of CFSE-loaded 
erythrocytes treated with SMase and stained with anti-CD235a-PE. The vesicles generated during the treatment 
of these cells were stained with anti-CD235a-PE and Annexin V-Alexa 647. Bottom right: Vesicles that were 
within the standard FSC/SSC vesicle range and that were positive for Annexin V are shown in the CFSE/CD235a 
density plot. For the assessment of dimensions, only PS+CD235a+ vesicles were considered. Data from five 
healthy volunteers are presented. The graphs present mean values, error bars represent standard deviation, and 
* = p < 0.05. 
 
The recognition of ceramide on only a subpopulation of the cells after 5 mU/mL SMase 
treatment, and the high dependence of antibody binding on the fixative used, suggest that 
the specificity and activity of this antibody is strongly affected by membrane organization. 
Next, we investigated whether SMase-induced membrane reorganization also affected the 
interaction between the plasma membrane and the cytoskeleton. Differential membrane 
protein extraction showed that the insoluble fraction of band 3 increased upon SMase 
treatment (supplemental Figure S2). In contrast, the extractability of β-actin with detergent 
increased upon SMase treatment. These changes implicate that, in addition to the 
membrane microdomain organization at the protein and lipid levels, also the cytoskeletal 
integrity and the interaction between plasma membrane and cytoskeleton are altered by 
SMase. 
SMase enhances erythrocyte vesicle formation 
During aging, the erythrocyte produces numerous vesicles that expose removal signals 
including PS, that are enriched in damaged membrane patches, and that are rapidly 
removed from the circulation. Physiologically, erythrocyte vesiculation may constitute a 
protective mechanism to prevent untimely erythrocyte removal [27]. Increased erythrocyte 
vesicle numbers were observed in several inflammation-associated diseases, including 
chronic renal failure, sickle cell disease and β-thalassemia [18]. Therefore, we investigated 
whether erythrocyte vesiculation rate and vesicle composition are affected by SMase 
treatment. 
Erythrocytes were allowed to vesiculate in vitro in the presence or absence of SMase. The 
vesicles generated in vitro and the plasma vesicles from the corresponding healthy 
volunteers were assessed for PS exposure and the presence of the erythrocyte-specific 
marker glycophorin A (CD235a). Erythrocyte-derived plasma vesicles, control vesicles 
 
Chapter 4 
 
72 
generated in vitro, and vesicles from SMase-treated erythrocytes all exposed PS and 
expressed CD235a (Figure 4A). Plasma vesicles and control vesicles formed a single 
population with a comparable, high PS exposure and CD235a expression. An additional 
population with clearly reduced PS exposure and CD235a expression was observed in the 
SMase-induced vesicles (Figure 4A and B). In contrast, glycophorin C expression was found 
to be identical in all conditions (data not shown). Based on the forward scatter, all 
PS+CD235a+ vesicles had similar dimensions (Figure 4B). In addition to these qualitative 
differences between control and SMase-induced vesicles erythrocyte, vesiculation was 
enhanced more than 20-fold when the cells were exposed to SMase (Figure 4C). This 
heterogeneity in PS exposure and CD235a expression indicates that SMase-induced 
vesiculation differs qualitatively from vesiculation in the absence of SMase. Finally, CFSE-
loaded erythrocytes generated CFSE-positive vesicles during SMase treatment (Figure 4D), 
showing that these vesicles contain cytoplasmic content of the parent cells. 
Loss of osmotic responsiveness in erythrocytes treated with SMase  
Following the analysis of the impact of SMase treatment on the structural organization of 
erythrocytes, we were interested in potential functional implications of SMase exposure. In 
the circulation, erythrocytes are constantly exposed to changing osmolalities, in particular 
when passing through the kidneys, and osmotic stress is known to induce PS exposure [28]. 
In order to study the effect of SMase on the osmotic responsiveness and fragility of 
erythrocytes, SMase-treated erythrocytes were exposed to different osmolalities and 
analyzed by flow cytometry.  
When erythrocytes were treated with SMase activities of 1 mU/mL and higher, a population 
could be discerned with a low sideward scatter that was not seen in control erythrocytes 
(Figure 5). These populations had a nearly identical CFSE content and forward scatter, 
indicating that they had intact membranes and were of comparable size. When exposed to a 
hypertonic or hypotonic buffer, the SMase-treated erythrocytes with a normal sideward 
scatter and the control erythrocytes shrank and swelled, respectively (Figure 5). In contrast, 
the size of the additional population in the SMase-treated erythrocytes did not change upon 
incubation with these buffers, indicating a loss of osmotic responsiveness. When 
erythrocytes were treated with higher (≥10 mU/mL) SMase activities and subsequently 
incubated in hypotonic buffer, nearly all cells, including this additional population, were lysed, 
showing a SMase-induced increase in membrane fragility (Figure 5). 
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Figure 5 – Osmotic responsiveness and fragility of SMase-treated erythrocytes. CFSE-labeled erythrocytes 
from three healthy volunteers were treated with increasing activities of SMase for 15 min at 37ºC, and 
subsequently incubated with hypotonic, isotonic, and hypertonic buffer for 15 min at room temperature. The cells 
were analyzed by flow cytometry. A forward/sideward scatter (FSC and SSC, respectively) density plot of SMase-
treated erythrocytes is shown in the upper-right. A FSC/CFSE density plot of erythrocyte subpopulation A is 
shown in the upper-left. Forward scatter of subpopulations A and B are depicted in the bottom graphs. 
Populations of < 2500 cells are not shown in the graphs. The graphs present mean values, error bars represent 
standard deviation, and * p < 0.05.  
 
SMase enhances erythrocyte retention in a spleen-mimicking model 
Sequestration of poorly deformable erythrocytes by the spleen is known to be critically 
involved in the decreased erythrocyte lifespan and anemia in several erythrocyte disorders 
[2]. The observed changes in erythrocyte morphology, ceramide formation, and membrane 
organization upon SMase treatment, likely also affect erythrocyte deformability. In order to 
determine whether SMase treatment affected deformability and splenic retention, we used a 
bead sorting device that mimics the mechanical deformation that erythrocytes experience in 
the spleen. 
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Erythrocytes were treated with SMase for 15 min at 37°C, labeled with CFSE and perfused 
through the spleen-mimicking model. Treatment with SMase induced a decrease in the 
permeation of the model spleen, concomitant with an increase in the retention (Figure 6). As 
before, SMase treatment reduced erythrocyte size, as reflected by forward scatter (Figure 6). 
 
 
 
Figure 6 – Perfusion of SMase-treated erythrocytes through a spleen-mimicking device. A suspension 
consisting of approximately 5% CFSE-labeled erythrocytes treated with SMase for 15 min at 37°C and 95% 
untreated/unlabeled erythrocytes was passed through a bead sorting device at a flow rate of 60 mL/h (see 
Materials and Methods). Flow cytometry was used to determine the percentage of labeled cells in the initial 
upstream compartment, the bead compartment, and the downstream fractions. Forward scatter (FSC) is 
presented as a measure for erythrocyte diameter. Representative data from one of two experiments are shown. 
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Age and storage of erythrocytes increase their sensitivity to SMase 
Erythrocytes become more sensitive to stressors such as energy depletion and 
hyperosmotic conditions with age and storage time [28-30]. Since SMase plasma levels 
increase during inflammation, and critically ill patients often receive erythrocyte transfusions, 
the sensitivity of stored erythrocytes for SMase-induced changes in cell size and PS 
exposure were studied by flow cytometry. 
Erythrocytes from six healthy donors were obtained immediately after donation, and after 14 
and 35 days of storage under blood bank conditions. After incubation with 1 mU/mL SMase 
for 15 min at 37°C, we observed a much more pronounced size reduction and increase in 
PS exposure for 35 day stored erythrocytes, compared to fresh and 14 day stored cells 
(Figure 7A). 
 
 
Figure 7 – SMase-induced size change and PS exposure in stored and aged erythrocytes. Flow cytometry 
of erythrocytes treated with SMase. Annexin V-FLUOS staining was performed to determine the percentage of 
phosphatidylserine (PS)-exposing erythrocytes. Forward scatter is presented as a measure of erythrocyte 
diameter. (A), Fresh, 14 and 35 days stored erythrocytes from six healthy donors treated with 1 mU/mL SMase 
for 15 min at 37ºC. (B), Erythrocytes of various mean age obtained from a 27 year-old male donor by combined 
density and volumetric separation (see Materials and Methods), treated with 1 and 10 mU/mL SMase for 15 min 
at 37ºC. t, total erythrocyte product. Erythrocyte fractions 1 and 5 have the lowest and highest mean age, 
respectively. The graphs present mean values, error bars represent standard deviation, and * = p < 0.05. 
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As erythrocyte age might also affect the response to SMase-induced ceramide formation in 
the plasma membrane, a combination of volume and density separation was used to obtain 
well-defined erythrocyte populations of different mean age. These were treated with 1 and 
10 mU/mL SMase, and showed an age-dependent increase in the sensitivity for SMase-
induced PS exposure (Figure 7B).  
 
Discussion 
The chronic inflammation that arises in patients with various diseases, including sepsis, can 
induce anemia, which is associated with poor disease outcome [3]. Inflammation enhances 
SMase secretion, and ceramide formation and PS exposure were observed when 
erythrocytes were incubated with plasma from septic patients ex vivo [16]. PS exposure is a 
marker for cellular stress and contributes to erythrocyte removal [31]. So far, studies 
concerning SMase activity on erythrocytes focused on membrane lipid rearrangement and 
shape changes [13,32]. In this study we show that ceramide-induced membrane lipid 
rearrangement affects multiple processes that are critical for erythrocyte function and 
removal, including protein-protein interactions, membrane stability and vesiculation. 
Furthermore, we directly correlated these molecular changes to parameters relating to 
erythrocyte function in vivo by addressing sensitivity to osmotic stress, permeation through a 
spleen-mimicking device, and dependence on erythrocyte age. 
In agreement with earlier findings [13], we observed a reduction in cell size and increase in 
the percentage of PS-exposing erythrocytes upon SMase treatment of erythrocytes. Our 
time-lapse confocal microscopy experiments revealed that the transition of their typical 
discoid to a spherical shape preceded PS exposure, which was followed by disintegration 
and loss of cytoplasmic content. The combination of shape change and enhanced 
vesiculation explain the reduction in size observed by flow cytometry and confocal 
microscopy after SMase treatment.  
Anchorage of the plasma membrane to the cytoskeleton maintains the discoid shape and 
membrane stability of the erythrocyte, as several erythrocyte disorders that affect membrane 
anchorage to the cytoskeleton induce abnormal cell shape and enhanced hemolysis [2]. 
Similar to the observations in pathological erythrocytes, our analyses using differential 
membrane protein extraction demonstrated that this anchorage is also affected by SMase. 
This may be mediated by protein phosphorylation, which is known to regulate protein-protein 
interactions in the erythrocyte [33]. Furthermore, membrane lipid interaction with cytoskeletal 
proteins might be affected by SMase-induced membrane reorganization [34]. 
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An intriguing finding was the presence of large CFSE-positive protein clusters that appeared 
in conjunction with the detected membrane irregularities. As CFSE aspecifically reacts with 
the intracellular proteins - of which >95% is hemoglobin - the observed high-intensity CFSE 
signals are most likely hemoglobin clusters. This hemoglobin clustering is probably the 
indirect result of the effect of SMase on the conformation of band 3, which has a high affinity 
binding site for hemoglobin in its cytoplasmic domain [26].   
As shown by high-resolution, immunofluorescence microscopy analysis of CD59 and 
stomatin localization, SMase treatment not only led to morphological changes, but also to a 
reorganization of membrane microdomains. The resulting larger domains were comparable 
in size to the endovesicle-like structures observed with electron microscopy. Due to their 
small head group in comparison to the original phospholipids, ceramides induce negative 
membrane curvature which promotes both lipid membrane invagination and blebbing [10]. 
This provides a plausible explanation for the SMase-induced tubular plasma membrane 
invaginations. Endovesicles could result from membrane fusion in such tubular structures 
[35]. Membrane blebbing may also further contribute to the large, SMase-induced increase 
in vesiculation [27]. 
Also, we observed ceramide-enriched membrane platforms, which are known to originate in 
plasma membranes with high ceramide content [8]. The increase in membrane fragility can 
be attributed to the formation of these large ceramide-enriched membrane platforms, as 
earlier studies revealed them to be very rigid, resulting in a weak interface between the 
platform and the surrounding plasma membrane [10]. Small pores are known to form at this 
interface, which may readily explain the loss of osmotic responsiveness of the affected 
erythrocytes [10]. Splenic sequestration of abnormal erythrocytes with reduced deformability 
has been observed in several erythrocyte disorders, and is associated with a decreased life 
span and resulting hemolytic anemia in afflicted patients [2]. The presence of rigid ceramide 
platforms in SMase-treated erythrocytes may lead to enhanced splenic retention. Indeed, we 
could link SMase-induced ceramide formation to reduced deformability by showing that 
SMase treatment enhanced erythrocyte retention in a bead-sorting device that mimics the 
mechanical deformation that erythrocytes experience in the spleen. 
Vesiculation is an integral part of erythrocyte aging and appears to constitute a protective 
mechanism to enhance erythrocyte survival [27]. Vesicles from erythrocyte concentrates 
were found to modulate platelet function in vitro [36]. Furthermore, increased erythrocyte 
vesicle numbers were observed in several disease states (e.g. chronic renal failure, sickle 
cell disease and β-thalassemia) [18]. SMase-induced increase in erythrocyte vesiculation, 
probably resulting from a weakening of membrane anchorage, may contribute to disease 
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pathology due to the pro-coagulant nature of the vesicles [37]. The presence of two distinct 
vesicle populations as observed by annexin V and anti-CD235a double staining indicates 
that vesiculation occurs in distinct types of microdomains that are present on the erythrocyte 
membrane during SMase treatment. Furthermore, the high CFSE content of the 
microparticles generated by treatment of CFSE-loaded erythrocytes with SMase indicates 
that the microparticles contain a high concentration of cytoplasmic proteins. This suggests 
that they are sealed vesicles containing hemoglobin, similar to those generated in the 
circulation [27]. This is supported by the reddish color of the vesicle pellet.  
Positive-ion MALDI-TOF MS after chromatographic separation of the total lipid extract is a 
very sensitive analytical method for the detection of cell membrane ceramide content. The 
observation that 1 mU/mL SMase affected erythrocyte shape, membrane organization and 
osmotic responsiveness, even though membrane ceramide content was below the detection 
limit of the positive-ion MALDI-TOF MS, suggests that erythrocytes are very sensitive to 
ceramide-induced changes in membrane organization. The absence of other, non-specific 
breakdown products at higher enzyme activities excludes alternative degradation processes 
as the basis for these observations. 
Critically ill patients, in particular those suffering from severe inflammation and sepsis, 
frequently receive blood transfusions. We showed that erythrocyte storage under blood bank 
conditions increased the sensitivity to SMase. This may reduce erythrocyte survival after 
transfusion, especially in patients with enhanced SMase activity. Also, in healthy individuals, 
physiological erythrocyte age is associated with enhanced sensitivity. Therefore, cellular age 
likely underlies the observed heterogeneity in susceptibility to SMase per individual cell, as is 
particularly apparent in Figure S1 and Movie S1. These findings imply that the use of older 
erythrocyte concentrates in patients suffering from systemic inflammation might result in 
reduced transfusion efficacy and a higher risk of harmful side-effects, such as extravascular 
hemolysis and increased plasma iron concentrations that are associated with a SMase-
induced rapid clearance [38].  
In summary, we have shown that multiple, pathophysiologically relevant erythrocyte 
parameters are affected by SMase. These parameters are associated with changes that 
exceeded mere membrane lipid rearrangement, and included altered protein-protein 
interaction, membrane stability, deformability, and enhanced erythrocyte vesiculation. 
Furthermore, our findings suggest that enhanced SMase secretion during chronic 
inflammation contribute to the enhanced erythrocyte clearance that is often associated with 
inflammation. In particular, these data suggest that transfusion in patients with increased 
SMase activity should be restricted to fresh erythrocyte concentrates. 
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Materials and Methods 
Collection, isolation and storage of erythrocytes 
Fresh erythrocytes were isolated from whole blood (EDTA) donated by healthy human 
volunteers, using Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation. To 
obtain erythrocyte populations of different age, a combination of volume and density 
separation was used [27]. Erythrocyte concentrates were obtained using standard blood 
bank procedures. In short, whole blood (500 mL) was collected in a Composelect quadruple 
CPD-SAGM top-and-bottom bag system (Fresenius Kabi, Bad Homburg, Germany), 
containing 70 mL CPD as an anticoagulant. After cooling and centrifugation, erythrocytes 
were isolated using a Compomat G4 (Fresenius Kabi, Bad Homburg, Germany), after which 
110 mL SAG-M was added to the erythrocytes. The erythrocyte suspension was leukocyte-
depleted by in-line filtration, and subsequently stored at 2 to 6ºC. The study was performed 
following the guidelines of the local medical ethical committee and in accordance with the 
declaration of Helsinki. Written informed consent was obtained from all blood donors 
participating in this study. 
Solutions 
Erythrocytes were kept in Ringer solution (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 32 mM 
HEPES, 5 mM glucose, 2.5 mM CaCl2, pH 7.4). NaCl concentrations of 162.5 mM and 87.5 
mM NaCl were used for hyper- and hypotonic Ringer, respectively. Calcium-free Ringer was 
used during whole blood erythrocyte and vesicle isolation to prevent clotting. 
Erythrocyte lysis was performed using lysis buffer (10 mM HEPES, 1 mM EDTA, 1 mM 
EGTA, 1 mM benzamidine and 0.005 mM leupeptin, pH 8.0). Protein extractions were 
performed using extraction buffer (25 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1 mM benzamidine, 0.005 mM leupeptin, 1% Triton X-100, pH 7.4). When indicated, Triton 
X-100 was replaced by 10 mM n-Dodecyl-ß-D-Maltoside (DDM). 
SMase treatment 
Unless mentioned otherwise, 2×106 erythrocytes were incubated in 100 µL Ringer containing 
various concentrations of SMase (Sigma-Aldrich, St. Louis MO, USA; 159 U/mg; one unit of 
SMase hydrolyzes 1 µM of SM per min at pH 7.4 at 37ºC) for 15 min at 37ºC. After 
treatment, cells were washed twice with Ringer and centrifuged at 1000g for 3 min. When 
treated in the absence of extracellular calcium, cells were washed five times with calcium-
free Ringer before treatment in this buffer. Subsequent washing and staining of cells in 
Ringer was performed at 4ºC.  
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Flow cytometry 
To probe PS exposure, cells were washed with Ringer containing 0.2% bovine serum 
albumin (BSA, Sigma-Aldrich, St. Louis MO, USA) and stained with Annexin V-FLUOS 
(Roche, Basel, Switzerland; 1/25) for 1 h at room temperature. Alternatively, erythrocytes 
were stained with 1 µM CFSE diacetate (Invitrogen, Carlsbad CA, USA) in Ringer for 15 min 
at 37ºC prior to SMase treatment. Excess CFSE diacetate was removed by washing cells 
three times with Ringer containing 0.2% BSA. Flow cytometry was performed on a 
FACSCalibur system (BD Biosciences, Franklin Lakes NJ, USA) using Cellquest Pro 
software version 6.0. Per sample, 25,000 cells were measured and data analysis was 
performed using Cyan Summit software version 4.3. 
Confocal microscopy 
For time-lapse confocal laser scanning microscopy experiments, 200 µL Ringer containing 
1×106 CFSE diacetate-labeled erythrocytes, Annexin V-Alexa 647 (Roche, Basel, 
Switzerland; 1/20) and 10 mU SMase were added to a Lab-Tek chambered cover glass 
(Thermo Fisher Scientific, Rochester NY, USA). One min after addition of SMase to the 
erythrocytes, recording of images was started with 30 sec intervals for a total of 60 min.  
Mouse anti-CD59-Alexa 647 monoclonal antibody (clone MEM-43, AbD Serotec, Düsseldorf, 
Germany; 1/200) staining was performed on erythrocytes in Ringer buffer. Acrolein-fixated 
erythrocytes were used for combined antibody staining with mouse anti-stomatin (GARP-50, 
kindly provided by Rainer Prohaska, University of Vienna, Austria; 1/200) and rabbit 
polyclonal antiserum against the membrane domain of human band 3 (K2N6B/PMB3 [39]); 
1/100). Acrolein fixation and subsequent staining were performed as described by Matte et 
al [40]. BSA (1%) was used instead of fish skin gelatin for blocking purposes. Secondary 
antibodies were goat anti-mouse-Alexa 488 and goat anti-rabbit-Alexa 633 (Invitrogen, 
Carlsbad CA, USA; 1/1000). Ceramide staining on acrolein-fixated erythrocytes was 
performed using anti-ceramide IgM (clone MID 15B4, Enzo life sciences, Farmingdale NY, 
USA, 1/50) and isotype control IgM (BD Biosciences, Franklin Lakes NJ, USA, 1/50),  
followed by goat anti-mouse-Alexa 647 staining (Invitrogen, Carlsbad CA, USA; 1/200). 
Confocal laser scanning microscopy was performed on a TCS SP5 confocal laser scanning 
microscope (Leica Microsystems, Mannheim, Germany) equipped with a HCX Plan-
Apochromat 63X/N.A. 1.2 water immersion lens. Cells were imaged at a temperature-
controlled stage set at 37ºC. The Leica TCS SP5 LAS AF software was used for image 
acquisition. Image J version 1.45J was used for further image analysis. 
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Electron microscopy 
Erythrocytes were fixated with 1% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) 
for 1 h at room temperature. The cells were then washed twice in cacodylate buffer and 
post-fixated for 1 h in 1% osmium tetraoxide. After two more washes with cacodylate buffer, 
samples were pelleted in 2% agarose (ultra-low gelling temperature, Sigma-Aldrich, St. 
Louis MO, USA) and cells were dehydrated by incubation in an ascending series of aqueous 
ethanol for 15 min per incubation step. Cells were then incubated overnight in ethanol and 
Epon at a 1/1 ratio, subsequently incubated for 4 h in pure Epon and embedded at 37ºC 
overnight in fresh Epon. The samples were then stored at 60ºC overnight, after which 80 nm 
sections were made using a Reichert Ultracut 6 Microtome. After drying, sections were 
stained in uranyl acetate for 20 minutes and subsequently in lead citrate for 10 minutes. 
Sections were examined with a JEOL TEM 1010 (JEOL Ltd., Tokyo, Japan). 
Erythrocyte vesiculation 
All buffers used for vesicle generation, isolation and analysis were complemented with 0.2% 
BSA and filtered (0.22 µm) before use. Erythrocytes (1×109) were incubated with 5 mL 
Ringer containing 10 mU/mL SMase for 1 h. The cell suspension was centrifuged for 10 min 
at 1500g, and the supernatant was centrifuged again for 20 min at 1500g. Vesicles were 
then pelleted by centrifugation at 21,000g and 4ºC for 20 min. The vesicles were washed 
once with Ringer and resuspended in 25 µL Ringer. Vesicles from whole blood were isolated 
from 200 µL plasma as described above, with an additional calcium-free Ringer wash of the 
vesicle pellet after high speed centrifugation. 
Vesicles were stained with Annexin V-FLUOS and anti-CD235a-PE monoclonal antibody 
(clone KC16, Beckman Coulter, Brea CA, USA; 1/50) in a total volume of 50 µL Ringer for 
45 min at room temperature, and washed once with Ringer. Vesicles were resuspended in 
150 µL Ringer, and washed Flow-Count Fluorospheres (Beckman Coulter, Brea CA, USA) 
were added (1×104) for quantification. Samples were analyzed by flow cytometry as 
described for erythrocytes at high speed for 1 min, using a protocol optimized for vesicle 
analysis. Sulfate latex microspheres (Invitrogen, Carlsbad CA, USA; 0.9 µm) were used to 
determine the maximum upper boundary allowed for forward and sideward scatter gating. All 
staining solutions were centrifuged at 21,000g and 4ºC for 20 min prior to use to remove 
fluorescent aggregates. PE-conjugated IgG1 isotype control (Dako, Glostrup, Denmark) did 
not show any aspecific binding. 
Membrane protein extraction, SDS-PAGE and immunoblot 
Erythrocytes (1×109) were incubated with 5 mL Ringer containing 10 mU/mL SMase for 1 
hour and subsequently lysed in 1 mL lysis buffer. The membrane fraction was washed 
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repeatedly by centrifugation at 21,000g for 10 min to remove free hemoglobin. Membrane 
proteins were extracted by adding 200 µL extraction buffer and samples were vortexed for 
30 s. The samples were incubated for 30 min with regular vortexing and were subsequently 
centrifuged at 21,000g for 15 min. Laemmli sample buffer (BioRad, Hercules CA, USA) 
containing 5% 2-mercaptoethanol was added to the supernatant at a 1/1 ratio (v/v). The 
remaining pellet was washed once with phosphate-buffered saline (PBS, pH 7.4) and 
resuspended in 50 µL sample buffer. 
SDS-PAGE was performed using 12.5% running gels with in the Mini Protean 3 system 
(both BioRad, Hercules CA, USA), according to the method of Laemmli Either band 3 protein 
or actin were used as loading controls. Apparent molecular masses were calculated based 
on the Precision Plus Protein Standard (BioRad, Hercules CA, USA). After SDS-PAGE, the 
proteins were transferred to PVDF membranes using the iBlot system (Invitrogen, Carlsbad 
CA, USA). The membranes were then blocked with Odyssey Blocking Buffer (OBB, LI-COR, 
Lincoln NE, USA), and incubated for 16 h at 4ºC in OBB containing 0.1% Tween-20, rabbit 
anti-band 3 serum (K2N6B/PMB3(39); 1/5000) and mouse anti-β actin monoclonal antibody 
(clone AC-15, Sigma-Aldrich, St. Louis MO, USA; 1/5000). After washing with PBS 
containing 0.1% Tween-20, the blots were incubated for 1 h at room temperature in OBB, 
0.1% Tween-20, 0.01% SDS, goat anti-rabbit IgG-Alexa Fluor 680 (Invitrogen, Carlsbad CA, 
USA; 1/10,000), and goat anti-mouse IgG-IRDye 800 (LI-COR, Lincoln NE, USA; 1/10,000). 
This final incubation was followed by a single washing step with PBS containing 0.1% 
Tween-20, and three subsequent washes with PBS. Immunoblots were scanned using the 
Odyssey Infrared Imaging System (LI-COR, Lincoln NE, USA), and analyzed using Odyssey 
Software version 2.1. 
Positive-ion MALDI-TOF MS and 31P NMR analyses of membrane lipids 
Packed erythrocytes (300 µL) were incubated with 5 mL Ringer containing SMase for 1 hour 
and subsequently lysed and washed as described for membrane protein extraction. 
Membrane pellets (200 µL) were transferred to glass tubes and 2 mL methanol and 1 mL 
dichloromethane were added. After vortexing, another 1 mL dichloromethane and 1.6 mL 
0.5% acetic acid were added and vortexed once more. After 10 min centrifugation at 800g, 
the bottom dichloromethane layer was isolated. Residual lipids were extracted from the 
aqueous layer by extraction with 1 mL dichloromethane. The two dichloromethane fractions 
were pooled and the solvent evaporated. The lipid fraction was analyzed by positive-ion 
MALDI-TOF MS and 31P NMR spectroscopy as described by Dannenberger et al [41]. 
Shortly, the lipid extract was mixed 1:1 (v/v) with the matrix solution (0.5 M 2,5-
dihdyroxybenzoic acid in methanol) and 1 µL of this mixture was directly applied onto the 
MALDI target. All MALDI-TOF mass spectra were acquired on an Autoflex I mass 
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spectrometer (Bruker Daltonics, Bremen, Germany) with ion reflector. The system utilizes a 
pulsed 50 Hz nitrogen laser, emitting at 337 nm. The extraction voltage was 20 kV and gated 
matrix suppression was applied to prevent the saturation of the detector by matrix ions. All 
spectra were acquired in the reflector mode using delayed extraction conditions. Peak 
identities were additionally confirmed by recording post source decay spectra as previously 
described [42]. As the focus of this study is on SM, no negative-ion spectra were acquired 
because SM is much more sensitively detectable in the positive-ion mode [43]. 
Erythrocyte bead sorting device 
Erythrocyte retention/deformability was assessed using a bead sorting device that mimics 
the mechanical deformation that erythrocytes experience in the spleen [44]. After SMase 
treatment, erythrocytes (1×108) were labeled with CFSE diacetate. A 2% hematocrit 
suspension (600 µL) consisting of 5% treated/labeled and 95% untreated/unlabeled 
erythrocytes in Ringer with 1% BSA was passed through the bead sorting device at a flow 
rate of 60 mL/h. The untreated/unlabeled erythrocytes acted as both facilitators of steady 
perfusion of the cells of interest, and as an internal control for retention/deformability. Flow 
cytometry measurement (100,000 cells) of the initial upstream compartment, the bead 
compartment, and downstream fractions was performed to determine the ratio of labeled 
versus unlabeled erythrocytes in each separate fraction. 
Statistical analysis 
Differences between two groups of data were determined using a paired T test. Differences 
between multiple groups were assessed with repeated measures one-way ANOVA in 
combination with Tukey’s post-test. Reported p values are two sided, and a p value of < 0.05 
was used to assess statistical significance. 
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Figure S1 – Erythrocyte membrane irregularities, protein clustering and PS exposure during SMase 
treatment. Time-lapse confocal laser scanning microscopy of CFSE-labeled erythrocytes treated with 10 mU/mL 
SMase at 37ºC in the presence of Annexin V-Alexa 647 (also see Figure 1D and supplemental Movie 1). (A), 
Representative picture of erythrocytes at t = 45 min after the addition of SMase. Scale bar = 5 µm. (B), 
Quantification of CFSE cluster-positive and PS-exposing erythrocytes with or without observable membrane 
irregularities in bright-field. 200 cells were assessed in a single experiment (t = 45 min). Confocal laser scanning 
microscopy was used to image fluorescence as described in Materials and Methods. 
 
Chapter 4 
 
88 
 
 
Figure S2 – Differential membrane protein extraction of SMase-treated erythrocyte membrane fractions. 
Erythrocytes were treated with 10 mU/mL SMase at 37ºC for one hour. Membrane extractions were performed 
using extraction buffers containing either Triton X-100 or dodecyl maltoside. After SDS-PAGE of the soluble and 
insoluble protein fractions, immunoblot analysis was performed using monoclonal antibodies against band 3 (red) 
and β-actin (green). The blots were analyzed and the mean optical density (OD) of the bands was determined 
using the Odyssey Infrared Imaging System. Band 3 in the soluble protein fraction and β-actin in the insoluble 
protein fraction acted as loading controls. 
 
 
Supplemental movies S1, S2 and S3 are available at Cell Death & Disease’s website 
(http://www.nature.com/cddis) 
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Abstract 
Objective: Reduced erythrocyte survival and deformability contribute to the “anemia of 
inflammation” observed in severe sepsis. Erythrocyte structure and function depend on 
plasma membrane lipid composition and organization. We therefore aimed to determine 
whether this composition is affected by altered lipid metabolism in the circulation during 
systemic inflammation. 
Design: Case control study. 
Setting: Intensive care department of a university hospital. 
Patients and Subjects: 10 patients with septic shock, 10 healthy volunteers subjected to 
experimental endotoxemia, and 10 healthy controls. 
Measurements and Main Results: A sensitive matrix-assisted laser desorption and ionization 
time-of-flight mass spectrometry method was used to investigate erythrocyte membrane lipid 
content. Incubation of erythrocytes of healthy blood group O, Rhesus-negative donors with 
plasma from patients with septic shock resulted in membrane phosphatidylcholine hydrolysis 
into lysophosphatidylcholine (LPC). Ceramide or lysophospholipids other than LPC were not 
observed in this study. Plasmas taken during experimental human endotoxemia did not 
induce LPC formation. Secretory phospholipase A2 IIA was enhanced in all patient plasmas 
and plasmas from endotoxin-treated subjects, but could not be correlated to its ability to 
generate LPC in erythrocytes. Erythrocyte phosphatidylserine exposure increased during 
experimental endotoxemia. 
Conclusions: Erythrocyte membrane lipid remodeling reflected by enhanced LPC formation 
and PS exposure occurs during systemic inflammation in a secretory phospholipase A2 IIA-
independent manner. 
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Introduction  
In patients with inflammation, anemia is associated with a poor disease outcome. Next to 
changes in systemic iron homeostasis and defective erythropoiesis [1,2], reduced 
erythrocyte lifespan is a cause of “anemia of inflammation” [3-5]. This condition is common in 
patients suffering from sepsis [6]. Erythrocyte shape, deformability, and aggregability were 
shown to be altered in these patients [7,8]. Reduced erythrocyte deformability may 
contribute to the microcirculatory alterations that are linked with a poor disease outcome in 
septic patients [8], and to untimely erythrocyte removal by sequestration in the spleen [9]. 
Erythrocyte structure and function are dependent on plasma membrane lipid composition 
[10,11], as exemplified by the altered erythrocyte morphology and survival in patients with 
hemoglobinopathies and various liver diseases, which are caused by a disturbed membrane 
lipid asymmetry and lipid metabolism, respectively [11,12]. Also in patients with sepsis, 
membrane lipid composition may contribute to alterations in erythrocyte function. Indeed, 
incubation of erythrocytes from healthy volunteers with plasma of septic patients was found 
to induce phosphatidylserine (PS) exposure and membrane ceramide formation [13], both of 
which have functional consequences for the erythrocyte [10,14]. 
Phospholipids constitute the majority of the erythrocyte plasma membrane lipids, with the 
glycerophospholipid (GPL) phosphatidylcholine (PC) and the sphingolipid sphingomyelin 
(SM) dominating the outer membrane of the lipid bilayer [10,11]. Secretory phospholipase A2 
(sPLA2) and sphingomyelinase (SMase) catalyze the hydrolysis of GPLs into 
lysophospholipids (LPLs) and fatty acids, and SM into ceramide and choline, respectively. 
The activity of both lipases is enhanced in the plasma of patients suffering from sepsis 
[15,16], and the lipids they generate have been shown to play a role in the pathology of 
various inflammatory diseases [17]. Erythrocyte deformability and survival were shown to be 
negatively influenced by sPLA2 and SMase or by the direct incorporation of their lipid 
products in vitro [9,14,18,19]. 
The aim of the current study was to investigate the involvement of lipase activity in the 
erythrocyte-related pathophysiology during systemic inflammation in patients with sepsis and 
in experimental human endotoxemia. Using a sensitive matrix-assisted laser desorption and 
ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) approach, we investigated 
the lipid composition of erythrocytes after incubation with the plasma of patients suffering 
from septic shock and with plasma of subjects participating in a human experimental 
endotoxemia model. A mechanistic explanation for the observed changes was explored by 
measuring plasma sPLA2 IIA levels and erythrocyte PS exposure. 
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Methods 
Septic Patients 
Four mL of lithium–heparin anticoagulated (Vacutainer, BD Biosciences, San Jose, CA, 
USA) blood was collected from 10 septic shock patients, residing in the department of 
Intensive Care Medicine of the Radboud University Medical Centre, Nijmegen, the 
Netherlands. Septic shock was defined as having two or more systemic inflammatory 
response syndrome (SIRS) criteria [20], in combination with a proven or suspected infection 
and the need for vasopressor therapy following adequate fluid resuscitation. The study has 
been carried out in the Netherlands in accordance with the applicable rules concerning the 
review of research ethics committees and informed consent. Blood from all patients was 
drawn within the first 24 hours after the start of vasopressor therapy. Plasma was obtained 
by centrifugation (2000×g, 4°C) under sterile conditions. Erythrocytes were isolated using 
Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation and washed with calcium-
free Ringer’s solution (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 32 mM HEPES, 5 mM 
glucose, pH 7.4). Plasma and erythrocyte membranes were snap-frozen and stored at -80°C 
following isolation.  
Healthy volunteers 
Ten healthy volunteers donated 4 mL of lithium–heparin anticoagulated blood to serve as 
control, after having provided written informed consent to the study protocol. Plasma was 
obtained by centrifugation (2000×g, 4°C) under sterile conditions. Erythrocytes were isolated 
and processed as described above.  
Human Endotoxemia Trial 
Subjects: In order to investigate the effects of systemic inflammation in a controlled 
environment, a model of experimental human endotoxemia was used. This study was part of 
a larger endotoxemia trial that was designed to investigate the effect of iron administration 
and iron chelation on the innate immune response in healthy males (clinicaltrials.gov 
identifier: NCT01349699). In order to prevent confounding by the different pharmacological 
interventions, our analyses were performed on data of the ten placebo-LPS-treated subjects 
only. The trial was approved by the local ethics committee, and carried out according to GCP 
standards and the declaration of Helsinki. All volunteers gave written informed consent and 
had a normal physical examination, electrocardiography, and routine laboratory values 
before the start of the experiment. Volunteers did not take any prescription drugs and 
refrained from caffeine and alcohol intake 24 h prior to endotoxemia. The subjects were 
admitted to our clinical research unit on the day of the experiment and were kept under 
observation during 10 h. 
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Experimental Protocol: A detailed protocol of the human endotoxemia trial was previously 
described [21]. Briefly, a venous cannula was placed for administration of fluids to ensure an 
optimal hydration status [22], and an arterial catheter was placed in the radial artery to 
permit the continuous measurement of blood pressure, as well as blood drawing. Heart rate, 
intra-arterial blood pressure, and temperature were monitored throughout the experiment 
and the subjects were supervised at all time. They received 1.5 L 2.5% glucose/0.45% saline 
solution in 1 h immediately before LPS infusion (pre-hydration), followed by 150 mL/h until 6 
h after LPS infusion, and 75 mL/h until the end of the experiment. E. coli endotoxin 
(Escherichia coli O:113, Clinical Center Reference Endotoxin, National Institute of Health, 
Bethesda, MD) was reconstituted in 0.9% NaCl for injection and vortex-mixed for at least 10 
min. At t=0 hours, 2 ng/kg E. coli endotoxin was injected intravenously. Blood was collected 
at various time points thereafter. Plasma from lithium–heparin anticoagulated (Vacutainer, 
BD Biosciences, San Jose, CA, USA) blood was obtained by centrifugation, snap-frozen and 
stored at -80°C under sterile conditions. Erythrocytes from 4 mL of EDTA anticoagulated 
(Vacutainer, BD Biosciences, San Jose, CA, USA) blood were isolated using Ficoll (GE 
Healthcare, Waukesha WI, USA) density centrifugation and washed with calcium-free Ringer 
for flow cytometry analysis within 4 hours after collection. 
sPLA2 IIA and Cytokine Measurements 
Plasma sPLA2 IIA concentrations were determined using a sPLA2 ELISA assay (sPLA2 
(human Type IIA) EIA Kit, Cayman Chemical, Ann Arbor, MI, USA) according to the 
manufacturer’s instructions. Plasma concentrations of tumour necrosis factor (TNF)-α and 
interleukin-6 (IL-6) were determined at various time points using a simultaneous Luminex 
assay (Bio-Plex cytokine assay, Bio-Rad, Hercules, CA, USA) according to the 
manufacturer’s instructions. 
Erythrocyte isolation from blood group O, Rhesus negative donors 
Healthy volunteer EDTA-anti-coagulated (Vacutainer, BD Biosciences, San Jose, CA, USA) 
blood was collected from several blood group O, Rhesus-negative donors, and erythrocytes 
were isolated using Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation. 
Plasma incubation 
The allogeneic blood group O, Rhesus-negative erythrocytes were incubated in the plasma 
of patients or healthy volunteers at 10% hematocrit in a final volume of 500 µL, for 20 h at 
37°C with gentle agitation. Incubation of the erythrocytes with calcium-containing (2.5 mM 
CaCl2) Ringer with or without bee venom sPLA2 type III (Cayman Chemical, Ann Arbor, MI, 
USA) served as positive and negative controls for (sPLA2-induced) lysophospholipid 
formation, respectively. The absorption at 415 nm of the supernatant was determined to 
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assess hemolysis. After incubation, the erythrocytes were washed with calcium-free Ringer 
prior to flow cytometry and membrane lipid analyses.  
Flow cytometry 
Erythrocytes were probed for PS exposure by incubation with Annexin V-FLUOS (Roche, 
Basel, Switzerland; 1/25) for 1 h at room temperature in calcium-containing Ringer. PE 
conjugated anti-CD235a antibody (clone KC16, Beckman Coulter, Brea CA, USA; 1/100) 
was included as an erythrocyte marker. Flow cytometry was performed on a FACSCalibur 
system (BD Biosciences, Franklin Lakes NJ, USA) using Cellquest Pro software version 6.0. 
Per sample, 100,000 cells were measured and data analysis was performed using Cyan 
Summit software version 4.3. 
MALDI-TOF MS detection of membrane lipids 
Erythrocytes (50 µL) were lysed and the lysate membranes were washed repeatedly with 
lysis buffer (10 mM HEPES, 1 mM EDTA, 1 m EGTA, pH 8.0) by centrifugation at 21,000×g 
for 10 min to remove free hemoglobin. Membrane pellets were resuspended and transferred 
to glass tubes and 500 µL methanol and 250 µL dichloromethane were added. After 
vortexing, another 250 µL dichloromethane and 400 µL 0.5% acetic acid were added and 
vortexed once more. After 10 min centrifugation at 800×g, the bottom dichloromethane layer 
was isolated. Residual lipids were extracted from the aqueous layer by extraction with 250 
µL dichloromethane. The two dichloromethane fractions were pooled and the solvent was 
evaporated. For some plasmas, lipids were isolated directly from 100 µL plasma using the 
method described for membrane pellets above. The lipid fraction was analyzed by positive-
ion (and in selected cases also negative-ion) MALDI-TOF MS as described previously [23]. 
Shortly, the lipid extract was mixed 1:1 (v/v) with the matrix solution (0.5 M 2,5-
dihdyroxybenzoic acid in methanol) and 1 µl of this mixture was directly applied onto the 
MALDI target. For negative ion mass spectra, 9-aminoacridine (9-AA) (Fisher Scientific 
GmbH, Nidderau, Germany) as 10 mg/mL solution in 60/40 (v/v) isopropanol/acetonitrile [24] 
was used and mixed 1:1 (v/v) with the samples of the lipid extracts. 
All MALDI-TOF mass spectra were acquired on an Autoflex I mass spectrometer (Bruker 
Daltonics, Bremen, Germany) with ion reflector. The system utilized a pulsed 50 Hz nitrogen 
laser, emitting at 337 nm. The extraction voltage was 20 kV and gated matrix suppression 
was applied to prevent the saturation of the detector by matrix ions. All spectra were 
acquired in the reflector mode using delayed extraction conditions. Peak identities were 
additionally confirmed by recording post source decay spectra as previously described [25]. 
Quantitative data can be obtained with a standard deviation of ±10% [26]. 
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Thin layer chromatography (TLC) 
Lipid extracts were applied onto high performance TLC silica gel 60 plates (10×10 cm in 
size, on aluminum backs; Merck, Darmstadt, Germany), using a Linomat 5 device (CAMAG, 
Berlin, Germany), and developed in vertical TLC chambers with CHCl3, ethanol, water, and 
triethylamine (30:35:7:35, v/v/v/v) as the solvent system. Lipids were visualized by spraying 
the plate with primuline (Direct Yellow 59) as previously described [27]. Upon illumination 
with UV light (366 nm), individual lipid classes were detected as colored spots. These spots 
were assessed using a digital image system in combination with the program Argus X1 
(BioStep, Jahnsdorf, Germany). MALDI mass spectra were recorded directly from the TLC 
plate as described before [28]. 
Statistical analysis 
Differences in the percentages of total membrane LysoPC (LPC) between two groups were 
determined using Fisher’s exact test. A repeated measures one-way ANOVA in combination 
with Tukey’s post-test was used to assess changes in erythrocyte PS exposure over time for 
the human endotoxemia model. Differences between two groups of continuous data were 
determined using the Mann Whitney U test. The relation between two parameters was 
assessed by performing a Pearson correlation. Reported values are two-sided, and a p 
value of <0.05 was used to assess statistical significance. 
 
Results 
Demographic characteristics  
Characteristics of the septic patients are provided in Table 1. Characteristics of the healthy 
subjects who participated in the endotoxemia trial and the healthy volunteers that served as 
controls for the septic patient group are presented in Table 2. 
Enhanced LPC generation in erythrocytes incubated with septic patient plasma 
We investigated the changes in membrane lipid composition in detail by positive-ion MALDI-
TOF MS analysis of allogeneic blood group O, Rhesus-negative erythrocytes incubated 
overnight with plasma of healthy volunteers and of patients suffering from septic shock. This 
ex vivo approach allowed us to mimic erythrocyte lipid remodeling as it would occur in the 
circulation, without losing affected erythrocytes due to hemolysis and clearance. The number 
of PS-exposing erythrocytes after incubation, assessed using Annexin V staining and flow 
cytometry, was within the normal range observed in vivo [29] for both patient (0.39%±0.11) 
and healthy volunteer (0.43%±0.07) plasma. A small degree of hemolysis (<1%) was 
observed after incubation (data not shown). This low degree of PS exposure and hemolysis 
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for control plasmas indicates that the assay procedure did not cause cellular stress, a 
feature which might have influenced the LPC formation ex vivo. These data also 
demonstrate that patient plasma hardly induced any PS exposure. 
 
Table 1. Demographic characteristics of septic patients 
Pt Nr. Sex 
(M/F) 
Age 
(years) 
Diagnosis APACHE II Hb 
(mmol/l) 
Transfusion history 
1 V 54 pneumosepsis 28 4.9 None 
2 M 68 abdominal sepsis after 
intestinal ischemia 
 5.1 Day before blood drawing : 
     3 thrombocyte transfusions 
     3 plasma transfusions 
Day of blood drawing: 
     2 thrombocyte transfusions 
     8 plasma transfusions 
     9 erythrocyte transfusions 
3 V 81 abdominal sepsis in 
ulcerative colitis 
28 6.0 None 
4 M 59 infected hip prosthesis  4.9 Day before blood drawing : 
     1 erythrocyte transfusion 
Day of blood drawing: 
     1 erythrocyte transfusion 
5 M 75 cholangitis 23 8.6 Day before blood drawing : 
     2 thrombocyte transfusions 
     2 plasma transfusions 
Day of blood drawing: 
     1 thrombocyte transfusion 
6 M 82 abdominal sepsis after 
intestinal ischemia 
23 7.5 Day before blood drawing : 
     3 erythrocyte transfusions 
7 M 34 pneumosepsis 14 7.8 None 
8 M 84 urosepsis 16 6.3 None 
9 V 51 pneumosepsis 27 5.9 None 
10 V 65 toxicodermia 23 6.6 None 
Mean 
± SD 
 66.3  
± 16.1 
 22.8  
± 5.3 
6.4  
± 1.3 
 
 
 
Table 2: Characteristics of healthy subjects 
 Endotoxemia subjects Healthy volunteers 
N 10 10 
Age (years ± SD) 22.7 ± 2.8 34.7 ± 14.8 
Sex (M/F) 10 / 0 8 / 2 
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Using the positive-ion mode, both lysophosphatidylcholine (LPC) and ceramide species can 
be readily detected in plasma membrane lipid extracts [30]. While no LPC or ceramide could 
be observed after the incubation of erythrocytes in Ringer’s solution, incubation with septic 
patient plasma, and to a lesser extent with healthy volunteer plasma, caused the formation 
of LPC, but not of ceramide (Figure 1A). Although reactive oxygen species (ROS) can also 
generate LPLs, these ROS-produced LPLs were not observed in our study, even though 
they are readily detectable by means of MS and easily discernible from other LPLs and PLs 
[31]. The observed LPC percentages were within the same range as observed after 
incubating the erythrocytes of different blood donors with 20 and 100 ng/mL sPLA2 (Figure 
1B). Additionally, the results suggest an erythrocyte donor-dependent variation in the 
susceptibility to sPLA2-induced LPC generation (Figure 1B). 
Compared to that of the healthy volunteers, LPC formation was significantly enhanced in 
samples treated with plasma from septic patients (Figure 1C). This suggests that the latter 
possessed enhanced phospholipase activity that might affect erythrocytes in the circulation 
of patients with sepsis. No LPC could be detected in the healthy volunteer and patient 
erythrocytes. 
The percentage of LPC in the total PC pool in the plasma itself was lower for the septic 
patients (0.63±0.35, n=3), than for the healthy volunteers (4.91±0.49, n=3), confirming earlier 
observations [32]. This observation makes incorporation of LPC from the plasma into the 
erythrocyte membrane an unlikely explanation for the observed increase after incubation 
with patient plasma. 
Enhanced LPC generation does not correlate to the sPLA2 IIA plasma concentration 
Phospholipases of the sPLA2 family are the plasma components that generate LPC and 
other lysophospholipids in vivo [33]. Only sPLA2 type IIA is upregulated during sepsis [34], 
making its lipase activity a primary candidate responsible for the observed LPC formation. 
Therefore, we determined the sPLA2 IIA concentrations in the patient and control plasmas to 
assess their sepsis-associated involvement in observed LPC generation in erythrocytes. 
All septic patients had enhanced plasma sPLA2 IIA concentrations (50.2-1654.0 ng/mL) as 
compared to the healthy volunteers (1.3-9.3 ng/mL), corroborating earlier observations 
(Figure 1D) [15,34]. However, there was no correlation between the observed degree of LPC 
formation and the sPLA2 IIA concentration in the septic patient plasmas (Figure 1E), 
indicating other causes for the enhanced generation of LPC. Also, no correlations were 
observed between percentage LPC and sPLA2 IIA concentration with the following known 
patient parameters; sex, age, weight, length, focus of infection, APACHE II, temperature, 
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mean arterial pressure, heart rate, fluid balance, Glasgow coma scale, PaO2, FiO2, 
thrombocytes, bilirubin, creatinine and leukocytes. 
 
 
Figure 1. Septic patient plasma-induced LPC formation in the erythrocyte membrane. Three representative 
examples of positive-ion MALDI-TOF MS spectra of membrane lipid extracts of allogeneic erythrocytes incubated 
overnight at 37°C with i) plasma from septic patients, ii) plasma from healthy controls, and iii) Ringer solution (A). 
All peaks are labeled according to their mass-to-charge (m/z) ratios and assignments of the most prominent 
peaks are given directly in the figure. The percentage of hydrolyzed PC (LPC) was determined by comparing the 
proton and sodium adducts of LPC 16:0 (m/z 496.3 and 518.3), to the combined pool of LPC 16:0 and PC 
16:0/18:2 (m/z 758.6 and 780.6). LPC formation after incubation of erythrocytes of three different donors with 
Ringer containing 20 and 100 ng/mL sPLA2 (B). LPC formation after overnight incubation with plasma from 10 
septic patients and 10 healthy controls (C). The human sPLA2 IIA concentration in all plasmas was determined 
using an ELISA (D). The sPLA2 IIA concentrations measured in patients did not correlate (r = -0.44, P = 0.22) to 
the observed LPC percentage (E). Means are shown and *P<0.05. Lipid abbreviations: LPC = 
lysophosphatidylcholine, PC = phosphatidylcholine, SM = sphingomyelin. 
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LPC generation and sPLA2 IIA plasma concentration in human endotoxemia 
Sepsis is a medical condition that encompasses a highly heterogeneous group of clinical 
disorders, varying with origin of infection, bacteriology, and progression [35]. In order to 
overcome this heterogeneity and to address to which extent endotoxemia affects erythrocyte 
lipid metabolism, we used a human endotoxemia model to study the LPC formation in 
erythrocytes ex vivo. Subjects enrolled in the trial were infused with 2 ng/kg LPS, and blood 
samples were drawn just prior to, and 8 hours after the administration. Allogeneic blood 
group O, Rhesus-negative erythrocytes were then incubated with the obtained plasmas, and 
their membrane lipid content was analyzed by positive-ion MALDI-TOF MS, and plasma 
sPLA2 IIA concentrations were measured. The 8-hour time point was based on the previous 
observation that sPLA2 IIA plasma concentration peaked between 4 and 12 hours after LPS 
infusion in a comparable endotoxemia trial [36]. sPLA2 IIA concentrations increased in 
almost all subjects after LPS infusion (Figure 2A), albeit not to the extent observed in the 
septic patients, corroborating earlier results [36]. 
 
 
Figure 2. Erythrocyte lipid remodeling during human experimental endotoxemia-induced inflammation. 
Allogeneic erythrocytes were incubated overnight at 37°C with plasma obtained from 10 endotoxemia trial 
subjects just prior to (t=0) and eight hours after (t=8) the administration of 2 ng/kg clinical grade LPS. The sPLA2 
IIA concentration in all plasma samples was determined using an ELISA (A). The sPLA2 IIA concentrations at t=0 
were correlated to the concentrations at t=8 (r = 0.89, P<0.001) (B). The percentage of hydrolyzed PC (LPC) was 
determined by positive-ion MALDI-TOF MS, by comparing the intensities of the proton and sodium adducts of 
LPC 16:0 (m/z 496.3 and 518.3), with the combined pool of LPC 16:0 and PC 16:0/18:2 (m/z 758.6 and 780.6) 
(C). The percentage of PS-exposing erythrocytes was determined by flow cytometry detection of Annexin V-
FLUOS staining (D), and TNF-α (E) and IL-6 (F) plasma concentrations were assessed by Luminex. In panel A, 
C and D means are shown, *P<0.05, and error bars in panel D represent SEM. In panel E and F median values 
are shown, and the error bars represent the inter quartile range. 
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Interestingly, a strong correlation (r = 0.89, P<0.001) was observed between sPLA2 IIA 
levels before, and 8 hours after LPS infusion (Figure 2B). These data indicate that sPLA2 IIA 
status at baseline has predictive value for the sPLA2 IIA response upon (LPS-induced) 
inflammation. Furthermore, sPLA2 IIA concentration at t=0 also correlated (r = 0.68, 
P=0.032) with the rise in body temperature after LPS infusion.  
However, in contrast to that of septic patients, the plasma of the LPS-infused subjects did 
not induce any additional LPC formation in erythrocytes (Figure 2C). This corroborates our 
finding that sPLA2 IIA concentration appears not to be related with the observed LPC 
formation in septic patients (see above). 
Erythrocyte PS exposure is induced during the initial phase of human endotoxemia 
In vivo, LPC is rapidly converted into lysophosphatidic acid (LPA), a molecule that was found 
to induce the exposure of the removal signal PS in erythrocytes [37]. The initial observation 
that septic patient plasmas induce LPC generation in erythrocytes, therefore, led us to 
investigate erythrocyte PS exposure in the individuals enrolled in the endotoxemia trial. 
A significant increase in the number of PS-exposing erythrocytes was observed 6 and 8 
hours after LPS infusion, which had returned to baseline level at t=24 hours (Figure 2D). 
This increase in PS-exposing erythrocytes was observed after the onset of inflammation, as 
was determined by monitoring TNF-α (Figure 2E) and IL-6 (Figure 2F) plasma levels. These 
data show that acute systemic inflammation induces plasma membrane lipid remodeling in a 
subpopulation of erythrocytes, possibly rendering them susceptible to sPLA2 IIA in the 
circulation in vivo. However, it does not explain the LPC formation observed in erythrocytes 
incubated with plasma from septic patients. A strong positive correlation (r = 0.91, P=0.002) 
was observed between erythrocyte PS exposure before, and 6 hours after LPS infusion. 
These data indicate that erythrocyte PS exposure at baseline has predictive value for the 
tendency of erythrocyte to expose PS during (LPS-induced) inflammation.  
The observed lipase activity selectively targets PC in the erythrocyte 
sPLA2s do not only hydrolyze PC, but also other glycerophospholipids such as PS and 
phosphatidylethanolamine (PE), albeit with various affinities depending on the sPLA2 type 
[33]. Therefore, we evaluated the hydrolysis of other GPLs in the erythrocyte membrane by 
performing negative-ion MALDI-TOF MS and TLC analysis. Allogeneic erythrocytes were 
incubated with septic patient plasma selected for its potency to generate LPC. Indeed, high 
LPC levels were observed again by both positive-ion MALDI-TOF MS (Figure 3A) and TLC 
(Figure 3B). 
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Figure 3. Detection of lysophospholipids. Allogeneic erythrocytes were incubated overnight at 37°C with 
plasma of a septic patient. Both positive and negative-ion MALDI-TOF MS of isolated membrane lipids were 
performed (A). All peaks are labeled according to their m/z ratios. Note that there are intense signals of LPC, but 
no signals of other LPL species. A TLC was performed using the identical lipid extract (B) to verify the absence of 
LPL other than LPC. Lipid standards were included to delineate the different lipid species. The pale white band in 
the TLC is most probably caused by the presence of small amounts of hemoglobin that could not be completely 
removed during the extraction process [38]: due to its aromatic character it has a high probability to interfere with 
the absorption of the primuline dye. Lipid abbreviations: LPC = lysophosphatidylcholine, LPE = 
lysophosphatidylethanolamine, PA = phosphatidic acid, PC = phosphatidylcholine, PE = 
phosphatidylethanolamine, PG = phosphatidylglycerol, PI = phosphatidylinositol, PL = phospholipid, PS = 
phosphatidylserine, SM = sphingomyelin. 
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However, other LPLs such as LysoPE (LPE), LysoPS, and lysophosphatidylinositol could not 
be detected (Figure 3B). Incubation in Ringer that had been spiked with recombinant sPLA2 
was also unable to generate LPLs other than LPC (data not shown). Most likely the plasma 
phospholipases are unable to attack these GPLs, as they reside in the inner leaflet of the 
plasma membrane. 
 
In summary, we here show that plasma of septic patients caused enhanced LPC formation 
in erythrocytes ex vivo. This was not observed for plasma from LPS-infused subjects during 
an endotoxemia trial. Interestingly, erythrocyte membrane lipid remodeling was present in 
the form of PS exposure in the LPS-infused subjects. LPC formation could not be correlated 
to sPLA2 IIA for either the patients or the LPS-infused subjects. 
 
Discussion 
Reduced erythrocyte survival and deformability contribute to the “anemia of inflammation” 
and microcirculatory problems observed in patients suffering from sepsis [8]. Plasma 
membrane lipid composition is essential for erythrocyte homeostasis [10,11], and changes in 
lipid composition and/or distribution might explain altered erythrocyte characteristics in 
sepsis [7,8,13]. In the human body, the sPLA2 family of phospholipases is the principal 
catalysts for the hydrolysis of GPLs into LPLs and fatty acids, while SMase catalyzes the 
hydrolysis of SM into ceramide and phosphocholine. The activity of both enzymes is 
enhanced in patients suffering from severe sepsis [15,16], and LPLs and ceramide have 
been shown to play a role in the pathology of various inflammatory diseases [17]. sPLA2 has 
attracted particular attention as a therapeutic target in atherosclerosis due to its direct 
involvement in the development of this disease by modifying LDL and HDL [33,39]. In the 
current study we investigated the involvement of sPLA2 lipases in erythrocyte-mediated 
pathophysiology during systemic inflammation.  
In this study we show that the plasma of patients with severe sepsis triggers erythrocyte 
membrane lipid remodeling illustrated by enhanced LPC formation. sPLA2 IIA is the only 
sPLA2 family member of which the secretion is significantly promoted in the circulation 
during sepsis [34], which points towards its involvement in the observed LPC generation in 
erythrocytes. Indeed, we found sPLA2 IIA to be strongly enhanced in our septic patient 
plasmas. However, the plasma sPLA2 IIA concentration did not correlate with the amount of 
LPC generated in the erythrocytes. This might be due to the relatively small group size and 
the large heterogeneity of the patients studied, as patients with different causes of sepsis 
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were included, and nearly all patients had different co-morbidities. The heterogeneity in the 
causes and clinical presentation of sepsis [35] is exemplified by our observation that only 
five out of ten septic patient plasmas induced enhanced LPC formation. Interestingly, we did 
not detect an increase in LPC generation using the plasmas obtained during experimentally 
induced endotoxemia, even though inflammation and a subsequent rise in plasma sPLA2 IIA 
were observed. Thus, although the experimentally-induced acute endotoxemia is a useful 
model for several aspects of sepsis, it does not fully mimic sepsis at the erythrocyte level. 
This could be ascribed to the use of a model that mimics only the initial phase of septic 
shock. Alternatively, the enhanced lipase activity in the septic patients might be mediated by 
inflammatory pathways other than the Toll-like receptor-4 pathway that is triggered by LPS. 
The absence of enhanced LPC formation in the endotoxemia model also points towards the 
involvement of other sPLA2s, and/or the requirement of additional plasma factors to direct 
sPLA2 IIA activity towards erythrocytes. Alternatively, the lack of sPLA2 IIA involvement 
might be due to the strong binding preference of this enzyme for anionic GPLs such as PS, 
which in healthy cells primarily reside in the inner leaflet of the plasma membrane. In 
contrast, sPLA2 type V and X exhibit a much higher preference for PC as a substrate than 
other members of the sPLA2 family, and are thus able to attack healthy cells [33]. This 
makes type V and X sPLA2 possible candidates responsible for the observed LPC 
generation in our study, even though the concentration of these enzymes does not increase 
in the circulation during sepsis [34]. Transgenic sPLA2 X mice have revealed that the 
conversion of a secreted inactive sPLA2 X pro-peptide into the catalytically active enzyme is 
promoted during inflammation [40], effectively enhancing the activity of pre-existing sPLA2 X. 
Other factors that could play a role are plasma phospholipids, mainly in the form of 
lipoproteins, which are reduced in patients with severe sepsis [41]. This reduction was also 
observed during experimentally induced human endotoxemia, but only started appearing 12 
hours after infusion of LPS [42]. Since sPLA2s are able to attack PC in lipoproteins [43,44], 
the readily accessible plasma lipoproteins might compete with PC in erythrocytes for sPLA2 
binding. 
sPLA2 IIA has been implicated in the activation of the inflammatory processes responsible 
for multiple organ failure in sepsis [45,46], and its plasma level correlated with the rate of 
mortality [15,47]. During the human endotoxemia trial, we noticed that sPLA2 IIA status at 
baseline was predictive for the sPLA2 IIA response upon LPS infusion. This suggests that 
there is a pre-existing inter-individual variability in the sPLA2 IIA response to systemic 
inflammation. It remains to be elucidated whether this can be harnessed as a predictive 
biomarker for lipid remodeling/signaling in response to systemic inflammation. 
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The induction of LPC formation through plasma of the sepsis patients, as shown in our 
current study, points towards the involvement of membrane lipid remodeling in this process, 
and could potentially explain enhanced erythrocyte clearance in patients with severe sepsis. 
Therefore, we propose to assess erythrocyte clearance, removal markers, and membrane 
lipid remodeling and hydrolysis in future studies. 
In contrast to earlier findings [13], we did not observe the formation of ceramide after 
erythrocyte incubation with septic patient plasma. This discrepancy is probably caused by 
the use of different techniques to detect ceramide in the erythrocyte membrane. Kempe et 
al. combined a monoclonal mouse anti-ceramide IgM (clone 15B4) with flow cytometry to 
detect ceramide in erythrocytes [13]. Unfortunately, this antibody is aspecific as it does not 
only detect ceramide, but also recognizes phosphatidylcholine and sphingomyelin [48]. 
Furthermore, we have previously noticed that the reactivity of this antibody with the 
erythrocyte also depends on the membrane organization [14]. In contrast, the use of our 
current MS method enables both specific and sensitive detection of different ceramide 
species in membrane lipid preparations [30]. 
The absence of LPLs other than LPC in our study can be explained by the inability of the 
responsible plasma lipases to attack their substrate GPLs, since they primarily reside in the 
inner leaflet of the plasma membrane [10,11]. Enhanced LPC formation contributes to 
inflammatory signaling in sepsis [17], and LPC acts as a substrate for lysophospholipase D 
and LPC acetyltransferase, to produce the pro-inflammatory lipid mediators (LPA) and 
platelet-activating factor [49]. Enhanced activity of these enzymes might explain why LPC 
plasma levels are reduced in septic patients [32]. LPA has been suggested to open a 
calcium channel in the erythrocyte membrane [50], resulting in exposure of the removal 
signal PS and subsequent microparticle generation [37]. 
We observed an increase in the percentage of PS-exposing erythrocytes in healthy subjects 
after LPS infusion. PS exposure on the outer leaflet of the plasma membrane alters 
rheologic and hemostatic properties of the erythrocyte [10], and is a recognition signal for 
their removal [51-53]. Fever is one of the hallmarks of systemic inflammation, which is 
known to enhance phagocytic activity [54]. The negative correlation between PS exposure 
and body temperature indicates increased phagocytic activity in our patients. Since PS-
exposing erythrocytes are rapidly removed from the circulation, the increase in PS-exposing 
erythrocytes observed in our endotoxemia trial likely underrepresents the actual number of 
erythrocytes that expose PS after LPS infusion. In addition, PS exposure makes 
erythrocytes sensitive to sPLA2 IIA-mediated GPL hydrolysis in vitro [19,55], promoting 
further membrane lipid remodeling. In addition, significant LPC buildup in the erythrocyte 
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membrane can induce hemolysis [19,56], alter morphology, induce microparticle release, 
and reduce deformability leading to splenic retention ex vivo.[9] However, since LPC is 
quickly metabolized by lysophospholipases and acyltransferases [57], it is uncertain whether 
such a build-up will occur in vivo. Both the removal and/or metabolism hypotheses fit with 
our inability to detect LPC in the erythrocytes taken from the patients with septic shock.  
PS exposure and PC hydrolysis in the membrane may thus contribute to the reduced 
erythrocyte lifespan in “anemia of inflammation” [3-5]. This might also impact erythrocyte 
transfusion in septic patients, as blood bank erythrocytes are already more prone to expose 
PS [58]. This hypothesis is in line with the association of erythrocyte transfusion with 
increased morbidity and mortality in these patients [6]. Erythrocyte PS exposure just prior to 
LPS infusion was found to be predictive for the extent of erythrocyte PS exposure upon LPS-
induced inflammation. This is in line with our previous finding that PS exposure on stored 
erythrocytes predicts their extent of PS exposure after the application of osmotic stress [29]. 
Determining the PS exposure in erythrocyte concentrates might therefore allow the selection 
of preferred products for the transfusion of septic patients. Since blood bank erythrocytes 
were also found to be more susceptible for SMase activity, it would be interesting to assess 
whether this also applies to sPLA2s [14]. 
 
Conclusions 
We here provide evidence for erythrocyte membrane lipid remodeling during systemic 
inflammation, as illustrated by enhanced LPC formation and PS exposure during sepsis and 
endotoxemia. The enhanced LPC formation in erythrocytes could not be attributed to sPLA2 
IIA alone, and was not observed in experimentally induced endotoxemia. As membrane lipid 
remodeling affects erythrocyte integrity, it is necessary to focus future research on 
elucidating the identity of the phospholipase(s) involved in erythrocyte membrane LPC 
generation during sepsis. Comparing the endotoxemia model with actual septic patients 
would be helpful in short-listing relevant candidates, as the enhanced ability to hydrolyze PC 
is lacking in the endotoxemia model.  
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Summary 
Microparticles (MPs) are small plasma membrane-derived vesicles that can expose 
molecules originating from their parental cells. As vectors of biological information they are 
likely to play an active role in both homeostasis and pathogenesis, making them promising 
biomarkers and nanomedicine tools. Therefore, there is an urgent need for standardization 
of MP isolation and analysis protocols to propel our understanding of MP biology to the next 
level. Based on current methodology and recent insights, this chapter proposes an optimized 
protocol for the isolation and biochemical characterization of MPs. 
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Introduction 
MPs constitute a promising alternative microparticulated drug delivery system, with 
significant advantages over liposomes and nanoparticles [1,2]. Since MPs are an integral 
part of the regular blood transfusion products, their biocompatibility poses a relatively small 
challenge compared to other delivery vehicles. Especially erythrocyte transfusion units 
provide a reliable natural source for large quantities of erythrocyte-derived MPs, often 
termed red cell MPs (RMPs). Their negative surface charge and rapid clearance by the 
reticulo-endothelial system may be used for efficient targeting to resident and circulating 
macrophages as well as to the vascular endothelium [3]. This makes them promising agents 
for use in nanomedicine for the treatment of vascular diseases, as immunosuppressors in 
inflammatory and autoimmune diseases [4,5], and as delivery platforms for imaging agents 
[6]. 
MPs were first described by Peter Wolf in 1967, when he observed a halo of debris 
surrounding activated platelets which he termed “platelet dust” [7]. Since then the techniques 
that are available for MP detection have greatly improved and diversified, and now include 
flow cytometry, dynamic light scattering, nanoparticle tracking analysis, fluorescence 
correlation spectroscopy, immunoblotting, mass spectrometry, and transmission electron 
microscopy and atomic force microscopy [8,9].  
Unfortunately, MP nomenclature has also diversified with time, replacing “dust” for an array 
of terms including nanoparticle, microvesicle, exosome-like vesicle, ectosome, oncosome, 
texosome, prostasome, epididymosome, and dexosome, depending on the sample source or 
isolation protocol used. To add to the confusion, microparticles are often designated as 
exosomes, smaller (40-100 nm) particles of endocytic origin, and apoptotic blebs (50-5000 
nm) released by dying cells [8,10,11]. 
Most commonly, MPs are defined as plasma membrane-derived vesicles with a diameter of 
100 to 1000 nm that expose molecules specific to the parental cell, with the majority residing 
in the 100 to 200 nm range [8,10,12]. Depending on their origin MPs may contain an array of 
signaling molecules, including receptors, cytokines, mRNA, microRNA and bioactive lipids. 
This molecular composition renders MPs vectors of biological information. As such they play 
an active role in homeostasis and pathogenesis, the latter including atherosclerosis, various 
malignancies, autoimmune disorders, and infection [10,13]. Therefore, MPs may be 
harnessed as diagnostic and/or prognostic biomarkers for disease [14-17].  
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The majority of the blood-borne MPs are generated by erythrocytes and platelets [12,18,19] 
RMPs are generated as part of the physiological erythrocyte aging process [20-22], and 
platelet-derived MPs (PMPs) are involved in coagulation after vascular injury [12]. During 
storage in the blood bank, erythrocytes and platelets continuously shed MPs, which might be 
responsible for some of the side-effects observed after transfusion [23,24]. 
As a consequence, proper identification and quantification of MPs is of great value, but the 
methods that are currently applied to isolate, characterize, and quantify MPs are far from 
standardized, and contain several technical hurdles [8,25]. The call for a consensus on both 
MP nomenclature, and methods for isolation and identification has therefore increased over 
the last years, and was one of the main topics during the first annual meeting of the 
International Society for Extracellular Vesicles [26]. A widely supported consensus on these 
aspects will prove vital for future MP research, as the current lack of methodological clarity 
obfuscates the identification and the molecular elucidation of their generation and of their 
biological function. 
This review briefly discusses the possibilities of RMPs and PMPs for future science and 
medicine, while focusing on the technical limitations and challenges in isolation and flow 
cytometry analysis of MPs from plasma and from transfusion products. 
 
RMPs and PMPs in health and disease 
RMPs 
During aging, the erythrocyte produces numerous RMPs exposing removal signals such as 
phosphatidylserine (PS) and autoantigens, which are probably responsible for their rapid 
removal from the circulation [3,19-21]. Physiologically, erythrocyte MP shedding may 
constitute a protective mechanism to prevent untimely erythrocyte removal [20-22]. 
Furthermore, increased or decreased RMP concentrations have been observed in the blood 
of patients with chronic renal failure, sickle cell disease, β-thalassemia, paroxysmal 
nocturnal hemoglobinuria, graft-versus-host-disease and Scott syndrome [14,15]. These 
findings suggest that RMP concentration (and possibly composition) may be employed as a 
biomarker for disease status. 
Data from in vitro studies suggest that RMPs are likely to be actively involved in 
pathophysiology as well. For example, RMPs from erythrocyte storage units were found to 
modulate platelet function [27], and are highly procoagulant [28,29]. RMPs can transfer 
biologically active molecules, exemplified by the transfer of CD59 from one erythrocyte to the 
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other by membrane fusion in cells from patients with paroxysmal nocturnal hemoglobinuria 
[30]. Furthermore, RMPs may contribute to the procoagulant state and vaso-occlusions in 
sickle cell disease [18,31], and RMPs from malaria-infected erythrocytes were found to be 
major inducers of systemic inflammation during malaria infection [32].  
PMPs 
In contrast to what the name implies, the majority of the PMPs in the circulation are not 
derived from platelets, but from megakaryocytes [33,34]. PMPs are likely to be important 
mediators of coagulation, not only by exposing procoagulant factors [12,29,35], but also by 
providing a platform for binding of additional platelets to the subendothelial matrix [12,36]. 
PMPs may be involved in various other processes, such as hemostasis, maintenance of 
vascular health, and immunity [16]. Prominent examples are the involvement of PMPs in 
vasoregeneration [37,38], the transfer of CD41 integrin and CXCR4 receptors from 
megakaryocytes to nucleated cells in vitro [39], and their assistance in leukocyte-leukocyte 
interaction via P-selectin binding to PSGL-1 [40]. In addition, PMPs can transfer microRNA 
to endothelial cells, and thereby reprogram them [41,42]. 
Like RMPs, PMP levels are altered in various disease states, indicating that they play a role 
in thrombotic and inflammatory diseases, as well as in cancer progression [16]. A recent 
example is the pivotal role of PMPs in rheumatoid arthritis, where enhanced glycoprotein VI-
mediated PMP generation may lead to PMP build-up in the joint fluid of patients suffering 
from inflammatory arthritis (but not osteoarthritis), inducing an inflammatory response via 
interleukin-1 signaling [43]. A related study showed the formation of highly pro-inflammatory 
PMP-immune complexes in patients with rheumatoid arthritis [44].  
MPs in transfusion medicine 
During blood bank storage, erythrocytes and platelets shed MPs [20,45]. These MPs might 
be responsible for some of the side-effects commonly observed after transfusion 
[4,5,23,24,46]. RMPs from storage products are enriched in removal signals such as PS, 
immunoglobulins, and complement [20,46]. The supernatant of erythrocyte transfusion units, 
which contains many RMPs that were shed during storage, was found to have the ability to 
modulate the functions of T cells [5], neutrophils [47], macrophages [4], and monocytes [48] 
in vitro. Transfusion supernatant also caused lung inflammation and coagulopathy in a rat 
model [49]. These findings strengthen the view that a high dose of RMPs received upon 
transfusion, might be responsible for or contribute to the inflammatory and/or immunological 
side-effects of transfusion, including autoantibody formation [50]. Storage may also prime 
erythrocytes to shed RMPs after transfusion [51], adding to the already present storage RMP 
burden. 
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Next to coagulation, platelets also have an important role as immune mediators [52,53], 
making PMPs likely candidates for immune regulation as well [24,54-56]. Side-effects of 
platelet transfusion include fever and transfusion-related acute lung injury [55]. and 
enhanced PMP levels in platelet units were shown to be correlated with various allergic 
transfusion reactions [54]. The ability of PMPs to interact with leukocytes via P-selectin 
binding to PSGL-1 [40,54], as well as their potential to induce CD154 (CD40L)-mediated B 
cell activation [57], underscore their ability to affect the immune system. The plethora of 
signaling molecules on PMPs makes it even more likely that they contribute to the 
transfusion burden [16,58]. While most circulating PMP derive from megakaryocytes [33,34], 
CD62-positive platelet-derived MPs constitute an important part of the storage PMP burden, 
and likely have a distinct biological function [54,59].  
MP removal 
One aspect of MPs that has received little attention thus far is their removal from the 
circulation. Phagocytosis is believed to be the main mechanism by which MPs are eliminated 
in vivo [3]. RMPs were rapidly removed in a rat model, mainly by the reticulo-endothelial 
system in the liver and in the bone marrow, and mediated by scavenger receptors [3]. 
The enrichment of RMPs in removal signals such as PS, immunoglobulins, and complement 
[20,22,46], likely causes this rapid removal by macrophages [3,22]. Further elucidation of the 
mechanisms involved in the generation of these signals, including PS exposure [60,61], 
autoantigen formation, and CD47 as a marker of ‘self’ and ‘non-self’ [62,63], might help to 
understand RMP removal. Both RMP and PMP removal seem to biphasic [64], but in 
contrast to RMPs, PMPs appear to have a half-life of hours instead of seconds [65]. PMPs 
are phagocytized by endothelial cells in a developmental endothelial locus-1-dependent 
manner [66]. This suggests that different pathways for MP removal exist depending on the 
cell of origin. 
 
MP analysis using differential centrifugation in combination with flow cytometry 
Focusing on RMPs and PMPs, this part of the review provides an overview of the current 
views on the most commonly used methods for the isolation, identification, quantitation and 
biochemical characterization of MPs in peripheral blood samples and transfusion products. 
We also provide new insights based on our own recent observations, which raise additional 
questions regarding current MP analysis strategies [8,67,68]. 
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The most common protocol for analysis of MPs consists of differential centrifugation followed 
by fluorescence flow cytometry analysis [69]. Flow cytometry does not allow one to define 
size distribution and is poor at detecting very small particles (<200 nm), such as exosomes 
and smaller MPs. This is exacerbated by “swarm” detection of multiple small MPs as a single 
event using flow cytometry [70]. Consequently, the detected MPs do not represent the entire 
population. The upside of flow cytometry is that it enables the distinction of MPs of different 
cellular origin and the analysis of biochemical composition using fluorescently-labeled 
antibodies and other probes (e.g. Figure 1) [9]. 
 
 
Figure 1. Flow cytometry analysis of PMPs and RMPs from plasma. Whole blood from a healthy volunteer 
was obtained in an EDTA Vacutainer and centrifuged for 5 min at 1500g. The plasma was depleted of platelets 
and large membrane fragments by 20 min centrifugation at 1500g. MPs were pelleted by 30 min centrifugation at 
20,000g. The MPs were washed with calcium-free Ringer solution, resuspended in regular Ringer solution and 
probed for PS (Annexin V), the PMP marker CD41 and the RMP marker CD235a. This protocol prevented clot 
formation. After additional washing, the MPs were resuspended and fluorescent count beads (10 µm diameter) 
were added for MP quantification. (A) Size beads (0.9 µm diameter) were used to delineate the upper boundary 
for FSC/SSC MP gating. (B, C) MPs were analyzed on a flow cytometer, gated according to forward/sideward 
scatter (FSC and SSC, respectively) for fluorescent probe (α-CD41 and α-CD235a) analysis. (D) PS exposure of 
PMP and RMP populations was also analyzed. All solutions used were complemented with 0.2% BSA and 
filtered (0.22 µm) before use. A FACSCalibur (BD Biosciences) flow cytometer was used in combination with 
Annexin V-FLUOS, and anti-CD235a-PE and anti-CD41-PC5 antibodies. Detectors/Amps: FSC – V=E01, 
Amp=9.99; SSC – V=375, Amp=1.50; FL1 – V=690; FL2 – V=665; FL3 – V=800. Compensation: FL1 – 0.9% 
FL2; FL2 – 27.0% FL1; FL2 – 2.5% FL3; FL3 – 15.0% FL2. 
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The options for MP isolation from sample fluids are very limited. They consist of differential 
centrifugation and/or gradient purification, resulting in impure MP preparations contaminated 
with exosomes, apoptotic blebs and protein aggregates including immune complexes 
[8,25,26]. In spite of these limitations, the combination of differential centrifugation and flow 
cytometry has proven to be invaluable for the detection of changes in the make-up and size 
of MP populations in various disease states [14-17]. 
Optimization of the pre-analytical handling of MPs and the analysis itself is still in its early 
stages, and there is a strong need for standardization of protocols, in order to enable better 
comparison of data [8,26,69]. There are a multitude of parameters that affect the final 
composition and biological activity of the isolated MP fraction, many of which will be 
discussed below. 
Blood collection 
The method of blood collection, including the needle diameter, application of a tourniquet, 
and the use of a vacutainer to withdraw blood may all affect the MP concentration in the 
sample. In addition, the type of anticoagulant used has a profound effect on observed MP 
numbers, as exemplified by the apparent loss of PMP and endothelial cell-derived MP in 
chelating anticoagulants [71,72]. For erythrocyte-derived RMP, no such data are available, 
but in our hands, citrate (Acid Citrate Dextrose, ACD) and heparin are both suboptimal, i.e. 
detecting less RMP, in comparison with EDTA (Figure 2A). This might be due to 
anticoagulant-mediated aggregation or adherence of RMPs to plastic, which results in a 
depletion of MPs and thus in an underestimation. Alternatively, specific anticoagulants may 
affect RMP stability. Regardless of the underlying mechanisms, these data indicate that 
variation in anticoagulant may very well contribute to the - sometimes considerable - 
variation in the MP subpopulation sizes in plasma [22,73]. Our results indicate that RMPs 
may be more abundant in the circulation than previously assessed using citrate [72,74], 
suggesting that RMPs might play a more important role in circulatory homeostasis than 
presently believed. 
The time between blood collection and MP isolation may affect the number of MPs in the 
sample, in part depending on the type of anticoagulant used [71,75,76]. We did not observe 
an increase in PMP nor in RMP number in the first four hours after blood collection using 
EDTA as an anticoagulant (Figure 2B). Thus, because of the effect of anticoagulant on 
biological activity of the MP fraction, standardization of the anticoagulant and the time 
between blood collection and processing is important to compare the results from different 
laboratories. 
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Figure 2. Impact of anticoagulant, wash buffer, and whole blood storage time on RMP and PMP 
enumeration. PMPs and RMPs from three healthy volunteers were isolated and quantified using α-CD41 and α-
CD235a antibodies as described in Figure 1. (A) Whole blood was obtained using different anticoagulants, and 
PMPs and RMPs from whole blood were isolated and quantified. (B) PMPs and RMPs from whole blood (EDTA) 
were isolated and quantified at different time points after blood withdrawal. (C) PMPs and RMPs from whole 
blood (EDTA) were pelleted and either stained directly in plasma, or washed and stained in phosphate-buffered 
saline (PBS), or calcium-free Ringer (IR) solution with or without BSA. The graphs represent mean values, error 
bars represent S.D., and *P<0.05 using repeated measures one-way ANOVA with Tukey’s post-test. 
 
Centrifugation 
The common centrifugation parameters used for MP isolation vary between 1,500 to 10,000 
g for 5 to 20 minutes in the initial centrifugation step to remove cells and platelets, followed 
by 13,000 to 100,000 g for 30 to 60 minutes to pellet MPs. These differences in 
centrifugation speed and time greatly affect the outcome of MP enumeration. Centrifugation 
may induce microparticle aggregation and PS exposure, and thereby also biological activity 
[68].  
In our hands, intact erythrocytes and platelets, and large membranous fragments are 
effectively removed by centrifugation between 1,200 and 2,000 g for 15 to 20 minutes, 
whereas the use of an initial centrifugation speed >2,000 g leads to a substantial loss of 
MPs. We obtained maximum MP counts in our flow cytometry setup (see the Legend to 
Figure 1), when MPs were pelleted at 20,000 g for 20 to 30 minutes in a commonly used 
table-top centrifuge. Ultracentrifugation will pellet smaller MPs in the pellet, including the so-
called nanovesicles and exosomes [8]. However, the detection limit of most flow cytometers 
will not allow the analysis of these smaller MPs [9]. Filtration using 0.8 µm porous 
membranes is occasionally used to remove residual platelets from MP isolates [25]. 
However, this may not only lead to platelet activation and/or MP fragmentation [77,78], but 
also leads, in our hands, to a severe loss of MPs (Figure 3). 
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Figure 3. Large-scale PMP isolation from platelet transfusion units. The contents of three 7 day old platelet 
apheresis ACD plasma products were centrifuged for 15 min at 2000g. Part of each supernatant was used for 0.8 
µm filtration. The remaining supernatant was aliquotted (1mL), and MPs were pelleted by 45 min centrifugation at 
20.000g, and washed with IR containing BSA. The MPs were then resuspended in 10 µL IR+BSA per aliquot, 
snap-frozen with liquid N2, and stored at -80°C. (A, B) Platelets and MPs in the unit itself (1:20 dilution), (B, C) 
MPs after isolation, (B) after filtration and after thawing were analyzed on a FACSCalibur flow cytometer, 
according to forward/sideward scatter (FSC and SSC, respectively), for assessment of CD41, CD235a and PS 
exposure. The graph represents mean values, error bars represent S.D., and *P<0.05 using repeated measures 
one-way ANOVA with Tukey’s post-test. 
 
Washing MPs 
The addition of a washing step after MP isolation may affect MP number and morphology 
[75], but has the advantage that it increases the signal/noise ratio (Figures 3 and 4) Washing 
enables reliable (calcium-dependent) Annexin V binding to detect PS-positive MPs when 
calcium-chelating anticoagulants were used in the collection of the blood. Also, washing is a 
prerequisite for cellular assays, proteomics analysis, and fluorescence and electron 
microscopy [21,58,68]. The impact of washing on MP recovery depends on the type of MP. 
Washing led to a significant decrease in the numbers of PMPs, but not of RMPs (Figure 2C). 
Little attention has been paid to the composition of the buffer used for MP washing. The use 
of the calcium-free Ringer (IR) solution, often used in experimental work with erythrocytes, 
did not give superior MP numbers compared to PBS (Figure 2C). However, the addition of 
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bovine serum albumin (BSA) is beneficial for maintaining MP numbers, probably by 
preventing MP adhesion to the tubes used or to each other, and/or by stabilizing MP integrity 
(Figure 2C). 
MP storage 
At present, the effect of freezing on the quantity and quality of MPs in the final sample is not 
clear [71,72,75,79,80], and there is no consensus on a uniform freezing and thawing method 
[81]. We prefer to snap-freeze platelet-poor plasma or concentrated transfusion unit-derived 
MPs prior to -80°C storage, and to quickly thaw samples in a 37°C water bath before 
analysis [79,81]. Using this approach, we observe a minimal loss of MPs after thawing 
(Figure 3 and 4). Occasionally, thawing platelet-poor plasma results in the formation of 
precipitates that can compromise the analysis (unpublished observations). Although the MPs 
appear to be intact as observed by electron microscopy (Figure 4), PS exposure is clearly 
enhanced in the process (Figure 4), indicating freeze/thaw-induced changes in membrane 
organization and concomitant changes in activity. 
Flow cytometry detection 
Flow cytometry is a popular method for fast enumeration of MPs and the determination of 
their cellular origin. Forward and sideward light scatter by MPs, although different from cells, 
provide a simple way of discerning different MP populations (Figure 1) [9]. 
After isolation and - optional - washing, cellular origin and putative biological activity of MPs 
is mostly assessed using fluorochrome-conjugated probes such as antibodies and/or 
annexin V. Detection may be hampered by the limited number of molecules of interest on the 
MP surface, due to their small size. Assessment of the binding of isotype control antibodies 
is essential to exclude aspecific antibody binding to MPs. We advise the use of MPs that do 
not express the antigen of interest as an additional negative control for antibody binding. 
MP enumeration by flow cytometry is usually achieved by addition of a known number of 
counting beads as an internal standard [67,68]. Hereto, brightly fluorescent polypropylene or 
latex microspheres with a larger diameter (~10 µm) than MP are typically used, since these 
can be detected separately from MPs by their size and bright fluorescence in all 
fluorescence detection channels. Calibrated beads with a size of ~1 µm are often used as an 
additional external standard to define the upper limit of the size gate used to quantify MPs. 
This size gate, combined with Annexin V staining, enables proper distinction between MPs 
from residual platelets and large membrane fragments [68]. 
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Figure 4. Large-scale RMP isolation from erythrocyte transfusion units. The contents of five 35 day old 
SAG-M erythrocyte units were centrifuged for 20 min at 1200g. The supernatants were then centrifuged again for 
20 min at 1200g, and aliquotted (1 mL). MPs were pelleted by 45 min centrifugation at 20,000g, and washed with 
IR containing BSA. The MPs were then resuspended in 10 µL IR+BSA per aliquot, snap-frozen with liquid N2, 
and stored at -80°C. (A, C) Cell fragments (including MPs) in the unit itself (1:20 dilution) and (B, C) MPs after 
isolation and (B) after thawing were analyzed on a FACSCalibur flow cytometer, according to forward/sideward 
scatter (FSC and SSC, respectively), for assessment of CD235a and PS exposure. (D) The mean fluorescence 
intensity (MFI) of the Annexin V staining for PS exposure is also shown. (E) Transmission electron microscopy 
was performed on a fixated MP pellet of a thawed aliquot. The graph represents mean values, error bars 
represent S.D., and *P<0.05 using repeated measures one-way ANOVA with Tukey’s post-test. 
 
PS exposure is probed using the calcium-dependent binding of fluorochrome-conjugated 
Annexin V. Although PS exposure is often used to distinguish true MPs from other particles, 
such as immunocomplexes, PS-negative MP populations have been identified [44,82]. We 
also found that a considerable part of the PMPs do not bind Annexin V (Figure 1). Circulating 
RMP could be divided in PSintermediate and PShigh populations (Figure 1), possibly reflecting two 
distinct modes of MP formation by erythrocytes. In contrast, only PShigh RMPs are observed 
in stored erythrocyte units (Figure 4). To distinguish MPs from false-positive protein 
aggregates, we recommended an additional Triton lysis control [25]. This is particularly 
important when detecting small MP subpopulations, as small numbers of false-positive 
events can severely impact the outcome. In this context, filtration of buffers, washing of 
count beads, and high speed centrifugation of staining solutions is essential to remove small 
fluorescent particles and protein precipitates that compromise MP analysis [80]. In our 
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experience, optimizing the forward/sideward scatter settings of the flow cytometer already 
enables the distinction of PMPs and RMPs (Figure 1). A clear delineation of both populations 
can thus be obtained by combining cell-specific antigen and PS detection with specific 
forward/sideward scatter profiles. The detection of a minor population that is positive for both 
an erythrocyte and a thrombocyte marker (Figure 1), may reflect PMP-RMP adhesion, fusion 
or “swarm” detection of multiple MPs as a single event [70]. 
Analysis of MPs by flow cytometry has been driven mainly by our knowledge of the proteins 
that are present on the plasma membranes of their parent cells. Inventories of the MP 
proteomes make it possible to overcome this obvious restriction. As a first result, recent 
proteomic data, especially on RMPs isolated from the blood and transfusion units [20,21,46], 
have extended the theories on MP generation [83,84]. In a similar fashion, progress is being 
made with understanding MP formation and pathological function through PMP proteomics 
[58,85,86]. We foresee that, in the near future, proteomics data will inspire the selection of 
antibodies for detection of disease-related MP subpopulations. Thus, development of new 
flow cytometry analysis approaches is dependent on proteomic analysis of MPs, provided 
they have been isolated using the same, standardized protocols. 
 
Isolation of transfusion unit-derived RMPs and PMPs 
Recently, we have developed and optimized a protocol for the large-scale isolation of RMPs 
and PMPs from transfusion units. Nearly all erythrocyte unit-derived MPs isolated with this 
protocol are positive for the erythrocyte marker glycophorin, spherical, and have a 
homogeneous size distribution of around 50-200 nm (Figure 4). Furthermore, the 
forward/sideward scatter profile matches that of RMPs found in the circulation (Figure 1). 
Large quantities of clinical grade RMPs can readily be isolated from erythrocyte transfusion 
units, and used to establish standardized MP measurement protocols and as a 
microparticulated drug delivery system. 
The isolation of MPs from platelet-units using differential centrifugation has proved to be 
more difficult, since platelets are only 2-3 µm in size [87]. As a consequence, there is 
substantial overlap in the flow cytometer forward scatter profile of platelets and their MPs, 
due to the limited size resolution of this technology. The differences in size and shape 
between platelets and MPs could be used to separate them more efficiently using scanning 
flow cytometry [88]. Using slightly higher centrifugation speeds, the platelet unit suspension 
can be depleted of platelets enabling the isolation of MPs. The PMP purity can be monitored 
by the percentage of PS-positive events and the forward scatter (Figure 3). A convenient 
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internal standard, as advised above, is provided by the RMPs in the plasma that is used to 
store the platelets. The forward/sideward scatter profile of the final product overlaps that of 
platelets found in the circulation, while PS exposure is significantly higher (Figures 1 and 4).  
 
Conclusion & Future Perspectives 
The growing recognition of the biological role of microparticles necessitates a 
standardization of MP isolation and analysis. This is a sine qua non to reliably detect and 
compare MP numbers, origin and biological activity in health and disease. Initiatives to 
standardize cross-laboratory MP measurements have already been started by the 
International Society on Thrombosis and Hemostasis and the International Society for 
Extracellular Vesicles [26,69]. The present comparison of currently used methods for 
isolation and analysis of MPs, inspired by our recently obtained data, intends to contribute to 
these initiatives. A simplified overview of our standard protocol for the isolation and analysis 
of MPs from various sources is provided in Figure 5. 
New methods are currently developed to detect even the smallest MPs, enabling reliable 
semi-quantitative enumeration of MPs in biological fluids [89,90]. These methods employ 
new flow cytometers equipped with a high-power laser and high-performance photo 
multiplier tubes and wide angle FSC measurements, in combination with bright 
fluorochromes [84,91]. Since RMPs and PMPs are easily detectable in plasma compared to 
other MPs, and can be obtained in large quantities from transfusion products, we propose to 
use RMPs and/or PMPs to establish standardized MP measurement protocols. Combining 
these unambiguous protocols with a selective isolation method such as fluorescence-
activated sorting or immunoaffinity capture [21,92], and rapidly expanding proteomic 
approaches [20,21,46,58,85,86], will provide reliable information on the mechanism(s) 
involved in their generation and on their biological function. They will also enable the 
meaningful use of RMPs and PMPs as tools in nanomedicine and as biomarkers in a variety 
of pathological conditions. 
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Figure 5. Standard protocol for the isolation of MPs from various sources. 
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Executive summary 
Microparticles (MP) 
• There is a need for consensus on microparticle (MP) nomenclature 
• Standardized MP isolation and identification protocols are required to understand 
their biological function 
• With standardized protocols, MPs are a promising alternative microparticulated drug 
delivery system 
 
RMPs and PMPs in health and disease 
• Red cell MP (RMP) production is a protective mechanism to prevent untimely 
erythrocyte removal 
• Platelet-derived MPs (PMP) modulate coagulation and immune responses 
• RMPs and PMPs are potential biomarkers for various diseases and the quality of 
blood bank products 
 
MP isolation and flow cytometry 
• The use of citrate or heparin as anticoagulant leads to an underestimation of the 
RMP population size in the circulation 
• The optimal protocol for RMP and PMP isolation consists of: 1. Removal of cells by 
15 to 20 minutes centrifugation at 1,200 to 2,000 g; 2. MP isolation by 20 to 30 
minutes centrifugation at 20,000 g 
• Additional washing with a filtered buffer containing bovine serum albumin is required 
for optimal MP analysis by cellular assays, proteomics, and microscopy 
• Proper controls are required to avoid false positive events in flow cytometry analysis 
• Probing for PS using flow cytometry reveals the existence of multiple RMP 
subpopulations 
• Erythrocyte transfusion units are an excellent source for RMPs to establish 
standardized MP analysis protocols and microparticulated drug delivery systems 
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Abstract 
Self-tolerance and immune homeostasis is orchestrated by Foxp3+ regulatory T cells 
(Tregs). However, recent insights have revealed that upon stimulation Tregs may exhibit 
plasticity towards a pro-inflammatory phenotype, producing IL-17 and/or IFN-γ. Here, we 
report that platelet-derived microparticles (PMPs) have the capacity to prevent the 
differentiation of peripheral blood-derived Tregs into IL-17 and IFN-γ-producing cells, even in 
the presence of the pro-inflammatory cytokine IL-1β. The mechanism of action consisted of 
rapid and selective P-selectin dependent binding of PMPs to a specialized CCR6+HLA-DR+ 
memory-like Treg subset, probably disrupting their eventual differentiation into potentially 
pathogenic IL-17 producers. Our data also indicate that the inhibitory effect of PMPs on 
memory-like Treg differentiation may lie in their ability to affect cell proliferation. These 
findings open up the exciting possibility that PMPs actively regulate the immune response at 
sites of vascular inflammation, where they are known to accumulate and interact with 
leukocytes, consolidating the vascular healing process and preventing vascular disease. 
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Introduction  
Forkhead box p3 (Foxp3)+ regulatory T cells (Tregs) play a key role in maintaining dominant 
self-tolerance and immune homeostasis, and modulate immune responses during infection. 
The expression of the transcription factor Foxp3 is essential for their suppressive capacity 
towards effector cells, as is exemplified by the severe systemic autoimmunity observed in 
humans with impaired Foxp3 function [1]. 
In recent years, the classical view of helper CD4+ T (TH) cell subsets belonging to distinct cell 
lineages, has given way to the idea that these subsets exhibit a certain amount of plasticity, 
being able to alter their cytokine profile or even switch TH cell phenotype [2]. We have 
previously determined that CD4+CD25highFoxp3+ Tregs can differentiate into IL-17 and IFN-γ-
producing cells and lose their master regulator Foxp3 when activated, particularly in the 
presence of the pro-inflammatory cytokine IL-1 [3]. Such functional plasticity of human Tregs 
has been observed by others as well [4-7]. However, the mechanisms controlling Treg 
stability are just beginning to be unraveled. 
Platelets are small (~2 µm in diameter), circulating, enucleate cells that are derived from 
megakaryocytes residing in the bone marrow. Once thought to be restricted to their critical 
role in hemostasis by initiating blood clotting at sites of vascular injury, it is becoming 
increasingly clear that platelets can modulate immune responses through the expression of 
immunomodulatory molecules such as CD40L, Toll-like receptors, and various chemokines 
and cytokines, including IL-1 [8].  
Once activated, platelets not only release chemokines and cytokines [8], but also plasma 
membrane-derived microparticles into the circulation [9]. These platelet-derived 
microparticles (PMPs) are in the submicron range, and expose molecules specific to the 
parental cell as well as the lipid phosphatidylserine (PS). Their ability to transfer membrane 
receptors [10] and microRNA [11] to other cells, mark them as vectors of biological 
information. Like their parental cells, they are involved in hemostasis, maintenance of 
vascular health, and immunity [9,12]. An example of their involvement in immune responses, 
is their potential to induce CD40L-mediated B cell activation [13]. PMPs were also found to 
accumulate in the joint fluid of patients suffering from inflammatory arthritis, and are 
suggested to induce a local inflammatory response in the synovium through PMP-bound IL-
1-dependent signaling [14].  
The notion that PMPs can influence cells of the immune system under inflammatory 
conditions, combined with the knowledge that such conditions also affect Treg phenotype, 
 
Chapter 7 
 
136 
led us to investigate the effect of PMPs on Tregs. Here, we show that PMPs inhibit the 
differentiation of highly purified peripheral blood CD4+CD25highCD127lowFoxp3+ Tregs into IL-
17/IFN-γ-producing cells when stimulated with anti-CD3/CD28 monoclonal antibody (mAb) 
coated beads and cultured in the presence of IL-2, IL-15 and IL-1β. This PMP interaction 
with, and the subsequent inhibition of Treg differentiation, appears to be P-selectin-
dependent, as PMP blocking with an antagonistic anti-P-selectin mAb before co-culture 
restored the differentiation capacity of Tregs into 17/IFN-γ-producing cells. Prior to, and 
during Treg activation and subsequent differentiation, PMPs selectively bound Tregs 
expressing CCR6 and HLA-DR, believed to represent a memory-like Treg precursor subset 
for IL-17-producing cells [6,15]. Our data indicate that PMPs affect cell proliferation, 
providing a possible mechanism by which the memory-like Treg subset is inhibited. These 
findings open up the exciting possibility that PMPs actively regulate the immune response at 
sites of vascular injury, where PMPs are known to accumulate [16]. 
 
Results 
PMPs inhibit CD25highFoxp3+ Treg differentiation into IL-17-producing cells 
We reasoned that PMPs, with their arsenal of immune-mediating molecules [9], and their 
ability to interact with cells of the immune system [13,14], might impact the differentiation of 
Tregs into IL-17-producing T cells, such as we previously described [3]. As we required large 
amounts of PMPs for our studies, we used PMPs that were isolated from 7 day stored 
platelet apheresis products of healthy volunteers, as these products are known to 
accumulate PMPs during storage [17]. Their purity, size and number was assessed by flow 
cytometry analysis of the exposure of PS and the platelet-specific marker CD41 (Figure 1A). 
Over 99 % of all measured events were smaller than 1 µm in diameter, and more than 95 % 
stained positive for CD41 and PS. 
 
Figure 1. PMPs inhibit Treg differentiation into IL-17-producing cells. Flow cytometry analyses of Tregs that 
were cultured in the presence of anti-CD3/anti-CD28-coated beads, and human recombinant IL-2, IL-15, and IL-
1β, in the presence or absence of PMPs. Intracellular cytokine staining was performed after stimulation with PMA 
and ionomycin, in the presence of Brefeldin A. (A) CD41+PS+ PMPs <1 µm were purified from platelet apheresis 
units of healthy volunteers by differential centrifugation and analyzed by flow cytometry for phosphatidylserine 
(PS) and CD41 exposure as described in methods. Size beads (0.9 µm) were used to set a size exclusion gate, 
and fluorescent count beads (~10 µm) were added to the PMPs for quantification. The contour plots are 
representative for three donors. (B) Representative experiment showing intracellular IL-17 and IFN-γ staining of 
the Tregs at day 0. (C-D) Representative example of the intracellular IFN-γ, IL-17 and Foxp3 staining of Tregs 
that were cultured for 7 days with and without 5×106 PMPs. (E) A representative experiment performed with 
ascending PMP concentrations from three different healthy volunteers. Surface CCR6, CD27, and intracellular IL-
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17, IFN-γ, and Foxp3 staining of the Tregs at day 7 of culture are shown. Error bars represent SD. * P < 0.05. (F) 
Overview of experiments showing surface CCR6, CD27, CD62L, and intracellular IL-17, IFN-γ, and Foxp3 
staining of Tregs cultured for 7 days with ascending PMP concentrations. Each dot (n = 3-5 PBMC donors) 
represents the mean of a separate experiment with PMPs from three healthy volunteers tested in parallel. The 
average mean is presented as bars. * P < 0.05. 
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These PMPs were then co-cultured with a highly pure, well-defined, 
CD4+CD25highCD27+CD127lowFoxp3+ Treg population isolated from peripheral blood 
mononuclear cells (PBMCs) by fluorescence-activated cell sorting (Supplemental Figure S1). 
Typically, anti-CD3/CD28 mAb stimulation of this population in the presence of IL-2/IL-15 
and IL1-beta leads to a substantial number of IL-17 producing cells, with concomitant loss of 
Foxp3  [3]. 
The addition of PMPs to the freshly isolated Tregs at ratios of 1:8, 1:40, or 1:200 per cell, 
clearly inhibited the generation of IL-17 and IFN-γ-producing cells in a dose-dependent 
manner (Figure 1B-C and 1E-F). Similarly, the loss of Foxp3 expression was inhibited. 
(Figure 1D-F). Interestingly, of the few cells that still managed to acquire IL-17-producing 
capacity in the presence of PMPs, most did not lose their Foxp3, suggesting a transitory 
state due to inhibition. Previous studies have revealed that CD4+CD25+CD27+CD62L+ cells 
constitute a highly suppressive Treg subset [18-20]. In accordance with Foxp3, loss of CD27 
and CD62L was also prevented, while the percentage of cells that acquired the TH17 [21] 
and memory-associated [22] chemokine receptor CCR6 during culture was inhibited by the 
PMPs (Figure 1E and 1F). 
P-selectin mediates PMP inhibitory effect on Treg differentiation 
After establishing that PMPs affect cytokine production by Tregs, the question arose which 
molecular component(s) of the PMPs were responsible for the observed effect. We first 
asked ourselves whether the communication between PMPs and Tregs was contact-
dependent. A transwell setup was implemented to culture PMPs and Tregs in two separate 
compartments of a single volume, using identical culture conditions as mentioned before. 
Intracellular IL-17 expression was assessed on day 7 (Figure 2A), and showed that the 
Tregs were unaffected by the PMPs in the transwell setup, while the dose-dependent 
inhibition (P < 0.05) of Treg differentiation into IL-17-producing cells was observed in the 
standard contact-dependent setup as expected. 
 
Figure 2. PMP inhibition of Treg differentiation is P-selectin dependent. Tregs were cultured for 7 days in 
the presence of anti-CD3/anti-CD28-coated beads, and human recombinant IL-2, IL-15, and IL-1β, in the 
presence or absence of PMPs (n = 3 PMP donors). Intracellular cytokine staining was performed after stimulation 
with PMA and ionomycin, in the presence of Brefeldin A. (A) The intracellular IL-17 expression in Tregs that were 
co-cultured with PMPs as a standard mixed culture (control), or separated by a porous membrane (transwell). (B) 
The presence of the platelet-specific marker CD41 was assessed on the CD4+ Tregs after co-culture with 
ascending PMP concentrations. Each dot represents the mean of a separate experiment with PMPs from three 
healthy volunteers tested parallel to each other. The average mean is shown. (C) Representative contour plots of 
PMPs stained with anti-CD41-PE and FITC conjugated anti-P-selectin or isotype mAbs. The contour plots are 
representative for three donors. (D) Treg expression of PSGL-1 and CD25 at day 0 of culture. (E) Surface 
staining of CD27, CD41, and intracellular staining of IL-17 on Tregs co-cultured with untreated, isotype, or anti-P-
selectin mAb blocked PMPs. (F) Surface staining of CD62L, CCR6, and intracellular staining of Foxp3 and IFN-γ 
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on Tregs co-cultured with untreated, isotype, or anti-P-selectin mAb blocked PMPs. The graphs are 
representative for two experiments. Mean and SD are shown. * P < 0.05. Flow cytometry was employed for the 
analyses. 
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The contact-dependency ruled out the possibility of cytokine scavenging or release by the 
PMPs significantly affecting Treg differentiation. Therefore, we focused our attention on 
potential PMP membrane-bound molecules. Since CD40-CD40L co-stimulatory signaling 
was implicated in PMP-mediated signaling [13], and T cells can sense PS [23], we 
investigated their involvement. However, blocking of either CD40 in culture or PS on PMPs 
with an antagonistic anti-CD40 mAb or Annexin V, respectively, did not reduce the inhibitory 
effect of PMPs on Tregs (Supplemental Figure S2).  
As we observed clear staining for the platelet-specific marker CD41 on at least part of the 
Tregs co-cultured with PMPs (Figure 2B), even after repeated washing steps, we proposed 
that PMPs firmly bound to these cells and consequently, we hypothesized that adhesion 
molecules, several of which are present on the PMP membrane [9], might be involved in the 
interaction. Upon activation, platelets typically expose the adhesion molecule P-selectin, 
which they can pass onto the PMPs they generate [24]. Like their parental cells, PMPs are 
able to bind immune cells expressing P-selectin receptor P-selectin glycoprotein ligand-1 
(PSGL-1) [25,26]. This led us to investigate whether P-selectin is involved in the observed 
PMP adhesion to Tregs and/or the inhibition of their differentiation. First, we established that 
the majority of PMPs (86.3 ± 2.4%) indeed expressed P-selectin (Figure 2C), and that the 
Tregs express its receptor PSGL-1 at day 0 (Figure 2D), and subsequently performed 
blocking studies. Prior to co-culture with Tregs, PMPs were incubated with a FITC-
conjugated antagonistic anti-P-selectin mAb, an isotype control mAb, or incubated in plain 
buffer, and subsequently washed. While isotype mAb did not bind to the PMPs (0.4 ± 0.1%), 
PMPs were effectively blocked with the anti-P-selectin mAb (80.6 ± 4.4%). The anti-P-
selectin mAb was still present on the PMPs at day 7 of culture with Tregs (77.4 ± 7.1%). 
Notably, the blocking of P-selectin not only abrogated (CD41+) PMP adhesion to the Tregs 
(Figure 2E), it also greatly blunted their inhibitory effect on Treg differentiation into CCR6+ IL-
17-producing cells, as shown by CD27 and intracellular IL-17 staining (Figure 2E). Blocking 
of P-selectin also allowed for loss of Foxp3 and CD62L, and IFN-γ expression by Tregs 
(Figure 2F), corroborating these results. 
PMPs selectively target CCR6+HLA-DR+ memory-like and IL-17-producing Tregs 
Typically, only a subset of peripheral blood derived Tregs start producing IL-17 upon 
stimulation [3-7]. Further insight into the features of this subset might guide us in the 
characterization and regulation of these cells. Sparked by the observation that the PMPs 
only associated with a subset of the Tregs (Figure 2B), while inhibiting IL-17 production, we 
argued that we might use this characteristic to pinpoint the IL-17 precursors within the whole 
Treg population. 
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To establish the identity of the Treg subset(s) targeted by the PMPs, and to determine 
whether this interaction occurs before the Treg differentiation progresses, we followed PMP 
binding to Tregs in time over a 7 day culture (Figure 3). Binding of (CD41+) PMPs to Tregs 
already occurred within 1 day of culture (Figure 3A). The PMP binding to Tregs increased 
with enhanced expression of the P-selectin receptor PSGL-1 (Figure 3A), which is in line 
with the observed requirement of P-selectin in the PMP-Treg interaction. On day 7 a 
significant reduction in the percentage of CD41+ Tregs was observed (Figure 3A). 
 
 
 
Figure 3. PMPs selectively target CCR6+HLA-DR+ Tregs prior to, and during, activation. 
Tregs were cultured for 7 days in the presence of anti-CD3/anti-CD28-coated beads, human recombinant IL-2, 
IL-15, and IL-1β, and 5×106 PMPs. Tregs were stained for surface markers and analyzed by flow cytometry at 
day 0, 1, 4 and 7; (A) CD41+ PMP-bound Tregs, and the expression level of PSGL-1 on the Tregs. (B) 
CCR6+HLA-DR+ Tregs present in the CD41- and CD41+ subpopulations. (C) Example CCR6/HLA-DR dot plots of 
CD41- and CD41+ Tregs. Mean and SD for three PMP donors are shown. * P < 0.05. 
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Figure 4. PMPs are bound to Tregs expressing IL-17, IFN-γ, and Foxp3. Tregs were cultured for 7 days in the 
presence of anti-CD3/anti-CD28-coated beads, human recombinant IL-2, IL-15, and IL-1β, and 5×106 PMPs. 
Intracellular cytokine staining was performed after stimulation with PMA and ionomycin, in the presence of 
Brefeldin A. Surface and intracellular markers were combined with CD41 staining for flow cytometry analysis of 
their distribution in the PMP-negative and positive subpopulations; (A) IL-17-producing cells, (B) IFN-γ-producing 
cells, and (C) IL-17-producing cells that co-express Foxp3. Example IL-17/Foxp3 density plots of all cells, 
CD41- and CD41+ Tregs are shown. A density plot of Tregs cultured without PMPs is also shown as reference. 
Each dot represents the mean of a separate experiment (n = 3) with PMPs from three healthy volunteers tested 
parallel to each other. The average mean is shown. * P < 0.05. 
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CCR6 positive Tregs constitute a memory-like phenotype [22] that was found to harbor the 
majority of Tregs with potential IL-17-producing capacity [3,6,15]. Therefore, we assessed 
CD41 and CCR6 expression on the Tregs in time, combined with HLA-DR which defines a 
Treg subset with a higher cytokine-producing capacity [27]. Strikingly, a strong binding 
preference of PMPs was observed for CCR6+HLA-DR+ double-positive, but not for single-
positive Tregs, throughout days 1 to 7 of culture (Figure 3B-C). A preference for (memory) 
CD45RO+ and chemokine receptor CXCR3- Tregs was also observed (data not shown). 
As PMP co-culture did not fully inhibit IL-17 production, we wanted to check whether the 
remaining IL-17 producing cells revealed PMP binding at day 7 of culture. Indeed, nearly the 
entire CD41+ Treg pool exhibited enhanced intracellular IL-17 expression and contained 
approximately 5-fold more potent IL-17 producers, than the CD41- Treg population (Figure 
4A). Similar results were obtained for IFN-γ (Figure 4B). Importantly, upon closer 
examination of the IL-17-producing cells that interacted with the (CD41+) PMPs, the majority 
had retained their FoxP3 expression (Figure 4C), suggesting a state of partial inhibition. In 
contrast, the majority of IL-17-producing cells that did not have bound PMPs had fully lost 
their Foxp3 expression, similar to the IL-17-producing cells in the Treg culture without PMPs 
(Figure 4C). Thus, the PMPs selectively interact with CCR6+HLA-DR+ Tregs throughout co-
culture, inhibiting the differentiation of many of these cells into IL-17-producing cells, which 
was earlier demonstrated by us not to occur before day 6 of culture [3]. Furthermore, of the 
Tregs with bound PMPs that did acquire IL-17-producing capacity, most were in a Foxp3+IL-
17+ transitory state due to the inhibitory effect of the PMPs. 
 
Discussion 
In recent years it has become clear that Foxp3+ regulatory T cells, known as guardians of 
dominant self-tolerance and immune homeostasis [1], show plasticity towards IL-17 and IFN-
y production [3-7]. Furthermore, Treg plasticity has been observed towards IFN-y production 
in patients with type 1 diabetes [28], and towards IL-17 production in patients with psoriasis 
[29]. These new insights suggest a pro-inflammatory role for these cells that expands 
beyond the traditional view of Treg function. We have previously reported that this process is 
driven by IL-1β and IL-23 [3], and the involvement of other cytokines such as IL-6, IL-21 and 
TGF-β in T helper 17 (TH17) cell development have been established as well [30,31]. 
However, the signaling moieties governing Treg stability are only just beginning to be 
uncovered.  
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The immune functions that have recently been ascribed to platelets [8] and their 
microparticles [9,13,14], their ability to interact with lymphocytes [8,25,26], and the 
involvement of PMP bound IL-1 in inflammatory arthritis [14], led us to investigate the 
involvement of PMPs in the differentiation of Tregs into IL-17 and IFN-y-producing cells. 
Our main findings show that PMPs have the capacity to prevent Treg differentiation into IL-
17 and IFN-γ-producing cells when activated in the presence of IL-2, IL-15, and the pro-
inflammatory cytokine IL-1β. The mechanism of action consisted of rapid and selective P-
selectin dependent PMP binding to a CCR6+HLA-DR+ memory-like Treg subset, known to 
contain the majority of progenitor TH17-like cells [6,15], disrupting their eventual 
differentiation into IL-17 producers. The few Tregs with bound PMPs that did acquire IL-17-
producing capacity were in a Foxp3+IL-17+ transitory state, likely due to the inhibitory effect 
of the PMPs. 
Leukocytes play a central role in wound repair, and are recruited after coagulation and the 
resulting vascular inflammation is initiated [32]. PSGL-1 is the high affinity counter receptor 
for the cell adhesion molecule P-selectin. PSGL-1 is expressed on most leukocytes, and 
mediates their recruitment to inflamed endothelium by binding P and E-selectin expressed 
on activated endothelial cells [33]. P-selectin exposure by adherent activated platelets 
further assists leukocyte recruitment to the inflamed tissue [8]. Moreover, activated platelets 
release P-selectin positive PMPs [24], which also accumulate at sites of vascular injury [16], 
and are able to bind PSGL-1 positive leukocytes [25,26]. 
We show that PMPs can bind peripheral PSGL-1 positive memory-like Tregs through P-
selectin-mediated adhesion, possibly participating in their recruitment to sites of vascular 
injury. Tregs were indeed found to be involved in local tissue repair by restricting the pro-
inflammatory response in experimental kidney and lung injury mouse models [34,35]. 
Vascular infiltration of TH17 and TH1 cells is enhanced in patients with systemic vasculitis, 
and fewer Tregs were observed in the lesions [36,37]. Interestingly, Foxp3+ cells were 
shown to contribute to the IL-17 production in vascular lesions of these patients [38]. Our 
observations fuel the tantalizing possibility that PMPs might assist in the control, and 
eventual resolution, of inflammation during tissue repair, by stabilizing Treg phenotype and 
preventing their differentiation into TH1 or TH17-like cells in a pro-inflammatory 
microenvironment. One could argue that PMPs can easily enter inflamed tissue due to their 
small size and ability to interact with leukocytes, allowing them to hitchhike to the site of 
inflammation to exert their regulatory function. P-selectin expression on platelets was found 
to be upregulated in patients with systemic vasculitis [39]. Also, macrophages are key 
players in the regulation of tissue inflammation [40], express PSGL-1 which promotes 
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adherence and functional changes [41], and their pro-inflammatory capacity was also found 
to be inhibited by PMPs [42]. Finally, loss of P-selectin [43,44] and PSGL-1 [43] has been 
suggested to promote lupus. 
Increased PSGL-1 expression was observed on all Tregs concomitantly with PMP binding 
upon Treg activation. Nevertheless, the PMPs showed a high preference for CCR6+HLA-
DR+ double positive Tregs, suggesting additional requirements need to be met for effective 
PMP binding. A possible explanation for this differential binding is that only upon T cell 
activation gycosyltransferases required to modify PSGL-1 to its active binding state are 
upregulated [45]. 
PSGL-1 engagement induces downstream signaling events that affect T cell phenotype and 
function [33]. Deletion of PSGL-1 increased T cell proliferation and exacerbated 
inflammation in a mouse model [46]. Initial data suggest that PMPs can affect Treg 
proliferation (data not shown), and might constitute one of the mechanisms for their 
remarkable ability to hamper Treg differentiation into IL-17-producing cells, as we have 
previously shown that this transition requires sufficient cell proliferation [3]. Platelets have 
also been shown to attenuate T cell proliferation, but in contrast to PMPs, promoted T cell 
differentiation and pro-inflammatory cytokine production in vitro [47]. Although PMPs did not 
significantly alter overall cell death in our study, PSGL-1 cross-linking was found to induce 
death of activated T cells [48], and might also participate in the observed effect of PMPs on 
the CCR6+HLA-DR+ Treg subset. Other scenarios could include the involvement of 
additional signaling pathways next to PSGL-1, for example through the transfer of genetic 
information from PMPs to their bound Tregs [11], or by initiating Treg-Treg signaling by PMP 
binding to multiple Tregs [25]. The involvement of other adhesion molecules should also be 
considered, exemplified by the ability of CD18 to keep Treg differentiation into IL-17-
producing cells in check [49]. 
In contrast to what the name implies, most PMPs in the circulation were found not to 
originate from platelets, but are instead produced by megakaryocytes in the bone marrow 
[50,51]. These megakaryocyte-derived microparticles (MKMPs) are abundant in healthy 
individuals [9,12], while platelet-derived microparticles, identified by the expression of 
platelet activation markers P-selectin and/or CD63, are only observed during 
(cardiovascular) disease [24,52]. This implies that while MKMPs have a more systemic 
function, PMPs may act locally at sites of platelet activation, and each have their own distinct 
role in homeostasis. We used platelet apheresis units as a source for our PMPs, since they 
are known to generate relatively large quantities of PMPs in a controlled and sterile 
environment [53]. The majority of the isolated PMPs were P-selectin positive, and thus 
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originated from activated platelets in the concentrates. Our findings also add to the 
understanding of PMPs in platelet transfusion medicine, of which little is known thus far [54]. 
We have identified a novel function of PMPs to selectively bind a specialized subset of TH17-
like progenitor cells in the Treg compartment, and inhibit their differentiation into potentially 
pathogenic effector cells. The direct involvement of the cell adhesion molecule P-selectin 
and its counter receptor PSGL-1 in this process, suggests a role for PMPs in vascular 
healing by participating in the regulation of the required inflammatory response. 
 
Methods 
PMP isolation, storage and anti-P-selectin mAb blocking 
Single donor platelet-rich plasma (PRP) was collected from three healthy volunteers by 
apheresis upon written informed consent according to the Declaration of Helsinki for 
scientific use. Using a component collection system (MCS+, Haemonetics, Braintree, MA) in 
combination with Acid Citrate Dextrose Solution A, 300×109 leukoreduced (<1×106 
leukocytes/unit) platelets were collected in 300 mL of plasma, and stored in a lateral shaking 
device at 22 ± 2°C for 7 days.  
At day 7 of storage PMPs were isolated from the PRP product under sterile conditions using 
a differential centrifugation method previously described [55]: The PRP was centrifuged at 
2000g for 15 min to remove platelets and cell debris. The supernatant was aliquotted (1 mL), 
centrifuged for 45 min at 20.000g to pellet PMPs, and washed with 0.22 µm filtered calcium-
free Ringer’s solution (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 32 mM HEPES, 5 mM 
glucose, 0.2% bovine serum albumin, pH 7.4). The PMPs were then resuspended in 10 µL 
calcium-free Ringer’s solution, snap-frozen with liquid N2, and stored at -80°C until use. The 
microparticle purity and quantity was assessed by flow cytometry on a FACSCalibur system 
(BD Biosciences, Franklin Lakes NJ, USA) as previously described [56], using sulfate latex 
microspheres (0.9 µm; Invitrogen, Carlsbad CA, USA), washed Flow-Count Fluorospheres 
(Beckman Coulter, Brea CA, USA), and combined Annexin V-FLUOS (Roche, Basel, 
Switzerland) and anti-CD41-PE mAb (P2; Beckman Coulter) labeling. 
P-selectin blocking was performed by incubating PMPs for 30 min at room temperature in 1 
mL calcium-free Ringer’s solution containing anti-P-selectin-FITC mAb (10 µg/mL, AK-4; 
eBioscience, Uithoorn, The Netherlands), known to block P-selectin [57]. PMPs were 
pelleted by centrifugation and all but 10 µL of supernatant was removed. PMPs incubated 
with FITC-labeled isotype mAb or plain calcium-free Ringer’s solution served as a negative 
control. PMPs were then washed with calcium-free Ringer’s solution. Antibody binding was 
checked by flow cytometry directly after blocking, and on PMPs recovered from day 7 culture 
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medium of co-cultures with Tregs. PS blocking of PMPs with human recombinant Annexin V 
(100 µg/mL; kindly provided by Dr. W.L. van Heerde) was performed in a similar fashion, 
with the addition of 2.5 mM calcium during blocking and throughout culture to enable 
effective Annexin V binding. 
Cell isolation and culture of cells 
PBMCs were isolated by density gradient centrifugation (Lymphoprep; Nycomed-Pharma 
AS, Oslo, Norway) of buffy coats obtained from healthy donors upon written informed 
consent according to the Declaration of Helsinki with regard to scientific use. CD4+ T cells 
were purified from PBMCs by magnetic bead sorting using CD4 MicroBeads (Miltenyi Biotec, 
Leiden, The Netherlands) according to the manufacturer’s instructions. Purified CD4+ T cells 
were labeled with CD4-FITC (MT310; DAKO, Glostrup, Denmark) and CD25-PE (MA251; 
BD Biosciences, Erembodegem, Belgium), after which CD4+CD25high cells (Tregs) were 
isolated by high-purity flow cytometry cell sorting using an Aria cell sorter (Beckman 
Coulter). A rerun was performed to analyze the cell purity of the sorted cells; sorted cells 
were always >99% pure. 
Cells were cultured in culture medium (RPMI-1640 with glutamax supplemented with 0.02 
mM pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin [all from Gibco, Paisley, United 
Kingdom], and 10% human pooled serum) at 37°C, 95% humidity, and 5% CO2, in 96-well 
round-bottom plates (Greiner, Frickenhausen, Germany). Anti-CD3/anti-CD28-coated beads 
(1:10; Invitrogen, Breda, The Netherlands), and recombinant human cytokines IL-2 (25 
U/mL; Cetus, Amsterdam, The Netherlands), IL-15 (10 ng/mL), and IL-1β (50 ng/mL) 
(Biosource, Etten-Leur, The Netherlands) were added at the start of the cultures, in the 
presence or absence of an ascending number of PMPs. CD40 blocking on Tregs was 
performed by the addition of an antagonistic anti-CD40 mAb kindly provided by Dr. M. de 
Boer (1 µg/mL; Tanox Pharma B.V., Amsterdam, The Netherlands) at least 1 hour before the 
addition of PMPs. ThinCerts™ cell culture inserts (0.4 µm; Greiner Bio-one, Wemmel, 
Belgium) for 24-well flat-bottom plates were used for the transwell assay, with the cells and 
the PMPs placed in the upper and the lower compartments, respectively. 
Flow cytometry and antibodies 
Cells were phenotypically characterized using the FC500 and the GalliosTM Flow Cytometers 
(Beckman Coulter, Miami, FL, USA). The following conjugated mAb antibodies were used: 
CD4(MT310)-FITC, CD27(M-T271)-FITC (DAKO), CD25(M-A251)-PE, CCR6(11A9)-PE (BD 
Biosciences), PSGL-1(FLEG)-APC, CD25(BC96)-PeCy7, CD127(eBioRDR5)-PeCy7 
(eBioscience), CD4(SFCI12T4D11)-ECD or PeCy7, CD41(P2)-FITC or PE, 
CD62L(DREG56)-ECD, HLA-DR(Immu-357)-ECD (Beckman Coulter). Prior to flow 
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cytometry analyses, all conjugates were titrated and individually tested for sensitivity, 
resolution and compensation of spectral overlap. Isotype-matched antibodies were used to 
define marker settings. 
Intracellular analysis of Foxp3(PCH101)-FITC, IL-17A(EBIO64DEC17)-AlexaFluor647, and 
IFN-γ(4S.B3)-PeCy7 (eBioscience) was performed after fixation and permeabilization using 
Fix/Perm reagent (eBioscience). Before intracellular cytokine measurements, the cells were 
stimulated for 4 hours with PMA (12.5 ng/mL) plus ionomycin (500 ng/mL) in the presence of 
Brefeldin A (5 µg/mL; Sigma-Aldrich, Zwijndrecht, The Netherlands). All flow cytometry data 
were analyzed using Kaluza® software (Beckman Coulter). The “logicle” scale was applied 
in certain cases to better visualize negative populations. 
Statistics 
Paired t tests, repeated measures one-way (+Tukey’s post-test) or two-way (+Bonferroni 
post-test) ANOVAs were used for statistical analysis. The reported (two-sided) p values of 
<0.05 were considered significant and are indicated with an asterisk (*). Data in the text is 
presented as mean ± SD. 
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Figure S1. CD4+CD25highCD27+CD127lowFoxp3+ Tregs cell sorting. After CD4+ T cell isolation from PBMCs by 
magnetic bead sorting, CD4+CD25high T cells were purified by fluorescence-activated cell sorting. The sorted cells 
were checked for surface CD25, CD27, CD127, and intracellular FoxP3 expression. Flow cytometry was 
employed for the analyses. 
 
 
                    
Figure S2. CD40 and PS blocking does not affect PMP inhibition of Treg differentiation. Left: Intracellular 
staining of IL-17 on Tregs co-cultured with PMPs in the presence of anti-CD40 antagonistic mAb. Right: 
Intracellular staining of IL-17 on Tregs co-cultured with untreated and Annexin V blocked PMPs. Tregs were 
cultured for 7 days in the presence of anti-CD3/anti-CD28-coated beads, and human recombinant IL-2, IL-15, 
and IL-1β, in the presence of PMPs (n = 3 PMP donors). Intracellular cytokine staining was performed after 
stimulation with PMA and ionomycin, in the presence of Brefeldin A. Flow cytometry was employed for the 
analyses. Mean and SD are shown. 
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Summary and General Discussion 
Erythrocytes are unique in their ability to transport oxygen to, and remove CO2 from the 
peripheral tissues. Another unique feature of the erythrocyte is its extensive deformability, 
which is required to efficiently pass through the narrow capillaries of the microvasculature 
and the fenestrae in the spleen [1]. Their lack of intracellular organelles prevents 
erythrocytes from undergoing apoptosis in the manner of nucleated cells. However, 
erythrocytes have a well-defined life span of about 120 days [2], resulting in the removal of 
2.5 million old erythrocytes from the circulation per second.  
Although the exact mechanisms governing physiological erythrocyte removal remain elusive, 
significant progress has been made by the identification of a few key regulatory components. 
Binding of physiological autoantibodies to antigens that are formed as the result of oxidative 
damage, is assumed to be the essential trigger leading to erythrocyte phagocytosis by the 
reticulo-endothelial system [3]. Phosphatidylserine (PS) externalization to the outer plasma 
membrane leaflet plays a central role in the apoptosis of nucleated cells, as it leads to 
recognition and subsequent phagocytosis of these cells by macrophages. Research fueled 
by this knowledge has led to the consensus that PS exposure is a co-factor in the removal of 
damaged erythrocytes as well [4]. 
Erythrocyte vesiculation has been suggested to play an integral part in erythrocyte survival, 
by enabling the erythrocyte to get rid of damaged cell components [5]. Although much 
progress has been made in recent years in our ability to characterize the resulting 
extracellular microparticles, we are only just beginning to understand their function in the 
homeostasis of the human body. 
The majority of this thesis focusses on erythrocyte plasma membrane changes that occur 
during storage and systemic inflammation, in the context of erythrocyte removal. In the last 
part of this thesis, the attention shifts towards the characterization of extracellular 
microparticles in transfusion products, and the role of these microparticles in immune 
homeostasis. An overview of the current knowledge regarding these topics is provided in 
Chapter 1. 
 
Erythrocyte storage  
Erythrocyte transfusions save the lives of millions of patients coping with severe blood loss 
after trauma, inadequate erythrocyte production or enhanced erythrocyte clearance [6]. 
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However, erythrocyte transfusions can also have serious side effects, such as acute lung 
injury, severe organ damage due to iron deposition, vasoconstriction, and alloantibody and 
autoantibody formation [7]. Especially a frequent transfusion regime causes severe side 
effects, as is often the case for patients suffering from a myelodysplastic syndrome, aplastic 
anemia or a hemoglobinopathy. The structural and biochemical changes that occur during 
erythrocyte storage are thought to be responsible for these side effects [8]. 
A prominent side effect that arises often after repeated transfusions, is the generation of 
anti-erythrocyte autoantibodies [9]. A plausible explanation for this side effect is the 
formation of aberrant antigens during erythrocyte storage. In order to identify these antigens, 
we screened erythrocytes for pathologic antigen formation during storage (Chapter 2). We 
observed an increase in pathologic anti-erythrocyte autoantibody binding with storage time, 
demonstrating that non-physiological autoantigens are formed during storage. 
Immunochemical and mass spectrometric analysis revealed several candidate antigens on 
the erythrocytes, which differed from those on erythrocyte concentrate-derived 
microparticles. The latter suggests that storage microparticles have immunological activity 
that is different from stored erythrocytes. 
In the Netherlands, erythrocyte concentrates must be used for transfusion within 35 days 
after their collection, in order to meet the quality standards of a maximum of 0.8% hemolysis 
in the concentrate and 75% erythrocyte survival during the first 24 hours after transfusion 
[10,11]. Erythrocyte survival after transfusion is seldom measured due to practical 
limitations, but a large variation in erythrocyte survival is observed after transfusion [12], 
which is likely related to both the blood donor and the recipient patient. The commonly used 
parameters for erythrocyte concentrate quality, such as hemolysis and ATP concentration, 
are poor predictors of erythrocyte survival after transfusion [13-15]. 
In Chapter 3, we investigated whether PS exposure might be a parameter for donor-
dependent variation in erythrocyte product quality. PS exposure was found to vary between 
donors, both on freshly isolated and stored erythrocytes, and increased with time in most 
concentrates. The initial PS exposure was predictive for erythrocyte PS exposure upon 
stress in vitro, and was associated with hemolysis and microparticle concentration. These 
data reveal that the fraction of PS-exposing erythrocytes is a sensitive parameter of cell 
integrity in erythrocyte concentrates. Given its functional relationship with erythrocyte 
removal, PS exposure may be an indicator for erythrocyte survival after transfusion as well. 
During the 1940’s and 1950’s, several erythrocyte survival studies were performed in 
volunteers in vivo [16]. The wealth of biochemical data on erythrocyte changes during 
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storage that have been revealed since that time [8], including the work described in 
Chapters 2 and 3, calls for erythrocyte quality trials in vivo aimed at assessing the impact of 
these changes on erythrocyte survival. These trials can, for example, clarify whether 
erythrocyte HbA1c concentration [17], PS exposure, and/or vesiculation during storage may 
affect and/or predict erythrocyte survival after transfusion. If so, they can be used as a 
biomarker to select superior erythrocyte units, or even donors, for patients who require 
repeated transfusions over an extended period of time. Unfortunately, erythrocyte clearance 
characteristics in mice are different from those in humans [18], ruling out the use of mouse 
models for the reliable evaluation of erythrocyte survival parameters. The use of radioactive 
isotopes (e.g. chromium-51), and the recent biotinylation approach to label erythrocytes for 
erythrocyte survival trials, raise concerns regarding their potentially harmful side effects 
[19,20]. Instead, we propose to transfuse erythrocyte concentrates mismatched for minor 
blood group antigens, in order to enable identification and/or isolation of the transfused 
erythrocytes [12].  
The plethora of data available on the changes observed in the erythrocyte during storage [8] 
sparked the discussion that longer storage time increases the risk of side effects for the 
recipient. Controversy remains over whether or not erythrocyte storage time affects clinical 
outcome in the total patient population [21-23]. In order to resolve this controversy, two large 
clinical trials are currently underway, the US-based initiative Red Cell Storage Duration 
Study (RECESS), and the complementary UK and Canadian co-initiative Age of Blood 
Evaluation (ABLE) [22]. Meanwhile, we support the recent shift in research focus towards 
(the regulation of) intracellular changes during erythrocyte storage, made possible by new 
techniques such as proteomics and metabolomics [24], as this will propel our understanding 
of the erythrocyte storage lesion to the next level. Also, the use of novel ex vivo 
erythropoiesis techniques in combination with siRNA protein knockdown [25], lentiviral 
expression of proteins tagged with (fluorescent) reporter proteins, or lentiviral knockdown 
[26] will certainly contribute to our understanding of erythrocyte homeostasis in health and 
disease.  
 
Erythrocyte membrane lipid remodeling in the critically ill 
Erythrocyte transfusions are associated with increased morbidity and mortality in critically ill 
patients [27]. The systemic inflammation that is typically observed in these patients is likely 
to affect the function and survival of the transfused erythrocytes, and this effect may very 
well become more pronounced with storage. This notion is fueled by the observation that 
erythrocyte shape, deformability, and aggregability were altered in septic patients [28,29]. 
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Interestingly, incubation of erythrocytes from healthy volunteers with plasma of septic 
patients was found to induce PS exposure and hydrolysis of membrane sphingomyelin (SM), 
generating ceramide [30]. Ceramide formation is known to alter plasma membrane function 
and integrity [31]. Sphingomyelinase (SMase) is secreted into the circulation during 
inflammation, and is the primary catalyst for SM hydrolysis [32]. 
We studied the functional consequences of SMase on erythrocyte function in detail (Chapter 
4). We found that erythrocytes are very sensitive to SMase-induced ceramide formation. 
Ceramide build-up in the plasma membrane led to loss of discoid shape, followed by PS 
exposure, and subsequent loss of cell integrity. During this process, enhanced microparticle 
formation and reduced deformability were observed. Erythrocytes aged both in vivo and in 
vitro were far more sensitive to SMase-induced changes than younger erythrocytes.  
In Chapter 5, we describe the analysis of the plasma membrane lipid content of freshly 
isolated erythrocytes from healthy volunteers after incubation with the plasma of patients 
with septic shock. While ceramide could not be detected, we found markedly increased 
levels of lysophosphatidylcholine (LPC), which is produced by phospholipase A2. Although 
secretory phospholipase A2 IIA was greatly enhanced in the plasma of septic patients, its 
concentration did not correlate with the LPC levels. Enhanced LPC levels were not detected 
when erythrocytes were incubated with the plasma of healthy volunteers, in whom sepsis 
was simulated by infusion of a low dose of lipopolysaccharide. Thus, the experimentally-
induced acute endotoxemia model does not fully mimic sepsis at the erythrocyte level.  
Interestingly, erythrocyte PS exposure increased in these subjects after lipopolysaccharide 
infusion.  
These data show that the lipid constituents of the erythrocyte membrane are altered during 
systemic inflammation, which may affect erythrocyte survival in these patients. Stored 
erythrocytes have an enhanced sensitivity for the SMase-induced changes, as described in 
Chapter 4. The increase of this sensitivity with storage time indicates that the age of 
erythrocyte concentrates may very well affect transfusion outcome in patients with systemic 
inflammation. This issue may be clarified by the aforementioned clinical studies [22]. 
Although lipid metabolism is significantly altered during systemic inflammation [33], lipid 
alterations in the erythrocyte have not received much attention so far [34]. The work 
described in Chapter 5 paves the way for a more detailed investigation of the effects of 
lysophospholipids on the (stored) erythrocyte and the identity of the lipase(s) responsible for 
their formation. It will be informative to determine the fate of transfused erythrocytes, 
including removal rate, PS exposure and LPC content, in patients with systemic 
inflammation using the noninvasive minor antigen method referred to in the previous section. 
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The resulting data could then be correlated to other parameters of lipid metabolism, such as 
phospholipase activity in the plasma. 
 
Extracellular microparticles: harmful or helpful? 
During its time in the circulation, the erythrocyte loses membrane surface due to continuous 
vesiculation [5,35,36]. The resulting vesicles, often termed red cell microparticles (RMPs), 
are thought to result from an innate process that is intended to remove damaged/aged 
membrane patches, which postpones the recognition and elimination of functional 
erythrocytes [5,37-39]. Therefore, it comes as no surprise that erythrocytes shed similar 
microparticles during blood bank storage [37]. 
In the last decade, it has become clear that extracellular microparticles play an active role in 
homeostasis and pathogenesis, the latter including atherosclerosis, autoimmune disorders, 
and infection [40-42]. This has triggered investigations into the nature and function of 
microparticles of different origin, including RMPs. In Chapter 6, our current understanding of 
the potential involvement of RMPs in disease and transfusion side-effects is highlighted. 
RMPs are procoagulant [43,44], and impair vasodilation through NO scavenging [45]. Also, 
RMPs are involved in the procoagulant state and vaso-occlusions in patients with sickle cell 
disease [46,47]. Recent data show that RMPs from malaria-infected erythrocytes contribute 
to inflammation through potent macrophage stimulation [48], and these RMPs have even 
been suggested to be a means of cellular communication within the parasite population [49].  
Until now, RMPs were only incidentally recognized as potential mediators of transfusion-
related side-effects. As a result, only a few studies have been performed to assess the 
implications of the RMP transfusion burden for the recipient. RMPs contain high levels of 
bound immunoglobulins and complement factors [37], which implies that they have 
immunomodulatory properties. In Chapter 2, we observed that pathologic anti-erythrocyte 
autoantibodies recognize RMPs from erythrocyte concentrates, suggesting that RMPs 
expose pathologic autoantigens as well. As RMPs were rapidly removed by cells of the 
immune system in a rat model [36], a sudden peak in circulating allogeneic RMPs after 
transfusion is likely to affect immune homeostasis. Indeed, RMPs from erythrocyte 
concentrates were shown to have a pro-inflammatory effect on monocytes, and to boost 
subsequent T cell responses in vitro [50]. We therefore propose future investigations on 
RMPs as a potential trigger of erythrocyte transfusion-induced anti-erythrocyte autoantibody 
formation [9]. 
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In contrast to erythrocytes and RMPs, platelets are increasingly recognized to initiate and 
accelerate immune responses [51,52]. As reviewed in Chapter 6, platelet-derived 
microparticles (PMPs) possess pro-inflammatory properties of their own, illustrated by the 
observation that glycoprotein VI-mediated PMP generation causes PMPs to accumulate in 
the joint fluid of patients suffering from inflammatory arthritis (but not osteoarthritis), inducing 
an inflammatory response through interleukin-1 signaling [53]. Therefore, PMPs are now 
implicated to play a role in the inflammatory side-effects often observed after platelet 
transfusion [54]. Recent work has revealed that most ‘PMPs’ in the circulation do not 
originate from platelets at all, but are produced by megakaryocytes instead [55,56]. 
However, true PMPs, expressing the platelet activation marker P-selectin, are abundantly 
present in platelet concentrates [57,58], and may have inflammatory functions that are 
different than those of the megakaryocyte-derived microparticles found in the circulation. 
In Chapter 7, we present a novel regulatory function of PMPs in regulatory T cell (Treg) 
plasticity. Forkhead box p3 (Foxp3)-positive Tregs are essential for maintaining dominant 
self-tolerance and immune homeostasis [59]. However, recent insights have revealed that, 
upon stimulation, Tregs exhibit plasticity towards a pro-inflammatory phenotype, producing 
IL-17 and/or IFN-γ [60-64]. The signaling moieties governing Treg stability are only just 
beginning to be uncovered. We show that PMPs possess the capacity to inhibit cytokine IL-
1β-driven differentiation of peripheral blood-derived Tregs into IL-17 and IFN-γ-producing 
cells. This inhibitory effect was caused by rapid and selective binding of PMPs to a 
specialized CCR6+HLA-DR+ memory-like Treg subset, which is known to host progenitors of 
potentially pathogenic IL-17 producers [63,65]. Binding of, and inhibition by PMPs, was P-
selectin-dependent, since pre-treatment of PMPs with a P-selectin-blocking antibody 
inhibited their effect. Our data indicate that PMPs affect cell proliferation, providing a 
possible mechanism by which the memory-like Treg subset is affected.  
Leukocyte recruitment is an essential part of vascular healing [66], involving P-selectin-
mediated interaction with the vascular endothelium [67] and the adherence of activated 
platelets [68]. Vascular infiltration of TH17 and TH1 cells is enhanced in patients with 
systemic vasculitis and Foxp3+ Tregs were not observed in the lesions [69,70]. Interestingly, 
Foxp3+ cells contribute to the IL-17 production in vascular lesions of these patients [71]. P-
selectin-expressing PMPs that are released by activated platelets, also accumulate at sites 
of vascular injury [72]. Thus, our findings open up the possibility that PMPs might assist in 
the control, and eventual resolution, of inflammation during tissue repair, by stabilizing the 
Treg phenotype in a pro-inflammatory microenvironment. Also, macrophages play a central 
role in the regulation of tissue inflammation [73], and their function was also found to be 
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regulated by PMPs [74]. Finally, as we used platelet apheresis units as a source for P-
selectin-expressing PMPs, our findings add to the understanding of the effects of PMPs in 
platelet transfusion medicine. 
 
Conclusion 
In this thesis we provide new insights into the erythrocyte storage-induced biochemical 
changes of the erythrocyte plasma membrane that may contribute to unwanted side effects 
as well as reduced erythrocyte survival after transfusion. Also, our data indicate that 
erythrocyte membrane lipid remodeling is linked to reduced erythrocyte survival in patients 
with systemic inflammation, which might explain the increased morbidity and mortality 
observed in critically ill patients after transfusion. Future erythrocyte survival studies in vivo 
may help to identify the physiological and pathological significance of the observed changes.  
We have also identified a novel activity of PMPs, namely the binding to a specialized subset 
of Tregs, and the inhibition of their differentiation into pro-inflammatory cytokine-producing 
cells. The involvement of the cell adhesion molecule P-selectin suggests a role for PMPs in 
vascular healing by participating in the regulation of the inflammatory response. In vivo 
studies focusing on PMPs in vascular healing and inflammation may shed more light on the 
physiological relevance of the immune-regulating properties of PMPs.  
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Nederlandse Samenvatting 
Rode bloedcellen zijn verantwoordelijk voor het transport van zuurstof naar en de 
verwijdering van CO2 uit de organen in het lichaam. Om tot bij alle cellen te kunnen komen, 
moeten rode bloedcellen zeer vervormbaar zijn, zodat ze zelfs de kleinste haarvaatjes en 
het filtreersysteem in de milt kunnen passeren. In tegenstelling tot de meeste andere cellen 
bezitten rode bloedcellen geen intracellulaire organellen. Deze organellen voeren voor de 
cel essentiële functies uit, waaronder de gecontroleerde dood van de cel wanneer deze te 
oud en/of beschadigd is. Ondanks de afwezigheid van deze organellen hebben rode 
bloedcellen toch een goed gedefinieerde levensduur van ongeveer 120 dagen. Elke 
seconde worden er 2.5 miljoen oude bloedcellen uit onze bloedstroom verwijderd. Voor deze 
gereguleerde verwijdering is een belangrijke rol weggelegd voor het celmembraan, dat is 
opgebouwd uit eiwitten en vetten. 
Alhoewel de exacte mechanismen die verantwoordelijk zijn voor de verwijdering van rode 
bloedcellen niet bekend zijn, kennen we wel enkele belangrijke schakels. Gespecialiseerde 
eiwitten van het immuunsysteem, autoantistoffen genaamd, herkennen specifieke patronen 
(antigenen) in beschadigde eiwitten op het celmembraan van oude rode bloedcellen. De 
binding van deze autoantilichamen leidt tot de herkenning en verwijdering van deze rode 
bloedcellen door fagocyten, in opruimen gespecialiseerde cellen. Het verschijnen van het vet 
fosfatidylserine, dat zich normaliter aan de binnenzijde van het celmembraan bevindt, aan 
de buitenzijde van de cel helpt hierbij. 
Cellen kunnen delen van hun celmembraan afsnoeren en vervolgens afstoten in de vorm 
van vesikels, ook wel extracellulaire micropartikels genoemd. Alhoewel er de afgelopen 
jaren veel vooruitgang is geboekt met betrekking tot de identificatie en karakterisatie van 
deze micropartikels, weten we nog maar weinig over hun functie. Er wordt verondersteld dat 
rode bloedcellen hun levensduur vergroten door beschadigde delen van hun celmembraan 
te verwijderen via dergelijke micropartikels.  
Het grootste deel van dit proefschrift gaat over veranderingen die plaats vinden in het 
celmembraan van rode bloedcellen gedurende hun opslag in de bloedbank of in het lichaam 
tijdens gegeneraliseerde ontstekingsprocessen en die betrokken zijn bij hun uiteindelijke 
verwijdering uit het bloed. In de laatste twee hoofdstukken van dit proefschrift wordt er 
aandacht besteed aan de karakterisatie van micropartikels in bloedzakken en hun rol bij het 
moduleren van ons immuunsysteem. In Hoofdstuk 1 van dit proefschrift wordt een overzicht 
gegeven van de huidige stand van zaken betreffende deze onderwerpen. 
Ieder jaar redden bloedtransfusies de levens van miljoenen mensen. Helaas kunnen 
bloedtransfusies soms ook ernstige bijwerken hebben, zoals acute longschade, 
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orgaanschade door ijzerstapeling, vernauwing van de bloedvaten en de vorming van 
schadelijke (auto)antistoffen. Deze bijwerkingen worden hoogstwaarschijnlijk veroorzaakt 
door veranderingen die plaats vinden in de rode bloedcellen terwijl ze bewaard worden in de 
bloedbank. 
De vorming van schadelijke autoantistoffen die gericht zijn tegen rode bloedcellen is een 
bekende bijwerking van herhaalde bloedtransfusies. In sommige gevallen leiden deze 
antilichamen tot het verlies van rode bloedcellen, met bloedarmoede tot gevolg. Een 
plausibele verklaring voor dit fenomeen is het onstaan van abnormale antigenen op rode 
bloedcellen tijdens hun opslag in bloedzakken. In Hoofdstuk 2 hebben we de mogelijke 
vorming van dergelijke antigenen onderzocht. We zagen een toename in binding van 
schadelijke autoantistoffen gericht tegen rode bloedcellen naarmate rode bloedcellen langer 
bewaard werden. Dit toont aan dat er abnormale antigenen gevormd worden op rode 
bloedcellen tijdens hun opslag. Ook hebben we enkele membraaneiwitten kunnen aanwijzen 
waaruit de abnormale antigenen waarschijnlijk ontstaan. Een vergelijkbare aanpak liet zien 
dat rode bloedcel-micropartikels uit bloedzakken ook abnormale antigenen hebben, maar dit 
bleken niet helemaal dezelfde te zijn als die in de rode bloedcellen. 
In Nederland moeten rode bloedcel bloedzakken binnen 35 dagen na afname gebruikt 
worden om te kunnen voldoen aan de kwaliteitsnormen. Deze normen bestaan uit een 
maximaal verlies van 0.8% van de rode bloedcellen (hemolyse) gedurende hun opslag en 
een minimaal overlevingspercentage van 75% van de rode bloedcellen in de eerste 24 uur 
na transfusie. Hoewel het bekend is dat er een grote variatie is in dit overlevingspercentage, 
die waarschijnlijk afhangt van zowel de bloeddonor als de ontvanger, wordt dit vanwege 
praktische beperkingen maar zelden gemeten. Andere conventionele kwaliteitsparameters 
voor rode bloedceleenheden zijn helaas geen goede graadmeters voor rode 
bloedceloverleving na transfusie. 
In Hoofdstuk 3 hebben we onderzocht of de aanwezigheid van fosfatidylserine aan de 
buitenkant van de rode bloedcel gebruikt kan worden als een graadmeter voor 
bloeddonorafhankelijke variatie in de kwaliteit van bloedzakken. De mate van aanwezigheid 
van fosfatidylserine aan de buitenkant van de rode bloedcel varieerde van donor tot donor 
én nam toe met de bewaartijd van rode bloedceleenheden. Ook bleek het percentage rode 
bloedcellen met fosfatidylserine aan hun buitenkant in vers afgenomen bloed een goede 
voorspeller te zijn voor de toename in het percentage positieve rode bloedcellen na 
blootstelling aan experimentele stress die vergelijkbaar is met de stress die rode bloedcellen 
ondergaan in de bloedvaten. Ook kwam het percentage fosfatidylserine-positieve rode 
bloedcellen overeen met de mate van hemolyse en de hoeveelheid micropartikels in 
bloedzakken. Deze bevindingen laten zien dat het percentage rode bloedcellen met 
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fosfatidylserine aan hun buitenkant een bruikbare graadmeter is voor de kwaliteit van rode 
bloedcellen in bloedzakken. 
Transfusies van rode bloedcellen zijn geassocieerd met een verhoogde morbiditeit en 
mortaliteit bij ernstig zieke patiënten. De gegeneraliseerde ontsteking die doorgaans wordt 
waargenomen bij deze patiënten heeft naar alle waarschijnlijkheid een nadelig effect op de 
functie en levensduur van de getransfuseerde rode bloedcellen. Ook is het goed mogelijk 
dat de mate van dit effect toeneemt met de bewaartijd van de rode bloedcelzak. Deze notie 
wordt gevoed door eerdere waarnemingen dat onder andere de vorm en vervormbaarheid 
van rode bloedcellen veranderen in patiënten die een gegeneraliseerde ontsteking hebben 
ten gevolge van sepsis (bloedvergiftiging). Een eerdere studie liet zien dat, wanneer rode 
bloedcellen van gezonde vrijwilligers in contact kwamen met het bloedplasma van patiënten 
met sepsis, het aantal fosfatidylserine-positieve rode bloedcellen toenam. Ook werd 
sfingomyeline, een ander vet in het celmembraan, afgebroken tot ceramide. Van ceramide is 
bekend dat het een sterke invloed heeft op de functie en de integriteit van het celmembraan 
en daarmee op de rode bloedcel in zijn geheel. Ceramide wordt vooral gevormd door het 
enzym sfingomyelinase en dit enzym komt vrij in de bloedstroom tijdens gegeneraliseerde 
ontsteking. 
In Hoofdstuk 4 hebben we in detail onderzocht wat de gevolgen zijn van een behandeling 
van rode bloedcellen met sfingomyelinase. Rode bloedcellen bleken hiervoor zeer gevoelig 
te zijn. Behandeling met sfingomyelinase leidde tot een verlies van de kenmerkende 
discusvorm van de rode bloedcel, direct gevolgd door het verschijnen van fosfatidylserine 
aan de buitenkant van de cel en uiteindelijk celdood. Gedurende dit proces nam de 
vervormbaarheid van de cel af en ging hij meer micropartikels vormen. Oude rode 
bloedcellen van gezonde vrijwilligers en uit bloedzakken bleken veel gevoeliger voor de 
behandeling met sfingomyelinase dan jongere rode bloedcellen. Dit laatste zou gevolgen 
kunnen hebben voor de levensduur van bewaarde rode bloedcellen na transfusie in 
patiënten met gegeneraliseerde ontsteking. 
In Hoofdstuk 5 identificeerden we de vetten in het celmembraan van rode bloedcellen van 
gezonde vrijwilligers nadat deze waren blootgesteld aan het bloedplasma van patiënten met 
sepsis. We vonden geen ceramide, maar wel een duidelijke toename van het vet 
lysofosfatidylcholine. Dit wordt doorgaans geproduceerd door enzymen van de fosfolipase 
A2 familie. Alhoewel gesecreteerd fosfolipase A2 type IIA sterk verhoogd was in het 
bloedplasma van patiënten met sepsis, bleek er geen verband te zijn tussen de hoeveelheid 
van dit enzym en de hoeveelheid lysofosfatidylcholine die werd aangetroffen in de 
onderzochte celmembranen. Vervolgens kregen gezonde vrijwilligers een lage dosis van de 
bacteriële bouwsteen lipopolysaccharide toegediend, waarmee een milde, experimentele 
sepsis werd geïnduceerd. Daarna werden rode bloedcellen blootgesteld aan het 
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bloedplasma van deze vrijwilligers en werden de vetten in het celmembraan geanalyseerd. 
Een toename in lysofosfatidylcholine werd niet gevonden in deze rode bloedcellen. Dit toont 
aan dat het gebruikte experimentele model sepsis niet volledig nabootst, althans niet wat de 
rode bloedcel betreft. In deze vrijwilligers nam de mate van fosfatidylserine aan de 
buitenkant van rode bloedcellen wél toe. Deze gegevens laten zien dat de vetten in rode 
bloedcelmembranen veranderen tijdens gegeneraliseerde ontsteking. Dit kan gevolgen 
hebben voor de functie en levensduur van rode bloedcellen. 
Rode bloedcellen verliezen delen van hun membraan als micropartikels, die teruggevonden 
kunnen worden in het bloed. De rode bloedcel vormt deze micropartikels waarschijnlijk om 
beschadigde eiwitten en vetten uit het celmembraan te verwijderen en daarmee vroegtijdige 
herkenning en verwijdering te voorkómen. Micropartikels worden ook gevormd door rode 
bloedcellen in bloedzakken gedurende hun opslag in de bloedbank. De afgelopen jaren is 
het duidelijk geworden dat micropartikels afkomstig van verschillende soorten cellen een rol 
spelen in de fysiologie en pathologie van het menselijk lichaam. In Hoofdstuk 6 wordt een 
overzicht gegeven van de huidige kennis over de mogelijke betrokkenheid van 
micropartikels afkomstig van rode bloedcellen bij allerlei ziekteprocessen en de schadelijke 
bijwerkingen van transfusies. 
Bloedplaatjes zijn de kleinste cellen in ons bloed en onmisbaar voor de bloedstolling, dat 
bloedverlies stopt na beschadiging van een bloedvat. Bloedplaatjes zijn ook betrokken bij de 
activatie en ondersteuning van ons immuunsysteem. Het immuunsysteem beschermt ons 
tegen ziekteverwekkers zoals bacteriën en virussen en zorgt er ook voor dat onze weefsels 
goed functioneren. Bloedplaatjes worden net zoals rode bloedcellen verzameld en 
opgeslagen voor transfusie. Gedurende hun verblijf in de bloedstroom en opslag in 
bloedzakken produceren ook de bloedplaatjes micropartikels. Het is gebleken dat deze door 
plaatjes gevormde micropartikels (PMPs) net als plaatjes zelf de werking van ons 
immuunsysteem kunnen beïnvloeden. Ook dat wordt besproken in Hoofdstuk 6. 
In Hoofdstuk 7 beschrijven we onze ontdekking van een beschermend effect van PMPs op 
de stabiliteit van de regulatoire T cellen van het immuunsysteem. Regulatoire T cellen 
voorkomen dat het immuunsysteem zich tegen ons eigen lichaam keert en zorgen ervoor dat 
het immuunsysteem tot rust komt nadat het een infectie overwonnen heeft. Echter, in 
uitzonderlijke situaties kunnen regulatoire T cellen van aard veranderen en stoffen gaan 
produceren die het immuunsysteem juist activeren, zoals interleukine-17 en interferon-γ. In 
deze studie hebben we een model gebruikt waarin regulatoire T cellen hun beschermende 
functie deels verliezen en interleukine-17 en/of interferon-γ gaan produceren. Dit 
functieverlies kon worden geremd door toevoeging van PMPs. We hebben ook aangetoond 
dat de PMPs bij voorkeur binden aan een specifieke groep regulatoire T cellen waarvan 
bekend is dat die na stimulatie interleukine-17 produceren. Ook hebben we laten zien dat 
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deze interactie tussen PMPs en regulatoire T cellen tot stand komt via het membraaneiwit P-
selectine, dat aanwezig is op de PMPs. Deze bevindingen tonen aan dat PMPs mogelijk 
assisteren bij de controlerende rol van het immuunsysteem. 
Dit proefschrift biedt nieuwe inzichten in de biochemische veranderingen die plaatsvinden in 
het celmembraan van rode bloedcellen tijdens hun opslag en die bijdragen aan hun 
verminderde overleving na en de schadelijke bijwerkingen van transfusies. Verder maakt 
ons onderzoek zeer waarschijnlijk dat veranderingen in de vetten van het celmembraan 
kunnen leiden tot verminderde overleving van rode bloedcellen in patiënten met een 
gegeneraliseerde ontsteking. Ook beschrijven we een nieuwe functie van bloedplaatjes in 
het immuunsysteem, namelijk het reguleren van de activiteit van regulatoire T cellen door 
middel van micropartikels. 
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